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Effekte N-terminaler Mutationen des humanen 
Androgenrezeptors auf die Polyglutamintoxizität 
 
ZUSAMMENFASSUNG 
Neun neurodegenerative Krankheiten sind auf die Verlängerung einer 
Polyglutamin (PolyQ) Sequenz in unterschiedlichen Proteinen zurückzuführen. Die 
Zytotoxizität von jedem dieser Proteine ist mit einer Fehlfaltung des mutierten Proteins 
assoziiert. Dadurch kommt es zu Veränderungen in zellulären Prozessen und 
Interaktionen, sowie der damit verbundenen Bildung von unlöslichen Aggregaten und 
anderen toxisch wirkenden Spezies. Die Polyglutaminerkrankungen unterscheiden sich 
jedoch in ihrer Pathogenese und gewebespezifischen Wirkung, was auf den jeweiligen 
Proteinkontext bzw. PolyQ-angrenzenden Sequenzbereich zurückzuführen sein könnte. 
Für die Studien der hier vorliegenden Arbeit wurde der polyglutaminhaltige 
humane Androgenrezeptor (AR), Auslöser der spinalen und bulbären Muskelatrophie 
(SBMA), als Modell verwendet, um die Toxizität der PolyQ-Verlängerung zu 
analysieren. In früheren Experimenten wurden zwei mögliche Phosphorylierungsstellen 
im AR identifiziert, und die Mutation dieser Stellen schien eine Konformationsänderung 
im Protein hervorzurufen. Ausgehend von diesen Befunden wurden nun diese N-
terminalen Serin-Reste im Wildtyp AR (ARQ22) sowie in einem Rezeptor mit einer 
verlängerten PolyQ Sequenz (ARQ77) gegen Alanin ausgetauscht (ARQ22dm bzw. 
ARQ77dm). Mit Hilfe dieser Mutanten wurde dann der Effekt der durch die 
Serinmutation erzeugten Konformationsänderung auf die jeweiligen Aggregatformen und 
die damit verbundenen Toxizitätsprofile charakterisiert. 
Die Untersuchungen der Aggregation und Toxizität in kultivierten Zellen und in 
einem SBMA Drosophila Modell ergaben, dass sich die Effekte der 
Konformationsänderungen in Abhängigkeit von der Länge der PolyQ Sequenz 
unterscheiden. Im ARQ22 verursachten die Mutationen eine deutliche Verstärkung der 
Aggregation, sowie eine verminderte Überlebensrate und ein verändertes 
Bewegungsverhalten in Drosophila. Diese Veränderungen ähnelten dem Phänotyp des 
ARQ77/SBMA Modells, waren jedoch etwas schwächer ausgeprägt.  Im Gegensatz dazu 
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führten die Mutationen im ARQ77 zu einer Herabsetzung und Abschwächung der 
Aggregatbildung und Toxizität. Darüber hinaus erwiesen sich Inhibitoren, die zur 
Milderung der PolyQ Toxizität eingesetzt werden, als nicht sehr effektiv in der 
Hemmung der durch den ARQ22dm und AR77dm verursachten Toxizität. Somit wurden 
in dieser Arbeit zwei Aminosäurestellen identifiziert, welche die PolyQ-Toxizität des AR 
in gravierender Weise modulieren. Diese Ergebnisse können zukünftig genutzt werden, 
um zu klären, welche konformationellen Veränderungen im AR zur Aggregation führen 
und welche Aggregatformen für dessen toxische Wirkung verantwortlich sind. 
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ABSTRACT 
 Nine neurodegenerative diseases are caused by polyglutamine (polyQ) tract 
amplification in different proteins. The cytotoxicity of each of these proteins is associated 
with a misfolding of the mutant protein, resulting in the subsequent alteration of cellular 
processes and interactions as well as the interrelated formation of insoluble aggregates 
and other conformationally toxic species. However, the diseases differ in their pathology 
and tissue specificity of action, which may be due to protein context/regions neighboring 
the polyQ stretch.  
 For the purpose of the studies presented in ths work, the polyQ containing human 
androgen receptor (AR) that causes the disorder spinal and bulbar muscular atrophy 
(SBMA) was used to model polyQ toxicity. In previous investigations, two putative 
phosphorylation sites of the AR were identified, and it was demonstrated that mutation of 
these sites appeared to cause conformational change in the protein. Therefore, these N-
terminal serine residues were exchanged to alanine in the wild type AR 
(ARQ22/ARQ22dm) or a receptor with an amplified polyQ stretch (ARQ77/ARQ77dm). 
These mutants were then used to characterize variance in types of aggregates and the 
associated toxic profiles due to the different protein conformations that arose from the 
serine mutations.  
 Evaluating changes in aggregation and toxicity in cultured cells and in a 
Drosophila model of SBMA, it was found that the effects of the conformational changes 
differed depending on the length of the polyQ stretch. Mutations in the ARQ22 resulted 
in a marked increase in aggregation as well as decreased survival rates and altered 
locomotion behavior in Drosophila. These results were similar but not as severe as the 
ARQ77/SBMA model. In quite the opposite manner, mutations in the ARQ77 caused a 
decrease in aggregation and a lessened toxic effect in Drosophila. Moreover, it was found 
that inhibitor compounds used to ameliorate polyQ toxicity were not as efficient in 
inhibiting the varied toxicities exhibited by both the ARQ22dm and ARQ77dm. 
Therefore, two distinct amino acid sites that profoundly modulate polyQ toxicity in the 
AR have been identified. These results can be further utilized to understand the 
conformational changes in the AR that lead to aggregation as well as the types of 
aggregates that lead to toxicity. 
 iv
 v
TABLE OF CONTENTS 
 
Zusammenfassung          i 
Abstract          iii 
Table of contents         v 
List of tables and figures        x 
Abbreviations         xii 
 
1.0 INTRODUCTION        1 
 1.1 CAG repeat / polyglutamine disorders     1 
 1.1.1 The polyglutamine disorders are a subclass of the unstable 
 trinucleotide repeat disorders      1 
 1.1.2 The common mechanism of misfolding and aggregation  2 
 1.1.2.1 The dynamic process of aggregation    4 
 1.1.2.2 The cellular localization of aggregate species   5 
 1.1.3 Distinguishing between the polyglutamine disorders –  
 protein context        6 
 1.1.3.1 Fragments versus whole protein – caspase cleavage  6 
 1.1.3.2 Cis-acting modulators of polyglutamine toxicity   7 
 1.1.3.3 Phosphorylation of the polyglutamine proteins   9 
 1.2 Spinal and bulbar muscular atrophy as a model for  
  polyglutamine disorders      11 
 1.2.1 Kennedy’s Disease – the first polyQ disorder    11 
 1.2.2 The Androgen Receptor – a unique polyQ protein   13 
 1.2.2.1 Manipulating the AR in SBMA models – ligand binding, 
 nuclear localization, and transcriptional activity   15 
 1.2.2.2 Manipulating the AR in SBMA models – mutations of  
  sites of covalent modifications     16 
 1.2.2.3 Manipulating the AR in SBMA models – utilizing model 
 system to full potential      18 
 vi
 1.3 Animal models of the polyglutamine disorders    19 
 1.3.1 Mouse models        19 
 1.3.1.1 Mouse models of SBMA      20 
 1.3.2 Invertebrate models – Drosophila and C. elegans   21 
 1.3.2.1 Modeling SBMA in Drosophila     24 
 1.4 The path to therapy – therapeutic compounds for inhibiting  
 polyglutamine toxicity       26 
 1.4.1 SBMA specific therapies      26 
 1.4.2 General polyQ inhibitors      27 
 1.4.2.1 HDAC inhibitors       28 
 1.4.2.2 Melatonin as a candidate polyglutamine inhibitor  29 
 1.5 Aims          30 
2.0 MATERIALS AND METHODS      31 
 2.1 Materials         31 
 2.1.1 Chemicals and consumables      31 
 2.1.2 Enzymes         32 
 2.1.3 Plasmids and constructs       33 
 2.1.4 Bacteria and eukaryotic cells      34 
 2.1.5 Drosophila melanogaster lines      35 
 2.1.6 Antibodies        35 
 2.2 Methods         37 
 2.2.1 DNA- cloning techniques      37 
  2.2.1.1 DNA fragmentation with restriction enzymes   37 
  2.2.1.2 Separation of DNA fragments by agarose gel  
    electrophoresis       37 
  2.2.1.3 DNA extraction from agarose gel     38 
  2.2.1.4 Ligation of DNA fragments into plasmid vectors  38 
  2.2.1.5 Transformation of bacteria     38 
 2.2.2 Preparation of recombinant plasmid DNA from transformed  
   bacteria         39 
  2.2.2.1 Mini-preparation of plasmid DNA    39 
 vii
  2.2.2.2 Maxi-preparation of plasmid DNA    39 
  2.2.2.3 Phenol/chloroform extraction of plasmid DNA   40 
  2.2.2.4 Ethanol precipitation of plasmid DNA    41 
  2.2.2.5 Determination of nucleic acid concentration   41 
 2.2.3 Cell culture        41 
  2.2.3.1 Passaging of cells       41 
  2.2.3.2 Freezing and thawing of cells     41 
  2.2.3.3 Transient transfections      42 
  2.2.3.4 Analysis of gene expression through luciferase assay test 42 
  2.2.3.5 Immunofluorescence      43 
 2.2.4 Drosophila methods       45 
  2.2.4.1 Culturing of fly stocks      45 
  2.2.4.2 Preparation of fly food      45 
  2.2.4.3 Injections for germ-line transformation    46 
  2.2.4.4 Genetic crosses       49 
  2.2.4.5 Scanning electron microscopy     49 
  2.2.4.6 Immunohistochemistry      50 
  2.2.4.7 Locomotion analysis      50 
  2.2.4.8 Survival analysis       51 
 2.2.5 Methods for work with protein from cells and Drosophila  52 
  2.2.5.1 Preparation of protein lysates     52 
  2.2.5.2 Determination of protein concentration    53 
  2.2.5.3 Separation of protein by SDS polyacrylamide gel  
    electrophoresis       53 
  2.2.5.4 Western blotting       54 
  2.2.5.5 Stripping of Western blot membranes    55 
  2.2.5.6 Filter trap analysis of aggregates     55 
  2.2.5.7 Immunoprecipitation      56 
 
 
 
 viii
3.0 RESULTS          58 
 3.1 Mutation of distinct serine residues at the N-terminus of the AR 58 
  3.1.1 Two possible phosphorylation sites shown in vitro   58 
  3.1.2 Conformational changes induced by substitution of serine  
    residues 424 and 514       61 
 3.2 Cell culture model used to investigate in vivo effects of serine 
   site mutations         63 
  3.2.1 Mutation of serines 424 and 514 residues affects nuclear  
    localization and transactivation by the AR    63 
   3.2.1.1 Accumulation of AR in nucleus altered with AR mutants 64 
   3.2.1.2 Transactivation by wild type AR affected by polyQ stretch  
     and serine mutation      66 
  3.2.2 Mutation of serines 424 and 514 affects the formation of 
    intracellular inclusions by the AR     69 
   3.2.2.1 Inclusions differ in structural type and kinetics of formation 69 
   3.2.2.2 Both polyQ stretch and presence of serine mutations affect 
     solubility of inclusions      71 
   3.2.2.3 1C2 antibody preferentially recognizes expanded  
     polyQ region       74 
 3.3 Drosophila model of SBMA used to analyze effects of serine site 
  mutations          75 
  3.3.1 Conformational changes induced by mutation of serines 424 and 
    514 in Drosophila       75 
  3.3.2 Mutations of serines 424 and 514 affect nuclear accumulation 
    and aggregation of the AR in a fly model of SBMA   76 
   3.3.2.1 Mutant AR demonstrates altered nuclear localization in 
     fly lines        77 
   3.3.2.2 Aggregation and 1C2 recognition in fly lines comparable  
     to cell model       79 
  3.3.3 Neurodegeneration occurs in fly lines expressing AR with  
    mutations at serine residues 424 and 514    80 
 ix
  3.3.4 Mutation of serine residues 424 and 514 affects locomotion and 
    survival of fly lines expressing ARQ22 and ARQ77   81 
   3.3.4.1 Locomotion assay demonstrates subtle differences between 
     AR mutant lines       82 
   3.3.4.2 Transgenic lines demonstrate changes in survival dependent 
     upon serine site mutations     84 
 3.4 Inhibitors of polyQ toxicity used to demonstrate differential  
  toxicity due to serine site mutations     86 
  3.4.1 Sodium butyrate and melatonin inhibit neurodegeneration in 
    expanded polyQ fly lines      86 
  3.4.2 Serine mutations affect ability of sodium butyrate and melatonin 
    to rescue polyQ phenotype in quantitative assays   88 
   3.4.2.1 Sodium butrate and melatonin have varying effects on 
     locomotion       88 
   3.4.2.2 Sodium butyrate and melatonin differ in ability to rescue  
     AR mutants in survival analyses     91 
4.0 DISCUSSION         93 
 4.1 Alteration of specific residues affects AR conformation and  
  provides model system for evaluating polyQ toxicity    93 
 4.2 Altered conformations differentially affect nuclear accumulation  
  and transcriptional activity       96 
 4.3 Altered AR conformations yield characteristically diverse  
  aggregates         100 
 4.4 Inhibitor compounds act on specific subsets of the varied AR  
  toxicities         103 
 4.5 Final conclusions and outlook for AR-specific and general  
  polyglutamine toxicity studies      105 
REFERENCES         107 
Curriculum Vitae         129 
 
 
 x
LIST OF TABLES AND FIGURES 
 
TABLES 
Table 1.1 The polyglutamine disorders      2 
 
FIGURES 
Figure 1.1 A proposed model of polyQ toxicity     3 
Figure 1.2 Neuronal regions affected in SBMA     12 
Figure 1.3 Androgen receptor structural domains and phosphorylation sites 15 
Figure 1.4 Drosophila model system       23 
Figure 3.1 In vitro MAP Kinase ERK2 phosphorylation of the region  
   360-536 of the AR reveals two possible phosphorylation sites  60 
Figure 3.2 Mutation of serine residues 424 and 514 leads to conformational  
   changes in wild type AR and an AR with an extended polyQ stretch 62 
Figure 3.3 Kinetics of cytoplasmic-nuclear transport is altered after mutation  
   of serine residues 424 and 514      65 
Figure 3.4 Transactivation by the AR is altered in mutant variants   67 
Figure 3.5 Mutation of serines 424 and 514 alters kinetics of formation of  
   intracellular inclusions       70 
Figure 3.6 Differences in aggregate formation due to mutations at serine 
   residues 424 and 514       73 
Figure 3.7 Serine mutations do not alter 1C2 activity    74 
Figure 3.8 Mutation of serine residues 424 and 514 leads to conformational 
   changes in androgen receptors expressed in Drosophila   76 
Figure 3.9 Nuclear localization of AR in Drosophila    78 
Figure 3.10 Aggregation and conformation of AR in transgenic Drosophila 79 
Figure 3.11 Ligand-induced neurodegeneration of photoreceptor neurons in  
    flies containing amplified polyQ stretch and serine 424/514  
    mutations         81 
Figure 3.12 Locomotive and behavioral analysis of transgenic wandering 
    third-instar larvae       83 
 xi
 
Figure 3.13 Survival studies of larvae with ubiquitous neuronal expression  
    of AR with amplified polyQ stretch and AR containing mutated  
    serine sites         85 
Figure 3.14 Sodium butyrate and melatonin inhibit polyQ toxicity, but serine 
    mutations alter effectivity      87 
Figure 3.15 Effects of sodium butyrate and melatonin on larval locomotion 90 
Figure 3.16 Effects of sodium butyrate an melatonin on survival   92 
 xii
ABBREVIATIONS 
 
Aβ       β-amyloid 
AF       AR transcriptional activation function 
APS      ammonium persulfate 
AR      androgen receptor 
ARE      androgen responsive element 
AXH      ataxin / HBP1 
BSA      bovine serum albumin 
ºC       degrees Celcius 
cAMP      cyclic adenosine monophosphate 
cDNA      complementary DNA 
CHIP      C-terminus of Hsc-70 interacting protein 
CBP      CREB-binding protein 
CMV      cytomegalovirus 
CNS      central nervous system 
CREB      cAMP-responsive element binding protein 
C-terminal    carboxy terminal 
Cy       Cyanine 
DBD      DNA binding domain 
DHFR      dihydrofolate reductase 
DHT      5α-dihydrotestosterone 
DMEM     Dulbecco’s modified eagle’s medium 
DMSO     dimethylsulfoxide 
DNA      deoxyribonucleic acid 
DRPLA     dentatorubral-pallidoluysian atrophy  
DTT      dithiothreitol 
ECL      enhanced chemiluminescence  
EDTA      ethylenediaminetetraacetic acid   
ELAV      embryonic lethal abnormal vision 
ERK      extracellular signal-regulated protein kinase 
EtOH      ethanol 
eg.       exempli gratia, for instance 
et al.      et alii, and others 
fC       fibrous cytoplasmic 
FCS      fetal calf serum 
 xiii
Fig       figure 
fN       fibrous nuclear 
g       gram 
gC       globular cytoplasmic 
GMR      glass multimer reporter 
gN       globular nuclear 
h       hour 
HAT      histone acetyltransferase 
HBP1      HMG box-containing protein-1 
HCL      hydrogen chloride 
HDAC     histone deacetylase 
HMG      high mobility group 
HRP      horseradish peroxidase 
Hsp      heat shock protein 
htt       huntingtin 
IGF-1      insulin growth factor 1 
JNK      c-Jun NH2-terminal kinase 
kDa      kilodalton 
kcal      kilocalorie 
l       liter 
LBD      ligand binding domain 
LM      light microscopy 
MAPK     mitogen-activated protein kinase 
μ       micro- 
m       milli- 
m       meter 
M       molar 
MBP      myelin-based protein 
MeOH     methanol 
min      minute 
MMTV     mammary tumor virus 
mol      mole 
NLS      nuclear localization signal 
NTD      N-terminal domain 
N-terminal    amino terminal 
n       nano- 
OD      optical density 
 xiv
PAGE      polyacrylamide gel electrophoresis 
PBS      phosphate-buffered saline 
PBST      PBS with tween 
PBT      PBS with TritonX-100 
PI3K      phosphoinositide 3-kinase 
polyQ      polyglutamine 
PVDF      polyvinylidene difluoride 
RNA      ribonucleic acid 
rpm      rotations per minute 
RT       room temperature 
s       second 
SAPK      stress-activated kinase 
SAHA      suberoylanilide hydroxamic acid 
SBMA      spinal and bulbar muscular atrophy 
SCA      spinocerebellar ataxia 
SDS      sodiumdodecylsulfate 
SEM      scanning electron microscopy 
TAE      tri/acetate/EDTA electrophoresis buffer 
TEMED     tetramethylethylenediamine 
Tris      tris(hydroxymethyl)aminomethane 
UAS      upstream activating sequence 
UV      ultraviolet 
V       volt 
VEGF      vascular endothelial growth factor 
v/v       volume on volume 
w/v      weight on volume 
YAC      yeast artificial chromosome 
 
 1
1.0 INTRODUCTION 
 
1.1 CAG repeat / polyglutamine disorders 
 
1.1.1 The polyglutamine disorders are a subclass of the unstable trinucleotide 
repeat diseases 
 Trinucleotide repeat sequences that code for runs of specific amino acids occur 
throughout the genomes of many different species. However, the human genome appears 
to have a unique mutational mechanism which causes instability of specific nucleotide 
repeats (Gatchel and Zoghbi, 2005). This distinct aspect of the human genome has 
resulted in a class of inherited neurodegenerative disorders known as the unstable 
trinucleotide repeat diseases. This class of disorders is marked by the phenomenon 
known as “anticipation”, the observation that the severity of a disorder increases while 
the age of onset decreases as the disorder is passed down through the generations. The 
diseases vary in that the underlying mechanisms of the disorders can be a loss or gain-of-
function mutation at either the RNA or protein level (Riley and Orr, 2006). In this 
respect, the trinucleotide repeat diseases can be divided into two distinct categories. 
Disorders of the first category, Type I, are caused by the triplet repeat CAG, which is 
inserted into the open reading frame of a broadly expressed gene.  The CAG nucleotide 
sequence encodes the amino acid glutamine, giving this subclass of unstable trinucleotide 
repeat diseases the title “polyglutamine (polyQ) disorders”. The category of Type II 
disorders is distinguished by typically longer trinucleotide repeat expansions that are 
contained in noncoding regions (Reddy and Housman, 1997). 
 The Type I polyQ disorders have only emerged as a class of inherited 
neurodegenerative disorders over the past 15 years (Zoghbi and Orr, 2000). This group 
includes Huntington’s disease, spinal and bulbar muscular atrophy (SBMA), 
dentatorubral-pallidoluysian atrophy (DRPLA), and a number of spinocerebellar ataxias 
(SCA) (Table 1.1). Each disease, taken on its own, is quite rare; however, as a group they 
now represent the most common form of inherited neurodegenerative disease (Riley and 
Orr, 2006). In all of the nine known diseases, the CAG repeat expansions that appear in 
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the respective unrelated disease proteins result in a characteristic pathogenesis of 
progressive neuronal loss. With the exception of spinocerebellar ataxia 6 (SCA6), the 
disease threshold of the polyQ length is 35-40 amino acids. Beyond this threshold, an 
inverse relationship exists between the length of the CAG repeat region and the age of 
onset of the neuronal loss and clinical symptoms. The clinical manifestations usually 
commence in adulthood and progress over 10 to 30 years to an ultimately fatal state.  
 
Disease Protein Normal 
CAG 
length 
Pathological 
CAG  length 
Neuronal areas 
affected 
Clinical 
manifestation 
Huntington’s disease Huntingtin 11-34 40-120 corpus striatum, 
cerebral cortex 
chorea, impairment of 
cognitive function, 
emotional disturbance 
Dentatorubral-
pallidoluysian 
atrophy (Smith’s 
disease) 
Atrophin1 7-35 49-88 globus pallidus, 
dentatorubral and 
subthlamic nucleus 
choreanthetosis, ataxia, 
dementia, myoclonus 
and epilepsy 
Spinobulbar 
muscular atrophy 
(Kennedy’s disease) 
Androgen 
receptor 
9-38 40-62 anterior horn cells, 
bulbar neurons, dorsal 
root ganglia 
muscle weakness, 
atrophy and 
fasciculations 
Spinocerebellar 
ataxia type 1 
Ataxin-1 25-36 41-81 cerebellar cortex, 
dentate nucleus, 
brainstem 
ataxia, dysarthria, 
dysmetria and 
decreased vibration 
sense 
Spinocerebellar 
ataxia type 2 
Ataxin-2 15-24 35-59 cerebellum, pontine 
nuclei, substantia nigra 
 
ataxia, dysarthria 
Spinocerebellar 
ataxia type 3 
(Machado-Joseph 
disease) 
Ataxin-3 13-36 62-82 substantia nigra, globus 
pallidus, pontine 
nucleus, cerebellar 
cortex 
ataxia, dystonia and 
opthalmoplegia 
Spinocerebellar 
ataxia type 6 
Ataxin-6 / 
CACAA1A 
4-16 21-27 cerebellum, brainstem ataxia, dysarthria, 
nystagmus and 
vibratory loss 
Spinocerebellar 
ataxia type 7 
Ataxin-7 4-19 37-306 cerebellum, inferior 
olive, dentate nucleus 
cerebellar ataxia, 
dysarthria and 
dysphagia, cone-rod 
and retinal dystrophy 
Spinocerebellar 
ataxia type 17 
(TATA-binding 
protein disease) 
TATA-BP 25-42 47-63 cerebellum, caudate 
nucleus, putamen 
gait ataxia, dementia, 
bradykinesia, 
dysmetria 
 
Table 1.1 The polyglutamine disorders, adapted from Reddy and Housman, 1997 
 
1.1.2 The common mechanism of misfolding and aggregation 
 Despite differences that exist between the polyQ disorders, specifically in disease 
symptoms and patterning of neuronal degeneration, much research has argued that there 
must be a common underlying pathogenic mechanism resulting from the presence of the 
polyQ tract. Research tends to agree on a model where one aspect of this mechanism is 
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the adoption of an abnormal conformation by the mutant protein. A proposed basic model 
by Paulson et al., demonstrates how misfolding of an expanded polyQ stretch-containing 
protein could lead to the neurodegeneration seen in the polyQ disorders (Fig. 1.1) 
(Paulson et al., 2000). In this model, misfolding of the protein disrupts normal protein 
function, alters protein-protein interactions, and upsets the balance of protein 
homeostasis.  
 
 
Figure 1.1 A proposed model of polyQ toxicity (Paulson et al., 2002) 
 
 Although scientists tend to study the disorders individually, there is an 
expectation that an advance in one of the diseases will provide relevant understanding for 
the group as a whole. This theory has proven true in the case of the misfolding of the 
polyQ proteins. An important consequence of the misfolding process is the accumulation 
of the mutant polyQ, resulting in protein aggregates. Deposits of the aberrant huntingtin 
(htt) protein, which causes Huntington’s disease, were first seen in transgenic mice 
(Davies et al., 1997) and human patients (DiFiglia et al., 1997) in 1997. After this 
breakthrough observation, aggregates and inclusions were eventually identified in all of 
the other polyQ disorders; and aggregation quickly became the prominent pathological 
hallmark of the group of disorders as well as a main focus of research (Ross, 1997; 
Davies et al., 1999). However, many questions soon arose around the topic of 
 4
aggregation. Were aggregated deposits of polyQ protein a cause of toxicity or just a 
byproduct? Or going, a step further, were aggregates actually cytoprotective? In the 
literature, one could find support for each of these arguments. One tempting theory is to 
link each of these schools of thought by looking at aggregation as a dynamic process 
where earlier steps in the misfolding process are more directly linked to toxicity and the 
final physical state is a way of sequestering the toxic protein (Ross and Poirier, 2004).  
 
1.1.2.1 The dynamic process of aggregation 
 When the story of polyQ aggregation first began to take shape, aggregates were 
described simply as large and poorly soluble structures. But further investigation found 
them to have an extensive β-pleated sheet structure similar to the amyloid fibril structure 
of protein aggregates formed in other neurodegenerative diseases such as Alzheimer’s 
and Parkinson’s (Davies et al., 1997; Scherzinger et al., 1999). Amyloid fibrils are 
defined as filamentous structures with a width of approximately 10 nm and a length of 
0.1-10 μm (Sunde and Blake, 1998). The particular amyloid fibril indicated in 
Alzheimer’s disease is known as the β-amyloid (Aβ) peptide, and antibodies specific for 
the amyloid fibril conformation of the Aβ peptide have been shown to recognize 
aggregate structures derived from the polyQ proteins (O'Nuallain and Wetzel, 2002).  
In the search to unravel the mechanism of the misfolding process that starts from 
the native polyQ protein and progresses to the amyloid fibril conformation, the 
importance of intermediates in the aggregation process has become increasingly apparent. 
These amyloidal precursors can be grouped into a category of structures known as 
“soluble oligomeric intermediates”. These structures are larger than dimers and can have 
a globular/micelle formation or a fibril-like morphology. Those with the latter structure 
type are referred to as Aβ protofibrils (Lambert et al., 1998; Ross and Poirier, 2004). 
Protofibrils may be able to amass to become larger fiber-like structures, which then form 
the final physical state of the inclusion (Ross and Poirier, 2004).  
As knowledge of the aggregation process has advanced, researchers looking to the 
soluble oligomeric intermediates as the toxic species have honed in further on the specific 
subtypes. The spherical form of soluble oligomers were first represented to be the toxic 
species of amyloid-like Aβ peptide in Alzheimer’s disease and have now also been 
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shown to exist in other amyloidogenic proteins and peptides, including expanded polyQ 
containing proteins (Kayed et al., 2003; Wacker et al., 2004). A study of a protein 
containing a polyQ stretch of 91 amino acids identified globular aggregates 4-50 nm in 
diameter as the principal cytotoxic species in protein conformational diseases (Mukai et 
al., 2005). In general, globules and not fibrillar conformations of the polyQ stretch 
amplifications have been shown to be sufficient to induce cellular pathophysiology (Quist 
et al., 2005).   
 
1.1.2.2 The cellular localization of aggregate species 
 Yet another aspect of aggregation that is still under debate is the effect of nuclear 
versus cytoplasmic aggregates on the neuropathology of the polyQ disorders. The first 
deposits of the htt protein described in transgenic mice and patients in 1997 were of 
nuclear localization (Davies et al., 1997; DiFiglia et al., 1997). Since that time, much data 
has accumulated linking such nuclear-localized inclusions with polyQ toxicity. Most of 
these findings have stemmed from studies that manipulated to which cellular 
compartment the mutant polyQ proteins were directed. Cytoplasmic localization of the 
nuclear protein ataxin1 reduced toxicity and aggregate formation in a mouse model of 
SCA1 (Klement et al., 1998) while forced nuclear localization of an N-terminal fragment 
of the usually cytoplasmic htt protein resulted in an increase in toxicity (Peters et al., 
1999; Schilling et al., 2004). Furthermore, nuclear localization of the androgen receptor 
(AR) is required for toxicity in SBMA models (Takeyama et al., 2002; Walcott and 
Merry, 2002).  
 Varying evidence exists in the literature regarding the role of cytoplasmic 
aggregates in polyQ toxicity. In a Drosophila model of Huntington’s, accumulation of 
aggregates in the cytoplasm blocked axonal transport (Lee et al., 2004). Cytoplasmic htt 
aggregates were also shown to interfere with the normal mobility and trafficking of 
mitochondria (Chang et al., 2006). In the case of SBMA, aggregates in the cytoplasm 
have been suggested to act as protective “sinks”, trapping the polyQ until it can be 
degraded through proteasomal pathways (Rusmini et al., 2007). One theory regarding 
cytoplasmic aggregation is that autophagy is more efficient in the cytoplasm, thus the 
nucleus is the more vulnerable of the cellular compartments to polyQ toxicity (Iwata et 
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al., 2005). Another possibility is that localization of toxic aggregate species may vary 
between the disorders. Therefore, in the search for common mechanisms, researchers 
must still keep the individual proteins in mind. 
 
1.1.3 Distinguishing between the polyglutamine disorders - protein context 
When comparing the polyQ disorders, one must take into consideration that other 
than the polyQ tract, none of the disease proteins share any sequence similarity. 
Therefore, as witnessed by the commonalities among the polyQ diseases, the glutamine 
expansion itself plays a major role in aggregation formation and the correlated 
pathogenesis. However, the affected proteins must also strongly modulate the particular 
pathogenic mechanisms for the individual disorders. The greatest evidence for the 
involvement of other protein sequences in polyQ toxicity is the specificity of the neuronal 
subsets affected in each of the diseases (Table 1.1). For example in SCA1, cerebellar 
Purkinje cells are the prominent site of pathology (Genis et al., 1995; Robitaille et al., 
1995) whereas in SBMA it is the spinal motor neurons that are lost (Kennedy et al., 
1968). Hence much of the current research on the topic has focused on regions outside of 
the polyQ stretch, examining how specific sequences and domains as well as any 
resultant covalent modifications of the proteins affect the disease processes. As first 
predicted, some of these studies have resulted in common themes for all of the polyQ 
disorders, but some are perhaps relevant only to the individual diseases and cell-type 
specificity.  
 
1.1.3.1 Fragments versus whole protein- caspase cleavage 
The early stages of research that noted the importance of the influence of outside 
sequences on polyQ pathology began with the topic of caspase cleavage. At least seven 
of the nine reported polyQ proteins are substrates for caspases, the cystein protease cell 
death “executioners” (Ellerby et al., 1999a; Young et al., 2007). Initial studies found that 
regionally specific caspase cleavage of htt formed toxic, truncated fragments and was 
imperative for aggregation and cytotoxicity (Wellington et al., 1998; Ellerby et al., 
1999a; Wellington et al., 2000). Similar findings were also made for the AR (Ellerby et 
al., 1999b) and atrophin1 (Ellerby et al., 1999a). This lead to the conclusion that an 
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expanded glutamine peptide isolated from an intact protein is more toxic than when it is 
within the intact protein, arguing that sequences outside the glutamine stretch may 
dampen the deleterious effect of the expanded polyglutamine tract (Wellington and 
Hayden, 2000; Zoghbi and Botas, 2002).  
However, animal models utilizing truncated fragments have not been able to 
replicate some key features of the disorders. For example, a mouse model expressing an 
amino terminal human htt with an expanded polyQ of 120 showed widespread htt 
inclusions but no clinical evidence of neuronal dysfunction or degeneration. In contrast, a 
mouse expressing the full-length htt protein with the same polyQ length and the same 
level of huntingtin expression formed inclusions that were toxic (Slow et al., 2005). 
Expression of a full-length AR in mouse models is also imperative for replicating the 
neuronal degeneration seen in SBMA (Adachi et al., 2001; McManamny et al., 2002). 
These models provide evidence for the complex nature of the polyQ pathogenic 
mechanisms. Although N-terminal fragments produced by caspase cleavage of the mutant 
proteins appear to be a prerequisite for toxicity and to represent another common step in 
the pathogenesis of the protein aggregation diseases (Tarlac and Storey, 2003), their 
presence alone is not sufficient to entirely recapitulate the diseases in animal models. 
Thus, researchers have delved further into investigating sequences neighboring the polyQ 
stretches in order to determine their role in diminishing or enhancing the toxicity seen in 
human patients. 
 
1.1.3.2 Cis-acting modulators of polyglutamine toxicity 
 Apart from the generation of toxic protein fragments, scientists are finding that 
other regions such as particular domains, other amino acid runs, or even unspecified 
sequences also contribute to toxicity in an undefined manner. One of the first studies to 
provide evidence that a region other than the polyQ influenced disease pathology 
demonstrated that the AXH domain of ataxin1 participated in protein aggregation. The 
AXH domain (ataxin1/HBP1) is similar in structure to the high mobility group (HMG) 
box transcription factor HBP1 ((HMG box-containing protein-1) and plays a role in 
transcriptional repression of ataxin1. Interestingly, this region underwent a β-enriched 
structural conformation when isolated in vitro. Moreover, the study found that deletion of 
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this site or replacement with its HBP1 homolog significantly reduced aggregation in an 
SCA1 cell model (de Chiara et al., 2005). 
The effect of other amino acid runs on polyQ toxicity has also very recently come 
under investigation. The htt protein, for example, contains a proline-rich region 
immediately following the polyQ expansion. When wild-type or mutant derivatives of htt 
are expressed in a yeast system, neither protein form results in cell death. However, 
deletion of the proline-region was found to unmask the toxicity of htt with an expanded 
polyQ region (Dehay and Bertolotti, 2006). A similar study found that a FLAG-epitope 
(DYKDDDK) at the amino or carboxy terminus of the htt exon I unmasked the toxicity 
of an otherwise benign polyQ protein, whereas the endogenous polyproline region 
carboxy-terminal to the amplified polyQ tract was demonstrated to convert toxic proteins 
into non-toxic ones (Duennwald et al., 2006). Experimentally poly- or oligo-proline tracts 
placed at the carboxy-termini but not the amino-terminal region of polyQ polypeptides 
change the conformation and decrease the rate of aggregate formation of these proteins 
(Bhattacharyya et al., 2006). Proline regions are also found at the carboxy-termini of the 
polyQ regions in atrophin1 and the AR. While the proline region of atrophin1 has been 
found to be involved in the binding of interaction partners in a polyQ dependent manner 
(Okamura-Oho et al., 2003), any effects of the small proline stretch of the AR on polyQ 
toxicity have yet to be investigated. 
 An example of undefined outside sequences influencing polyQ toxicity has been 
demonstrated by the ability of the co-chaperone CHIP (C-terminus of Hsc-70 interacting 
protein) to protect against polyQ-induced neurodegeneration. CHIP is an E3 ligase that 
connects chaperones to the ubiquitin-proteasome machinery, which is responsible for 
protein quality control by degrading misfolded proteins such as the polyQ proteins and 
aiding in the refolding of nonnative proteins. CHIP has been shown to interact with the 
polyQ expanded mutants of ataxin3, htt (Jana et al., 2005), ataxin1, and most recently the 
AR (Adachi et al., 2007). Overexpression of CHIP was shown to ameliorate toxicity in a 
Drosophila model of SCA1 and also in a “protein context” manner. The researchers 
found that CHIP overexpression had no effect on an isolated polyQ tract of 127 but was 
again effective when the polyQ tract was in the context of a htt backbone (Al-Ramahi et 
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al., 2006). Therefore, it is again seen that the surrounding framework is crucial for polyQ 
pathology and the modulation of that pathology.  
 
1.1.3.3 Phosphorylation of the polyglutamine proteins 
Moving away from the discussion of specified regions and the protein backbones 
as a whole, recently mutations of specific amino acids outside the polyQ stretches that are 
sites for protein modifications have been shown to positively or negatively influence 
aggregate formation and toxicity of proteins such as the AR and ataxin1 (Emamian et al., 
2003; Thomas et al., 2004). The main focus of these studies has been the phosphorylation 
of the various polyQ disease-causing proteins. To date, several phosphorylation pathways 
including the insulin growth factor-1/Akt (IGF-1/Akt) pathway and the mitogen-activated 
protein kinase (MAPK) pathways have been implicated in the polyQ disease 
mechanisms. Again the htt protein was one of the first to be shown to be directly affected 
by phosphorylation, in this case by the serine/threonine pro-survival kinase Akt at htt 
serine 421. Akt is activated downstream of the IGF-1 receptor and phosphoinositide 3-
kinase (PI3K) in the IGF-1/Akt signaling pathway, a stimulator of cell growth and 
proliferation as well as an inhibitor of apoptosis. Activation of the IGF-1/Akt pathway 
was shown to result in phosphorylation of htt, which was essential for the resultant 
neuroprotective effects, increased cell survival, and decrease in intranuclear inclusions 
(Humbert et al., 2002). Positive effects of activating the IGF-1 pathway in cell models of 
SBMA have also been recently elucidated (Palazzolo et al., 2007). However, activation of 
Akt has been found to have quite the opposite effect on ataxin1, the protein responsible 
for SCA1. Researchers have found that Akt phosphorylation of ataxin1 serine 776 is an 
important step in the pathogenesis of the protein containing a polyQ expansion (Chen et 
al., 2003; Emamian et al., 2003).  
The MAPK pathways have not only been shown to direct phosphorylation of 
some of the polyQ proteins but also in turn to be upregulated by polyQ expanded mutant 
forms of the same proteins (LaFevre-Bernt and Ellerby, 2003; Apostol et al., 2006; 
Schilling et al., 2006). The superfamily of MAPKs comprises three major signaling 
pathways: the extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) cascade, the 
c-Jun NH2-terminal kinase or stress-activated kinase (JNK/SAPK) cascade, and the p38 
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family of kinases cascade (reviewed in (Robinson and Cobb, 1997). ERK1/2 signaling, 
which preferentially regulates cell growth and differentiation, is affected by both mutant 
htt and mutant AR. Activation of the ERK1/2 pathway by an AR containing an expanded 
polyQ region and a coupled phosphorylation at the N-terminus of the AR has been 
reported to be required for polyQ toxicity (LaFevre-Bernt and Ellerby, 2003). In contrast, 
activation of the ERK1/2 pathway by mutant htt is associated with cell survival. Instead, 
in the case of htt with a pathological polyQ stretch, it is the activation of the JNK/SAPK 
pathway that functions mainly in response to stress signals from inflammation or 
apoptosis that is associated with pathogenesis (Apostol et al., 2006). Although three 
ERK1 consensus sites have been identified in htt (Schilling et al., 2006), the effect of 
phosphorylation of these specific sites is unknown. In this same vein there are many 
phosphorylation sites and other sites of covalent modification whose influence on the 
various polyQ proteins has yet to be fully described. In a review on the role of protein 
context in the polyQ disorders, it was suggested that “all roads lead to a critical serine 
phosphorylation” (La Spada and Taylor, 2003). This statement accurately summarizes the 
idea that although understanding individual protein context is imperative to 
understanding the pathogenic mechanisms of the separate polyQ diseases, unifying 
themes can be extracted from very specific studies. 
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1.2 Spinal and bulbar muscular atrophy as a model for polyglutamine 
disorders 
 As can be witnessed by many of the aforementioned studies regarding 
aggregation and protein context, Huntington’s disease is the most common as well the 
most actively studied of the rare polyQ disorders. Therefore, many of the initial findings 
that are relevant to all of the polyQ diseases were first found in models of Huntington’s. 
Despite this fact, using Huntington’s as a polyQ disease model has its disadvantages. One 
major drawback is the lack of knowledge pertaining to the functional characterization of 
the wild type htt protein. Research has found roles for htt as an antiapoptotic protein 
(Leavitt et al., 2001) as well as a transcription factor (Gauthier et al., 2004), but many 
gaps have yet to filled, especially in regards to how an expanded polyQ region alters wild 
type huntingtin function. A lack of information pertaining to the native function of the 
proteins involved in the spinocerebellar ataxias also exists in the polyQ field. The one 
true exception to this scenario is the AR whose expanded polyQ stretch results in SBMA. 
The well-characterized properties of the AR make SBMA an attractive disease to study as 
a model for the polyQ disorders, and thus the particulars of SBMA and its associated 
protein will be discussed further in the following sections. 
 
1.2.1 Kennedy’s Disease- the first polyQ disorder 
 X-linked spinal and bulbar muscular atrophy (SBMA), or Kennedy’s disease, was 
first described in 1966 in a scientific abstract by William R. Kennedy, M.D. Two years 
later in 1968, a full report followed describing a sex-linked recessive trait that resulted in 
“progressive proximal spinal and bulbar muscular atrophy of late onset” (Kennedy et al., 
1968). For the next 20 years, any information regarding the disease described as a slowly 
progressive motor neuronopathy came from clinical studies of the rare patients. The sex-
linked aspect of the disease meant that only males were afflicted, and the late-onset 
manifestation of symptoms was typically between the ages of 30-50 years. Patients were 
found to exhibit proximal and facial-bulbar muscle weakness, atrophy, and consistent 
fasciculation (or muscle “twitching”) occurring especially about the lips, chin, and 
tongue. Hand tremors and debilitating muscle cramps were also reported (Stefanis et al., 
1975). Other manifestations were present in the form of endocrine abnormalities, which 
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included gynaecomastia, impaired spermatogenesis, reduced fertility, and testicular 
atrophy (Arbizu et al., 1983). In post-mortem examinations, it was revealed that the 
number of motor neurons in the spinal anterior horns as well as the facial and hypoglossal 
nuclei were severely reduced, and those that remained were atrophic (Fig 1.2) (Harding et 
al., 1982).  
 
 
Figure 1.2 Neuronal regions affected in SBMA from http://www.stanford.edu/group/hopes/rltdsci/trinuc 
 
 Finally in 1991 a breakthrough in the research of patient samples occurred, 
identifying the cause of the disease as a CAG-repeat expansion in the first exon of the 
androgen receptor (AR) gene located on the long arm of chromosome Xq13-21 (La 
Spada et al., 1991). Disease onset was found to occur when this CAG stretch contained 
more than 40 glutamine residues as opposed to the normal range of 9 to 34 glutamine 
residues. This was the first case in which a disease had been linked to an expansion 
mutation of a polyglutamine region, and it kick-started basic research of SBMA. The 
novel mutational discovery also soon led to the identification of the genes for 
Huntington’s and SCA1 (Banfi et al., 1994; Cha and Dure, 1994), resulting in a full 
explosion of basic science research for the newly designated “polyQ disorders”. 
Especially in this early period, as scientists were first beginning to analyze the neuronal 
dysfunction and protein aggregation associated with the polyQ proteins, studying SBMA 
was gainful due to the fact that: (1) the wild type AR was a protein whose physiological 
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functions had been extensively researched, and (2) functional properties of the AR 
allowed for easy manipulation of neurotoxicity in a laboratory setting.  
 
1.2.2 The Androgen Receptor – a unique polyQ protein 
 A member of the nuclear receptor superfamily, the AR is a ligand-inducible 
transcription factor that falls into the categorical subgroup of the steroid/thyroid hormone 
receptor family  (Mangelsdorf et al., 1995). The role of the AR is to mediate the action of 
the sex steroid hormones known as androgens. Androgens play critical roles in the sexual 
development of both males and females but are especially crucial for the male phenotype 
as key players in male sexual differentiation, development and maintenance of male 
secondary characteristics, and the initiation and maintenance of spermatogenesis (George 
and Wilson, 1994). Androgens act on a wide range of target tissues that include those 
closely associated with sexual development as well as the vascular system, central 
nervous system, gastrointestinal tract, immune system, skin, kidney, and lung (Wierman, 
2007). In addition, androgens are central in the development of age-related pathologies in 
men such as development of benign prostate hyperplasia and prostate cancer (Dehm and 
Tindall, 2007). Onset of SBMA can also be counted among these age-related 
pathophysiological events. In fact, the higher levels of circulating androgens in men is a 
central reason as to why females that are homozygous for SBMA display little to no 
symptoms. The prominent androgens in the aforementioned developments are 
testosterone and its metabolite 5α-dihydrotestosterone (DHT). DHT is produced from 
testosterone in the male urogenital tract and peripheral tissues by two isoenzymes of 5α-
reductase (Russell and Wilson, 1994). An increased binding affinity for the AR makes 
DHT the more potent of the two androgens.  
 In order to understand the action of androgens such as DHT, the structure of the 
AR must be taken into consideration (Fig. 1.3). The 110 kDa AR protein is structurally 
similar to its steroid receptor family members, which include the glucocorticoid, 
estrogen, mineralicorticoid, and progestin receptors. The modular structure of the AR 
includes a variable N-terminal domain (NTD) harboring AR transcriptional activation 
function (AF-1), a highly conserved central DNA binding domain (DBD), a short hinge 
region, and a highly conserved C-terminus containing the AR ligand binding domain 
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(LBD) and AF-2 coactivator binding surface (Bain et al., 2007). Other characteristic 
features include three homopolymer tracts of glutamine, glycine, and proline in the NTD 
and a critical nuclear localization signal (NLS) located at the junction of the DBD and 
hinge regions. Three dimensional structures of peptides from the LBD, which consists of 
up to 12 α helices that form a pocket for ligand capture, and AF-2 regions as well as the 
AR DBD have been resolved using X-ray crystallography (Matias et al., 2000). The AR 
N-terminal domain, which encompasses the AF-1 as well as the infamous polyQ region, 
is unstructured in solution and thus has been resistant to structural determination by 
crystallization.  
 In the classical model of AR subcellular dynamics, also referred to as the genomic 
action of the androgen receptor, the unliganded AR is confined in a multi-heteromeric 
inactive complex in the cytoplasm. This complex consists of members of the heat shock 
family of chaperones such as Hsp70 and Hsp90 and high molecular weight 
immunophilins and aids in giving the AR a ligand accessible conformation (Pratt and 
Toft, 1997). Upon binding of a ligand such as DHT, the last α helix of the LBD shifts to 
provide a key interaction interface. The composition of the AR/chaperone complex is 
also altered, allowing exposure of the NLS and subsequent translocation to the nucleus. 
There it interacts with DNA as a homodimer at androgen response elements (AREs) 
found in the regulatory regions of target genes. The resulting complex is able to recruit 
coactivators through the ligand-dependent transactivation function (AF-2) of the LBD 
and the autonomous activation function (AF-1) of the NTD and thus activate transcription 
of the specific target genes (Zhou et al., 1994; Jenster, 1998; Dehm and Tindall, 2007). 
The amino acid repeat regions of the NTD have additionally been reported to affect this 
process. AR transcriptional activity has been shown to be inversely correlated with the 
length of the polyQ stretch in vitro (Kazemi-Esfarjani et al., 1995) while complete 
deletion of the polyglycine region severely hampers transactivation activity (Gao et al., 
1996). Outside of its transcription factor status, the AR may also regulate events in the 
cytoplasm by participating in rapid/non-genomic signaling cascades (Freeman et al., 
2005). However, it is the binding of ligand and nuclear translocation that is the essential 
method of action for SBMA pathology; and therefore the AR is unique among the polyQ 
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proteins in its dependence on ligand activation (Takeyama et al., 2002; Chevalier-Larsen 
et al., 2004; Katsuno et al., 2004).  
 
 
 
 
Figure 1.3 Androgen receptor structural domains and phosphorylation sites 
 
1.2.2.1 Manipulating the AR in SBMA models – ligand binding, nuclear localization, 
and transcriptional activity 
 The ligand inducible properties of the AR have been used advantageously to study 
the specific disease mechanisms of SBMA as well as general toxic properties that are 
applicable for all of the polyQ disorders. With the ability to modulate the introduction of 
ligand to cell or animal model systems, induction of aggregation and toxicity and 
detrimental effects on particular cellular processes have been able to be examined in a 
controlled manner. For example, researchers have utilized androgen agonists and 
antagonists in conjunction with AR constructs of specific domains to determine the 
importance of nuclear translocation in the onset of SBMA. Using a Drosophila model of 
SBMA, one group found that using androgen antagonists such as hydroxyflutamide and 
bicalutamide that suppress the transactivation function of the mutant AR but still allow 
nuclear translocation resulted in an aggravated phenotype (Takeyama et al., 2002). In 
addition, an N-terminal fragment of the AR containing an expanded polyQ stretch and 
and NLS region but no DBD or LBD was sufficient to induce neurodegeneration in the 
fly model. These results suggested that the presence of the polyQ AR in the nucleus is a 
major factor for induction of toxicity. As nuclear localization is also a common theme 
among the polyQ disorders, having a clearly defined scenario for the AR also makes 
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SBMA a good model to examine the molecular mechanisms of polyQ toxicity in the 
nucleus.  
 Once a polyQ protein such as the AR is in the nucleus, one of the logical 
candidates for the progression of polyQ toxicity is an interference with gene 
transcription. In fact, a functional commonality of the polyQ proteins is that each 
functions at some level of transcriptional regulation, either directly or indirectly through 
intracellular signaling (Truant et al., 2007). Again, because the AR is itself a transcription 
factor whose presence in the nucleus can be modulated by hormone induction, SBMA 
models are ideal to study abnormal interactions with coactivator or corepressor 
molecules. The most obvious change for the polyQ expanded AR is its own suppressed 
transcriptional activity, as previously mentioned, that includes altered mediation by 
coactivators such as members of the group of the 160-kDa nuclear receptor (p160) 
coactivators and ARA24 (Hsiao et al., 1999; Irvine et al., 2000).  However, the presence 
of the polyQ stretch also alters other transcriptional pathways. One such abnormal 
interaction is the sequestration into nuclear inclusions of cAMP-responsive element 
binding protein (CREB)-binding protein (CBP), a transcriptional coactivator that is 
involved in numerous signaling cascades (McCampbell et al., 2000). This sequestration, 
which interferes with CREB and CBP-dependent transcription, was first discovered in 
SBMA and was subsequently found to apply to most if not all of the polyQ disorders 
(Steffan et al., 2000; Nucifora et al., 2001; Stenoien et al., 2002). Another change in 
interaction has been reported to occur in relation to AR/c-Jun mediated transcription. The 
AR and c-Jun interact normally to regulate each other’s transcriptional activity, and the 
polyQ stretch disrupts this interaction (Grierson et al., 1999). c-Jun acts as a mediator of 
cell survival and apoptosis and is part of the c-Jun NH2-terminal kinase (JNK) pathway, 
which responds to cellular stress and has also been associated with Huntington’s, SCA7, 
and DRPLA (Liu, 1998; Okamura-Oho et al., 2003; Merienne et al., 2007). 
 
1.2.2.2 Manipulating the AR in SBMA models – mutations of sites of covalent 
modifications 
 Between the events of ligand binding of the AR and activation of transcription of 
target genes, several post-translational modifications such as acetylation and 
 17
phosphorylation of the receptor occur (Fu et al., 2000; Gioeli et al., 2002; Lieberman et 
al., 2002). As previously discussed, covalent modifications of the polyQ proteins have 
been shown to have profound effects on the pathogenic mechanisms of the polyQ 
disorders.  SBMA is no exception; and moreover, the AR has the distinct advantage over 
the other polyQ proteins in that many of these acetylation and phosphorylation sites are 
already well characterized in the wild type context of the protein. An example is given by 
the ligand-dependent acetylation of the AR at lysines 630, 632, and 633. Acetylation of 
these sites, which are located next to the NLS on the carboxy-terminal side, has been 
associated with enhanced p300 coactivator binding and the regulation of transcription of 
certain target gene promoters (Fu et al., 2003) Mutation of these sites to alanine in the 
wild type AR resulted in disruption of ligand-dependent nuclear translocation, a marked 
increase in aggregation upon hormone treatment, and inhibition of proteasome function 
(Thomas et al., 2004). Each of these features was reminiscent of the polyQ expanded AR, 
suggesting that decreased acetylation of the AR containing a glutamine expansion may 
contribute to SBMA pathology.  
 The AR has been shown to be a phosphoprotein whose phosphorylation status 
changes after exposure to androgens (van Laar et al., 1990; van Laar et al., 1991). 
Compounded with the fact that most of these phosphorylation sites are located in the 
polyQ-containing NTD (Fig 1.2), it seems intuitive that phosphorylation could play an 
important role in the molecular mechanisms of SBMA. Specific phosphorylation sites 
that have been utilized in mutational studies thus far include Akt phosphorylation 
consensus sites at serine 215 and 792 (Palazzolo et al., 2007) as well as a MAPK 
phosphorylation consensus site at serine 514 (LaFevre-Bernt and Ellerby, 2003). In the 
case of AR phosphorylation due to the IGF-1/Akt pathway, overexpression of Akt has 
been shown to result in a destabilization of the receptor (Lin et al., 2002); and more 
specifically, Akt phosphorylation at serine 215 was previously shown to be associated 
with an inhibition of wild type AR mediated transcription (Taneja et al., 2005). In a 
recent study, Akt was also shown to phosphorylate the AR containing a polyQ expansion. 
Furthermore, mimicking phosphorylation at Akt serine sites 215 and 792 by substitution 
with aspartate residues resulted in reduced ligand-binding, nuclear translocation, and 
transcriptional activity of both the wild type and mutant AR. These effects also 
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corresponded with a reduced toxicity for the AR containing the polyQ expansion, 
suggesting that the IGF-1/Akt signaling pathway could be utilized for developing 
therapeutic targets. As briefly mentioned in an earlier section, the ERK1/2 pathway has 
also been implicated in SBMA. Disruption of ERK1/2 signaling using a specific inhibitor 
was found to reduce polyglutamine cell death and was also correlated with a change in 
AR phosphorylation (LaFevre-Bernt and Ellerby, 2003). This alteration in 
phosphorylation status was contributed to a change in phosphorylation at the MAPK 
consensus site serine 514. Substitution of this serine with an alanine residue again 
resulted in a reduction of polyQ toxicity as well as a reduction in associated caspase 
cleavage products. Unlike the serine 215 and 792 sites, how the phosphorylation status at 
serine 514 effects the wild type AR was not investigated.  
 
1.2.2.3 Manipulating the AR in SBMA models – utilizing model system to full potential  
  Current research has yielded several separate studies for the individual polyQ 
disorders that have revealed the significance of protein context and have demonstrated 
that manipulating neighboring sequences or domains of the polyQ proteins can greatly 
affect toxicity. Unfortunately, many of these studies have been narrowly focused and 
have not thoroughly examined effects on both wild type and polyQ expanded proteins.  
Studies involving covalent modifications have also tended to focus on global changes in 
aggregation and toxicity, without further classification of different types of aggregate 
species. Additionally, all of these studies were carried out in cell culture systems and 
have not been confirmed in animal models. In the case of the AR, where many sites of 
covalent modifications have yet to be characterized in the context of the polyQ stretch, 
there are several uninvestigated prospects that could yield much insight into the 
mechanisms of SBMA and the polyQ disorders as a group. These include: (1) 
investigation of characterized sites of covalent modification in wild type and polyQ 
backgrounds, (2) careful consideration to differences in aggregate species and toxicity, 
and (3) utilization of animal models. 
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1.3 Animal models of the polyglutamine disorders 
 Mouse and Drosophila models have now been created for most of the polyQ 
disorders. While these models have not been utilized to examine some of the subtleties 
involved in the importance of protein context for the polyQ disorders, they have enabled 
the field to advance in areas such as interacting partners that convey selective neuronal 
vulnerability (Sopher et al., 2004), characterization of toxic aggregate species (Li et al., 
2007), and potential therapeutic strategies (Pandey et al., 2007). However, recapitulating 
certain key aspects of the diseases has proven challenging. In the next sections, the 
difficulties, advantages, and disadvantages of the different types of models will be 
discussed with an emphasis on models for SBMA.  
 
1.3.1 Mouse models 
 The first polyQ mouse model was created in 1995 in order to replicate the disease 
symptoms observed in SCA1. This model was created using a full length ataxin1 with 
glutamine stretches of 30 and 82 amino acids, and ataxin1 expression was driven by a 
Purkinje cell-specific promoter (Burright et al., 1995). While this model was quite 
successful in mimicking many aspects of SCA1, morphological changes of the Purkinje 
cells did not exactly correlate with those seen in the human disease; and researchers were 
also still uncertain whether expression of the full-length protein was necessary for 
pathogenesis. These first particular dilemmas became common obstacles for the creation 
of reliable polyQ mouse models. The mouse models of Huntington’s, SCA3, and SBMA 
that soon followed therefore experimented with many different approaches to solve these 
problems. These approaches included testing the toxicity of truncated fragments versus 
full-length protein, working with different neuronal specific promoters, and 
experimenting with different levels of expression and polyQ lengths (Yamada et al., 
2007). To date, mouse models have been created for all of the polyglutamine disorders 
except SCA6 and SCA17.   
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1.3.1.1 Mouse models of SBMA 
 The earliest mouse models of SBMA were not as successful as the first SCA1 
mouse model in recapitulating aspects of the human disease. The first model, established 
in the same year as the SCA1 model, used a neuron specific promoter to drive human AR 
cDNA with a glutamine region of 44 amino acids, a common length in SBMA patients 
(Bingham et al., 1995). This model surprisingly did not exhibit any neurological defects 
and also lacked the generational repeat instability seen in families afflicted with SBMA. 
Two other early models also failed to demonstrate neurological phenotypes in mice up to 
two years of age despite being able to reproduce repeat instability (La Spada et al., 1998) 
or having higher expression levels and a longer polyQ length of 65.  
 The next two attempts to replicate SBMA in mouse models utilized truncated 
fragments rather than the full-length AR. One group created a model system using a 
truncated AR with a polyQ stretch of 112 driven by the widely expressed prion protein 
promoter or the neurofilament-light chain promoter, which exhibits a more limited 
expression pattern (Abel et al., 2001). A second group developed a mouse using the AR 
promoter to drive expression of a polyQ tract of 239 glutamines, an exaggerated size over 
what is seen in human patients (Adachi et al., 2001). Both models effectively reproduced 
neurological symptoms, which included gait abnormalities and muscle weakness. 
Neuronal nuclear inclusions were also found to be present throughout the brain and spinal 
cord. Severity and onset of symptoms varied with the expression patterns of the 
promoters as well as the length of the polyQ tracts. A major drawback to both models, 
however, was the lack of motor neuronal specificity as well as gender specificity. These 
particular aspects seemed to require components present in the full-length receptor.  
 The most recent group of transgenic models have all expressed the full-length AR 
but with different levels and patterns of expression and to varying degrees of success. 
The first of these full-length models used an AR with 97 glutamines under the control of 
the cytomegalovirus (CMV) enhancer and the chicken β-actin promoter (Katsuno et al., 
2002). These mice exhibited characteristic signs of muscle atrophy and neuronal 
intranuclear inclusions, and symptoms were enhanced in male mice. However, there was 
an absence of neuronal cell death. A similar scenario of neuronal inclusions but lack of 
cell death was also evident in mice expressing a 112 polyQ AR driven by the prion 
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promoter (Chevalier-Larsen et al., 2004). Oddly enough, the opposite development was 
seen in two other mouse models. Mice expressing an AR with 120 glutamines under the 
control of the CMV promoter experienced neuronal loss and muscular atrophy but 
showed a lack of inclusion formation (McManamny et al., 2002). The most recently 
published model took advantage of heterologous yeast artificial chromosome (YAC) 
transgenesis in order to express an AR containing 100 glutamines at near endogenous 
levels, under control of endogenous AR regulatory elements (Sopher et al., 2004). This 
model recapitulated key elements of motor neuronal specific cell death, muscle 
pathology, and gender specificity. However, these mice also failed to exhibit nuclear 
inclusions.  
 A mouse model that fully recapitulates all of the essential neuropathological 
aspects of SBMA, or any of the other polyQ disorders, has yet to be established. 
Nevertheless, the models have brought information to the field; including the knowledge 
that clinical onset of symptoms is not clearly dependent upon neuronal death. Rather, the 
phenotypes in mice lacking neuronal death may be due to increased neuronal dysfunction 
(Merry, 2005; Yamada et al., 2007). Additionally, the models have highlighted the idea 
that neuronal intranuclear inclusions may be cytoprotective and that pathology may be 
more directly linked to toxic intermediary structures. A recent study did indeed find that 
soluble oligomeric species underlined the pathology of the AR112 prion promoter mouse 
model (Li et al., 2007). The difficulties in producing accurate models, and especially in 
reproducing neuronal death, suggests that pathogenesis in the models is related to mutant 
protein levels and the amount of time a neuron is exposed to the mutant polyQ protein. It 
is possible that the approximate two year life span and aging process of the mouse may 
not be sufficient time for mouse neurons to acquire an amount of toxic intermediates and 
cellular damage that is comparable to that seen in the decades-long human process 
(Yamada et al., 2007). Therefore alternative approaches have also been sought to model 
the polyQ diseases.  
 
1.3.2 Invertebrate models –Drosophila and C. elegans 
 After initial efforts were made to mimic the polyQ disorders in mice, scientists 
experimented with invertebrate model systems to explore if other models could prove 
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successful where the mouse models were facing difficulties. Invertebrate models have a 
distinct advantage over their mammalian counterparts due to rapid reproductive cycles 
and short life spans (Fig 1.4), which allow rapid construction of different transgenic 
models and quick evaluation of pathological phenotypes as well as experimental 
therapeutic interventions. Yet another advantage is the ability to perform nonbiased 
screens for suppressors or enhancers of polyQ toxicity. To date, both Drosophila 
melanogaster (fruit fly) and Caenorhabditis elegans (nematode) models have been 
utilized to model human neurodegenerative diseases, including the polyQ disorders. 
Models of Alzheimer’s disease in Drosophila and C. elegans preceded work on the 
polyQ disorders and gave substantial evidence that these animal systems could be used to 
model such age-related disorders (Luo et al., 1992; Link, 1995).  
 The first Drosophila model of a polyQ disorder directed expression of an N-
terminal htt fragment to the fly eye using the eye specific expression construct pGMR 
(glass multimer reporter) (Jackson et al., 1998). The fly eye was specifically employed 
because of its proven viability as a genetic system for investigation of cellular processes, 
especially those associated with cell death (Wolff et al., 1997). The Drosophila eye is a 
highly regular and organized structure of around 800 individual units and any 
morphological disruption of this organization can be clearly visualized. This first study 
demonstrated that a polyQ expanded htt could induce age-related cell death by apoptosis 
and cause the formation of inclusions in neurons of the fly eye. The many Drosophila 
models that have followed have opted for the GAL4-UAS expression system (Fig. 1.4) in 
which a promoter (or enhancer) directs expression of the yeast transcriptional activator 
GAL4 in a specific pattern and GAL4 in turn directs transcription of the GAL4-
responsive UAS target gene in an identical pattern. Using this more flexible approach, 
investigators have been able to direct polyQ expression to the eye photoreceptors to look 
again at neurodegeneration in the eye, pan-neuronally to examine survival and behavioral 
effects, and to other types of cells to examine cell type specificity (Warrick et al., 1998). 
Another interesting aspect of using the GAL4-UAS system is that it provides an 
additional amplification step, leading to higher levels of expression of the particular 
polyQ construct. This results in an earlier onset of pathogenesis for these models in 
comparison to the first model produced by Jackson, et al. Fly models using the GAL4-
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UAS system have thus far been created for Huntington’s, SBMA, DRPLA, SCA1, SCA2, 
SCA3, and SCA7. In addition, expression of polyQ tracts alone has been shown to be 
sufficient to induce pathogenesis in Drosophila (Marsh et al., 2000). 
 
 
 
Figure 1.4 Drosophila model system (A) Life cycle of Drosophila melanogaster (Weigmann et al., 2003) 
(B) GAL4-UAS system in Drosophila 
 
 With models existing only for Huntington’s and isolated polyQ tracts, C. elegans 
have not been used quite as extensively as Drosophila to model the polyQ disorders. 
Nevertheless, the existing models have proven to be valuable to the field. One distinct 
advantage of the C. elegans model is the ability to precisely identify specific neurons and 
follow their development or survival throughout the animal's lifetime. Utilizing such 
methods, researchers found that neurons expressing a polyQ htt fragment exhibited 
functional impairment prior to aggregate formation, neurodegeneration, and cell death 
(Faber et al., 1999). The relative ease of visualization of the nematode’s structure has also 
allowed for investigation of protein aggregates; their influence on toxicity; and in turn, 
the influence of molecular chaperones on aggregate formation (Satyal et al., 2000). More 
recent studies have used the nematode to examine potential drug therapies (Voisine et al., 
2007) as well as roles of protein interaction partners (Parker et al., 2007).  
 Both Drosophila and C. elegans have been proven as sound model systems with 
their ability to replicate the aggregate formation, neurotoxicity, and behavioral 
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characteristics of the polyQ disorders. A recent study has also demonstrated that 
Drosophila polyQ models reproduce features of human CAG repeat instability, another 
central aspect of the polyQ disorders (Jung and Bonini, 2007). With this in mind, the 
Drosophila system perhaps has the advantage over C. elegans in that: (1) scientists have 
been utilizing Drosophila in genetics for about fifty years longer resulting in a model 
system that is therefore more widespread and (2) Drosophila have a more complex 
nervous system and behavioral paradigm with a development that is more similar to 
mammals. 
   
1.3.2.1 Modeling SBMA in Drosophila 
 For SBMA in particular, Drosophila models have been able to recapitulate key 
aspects of the polyQ disorder. The first SBMA fly models appeared almost 
simultaneously in 2002. The first model (Takeyama et al., 2002) expressed a full length 
human AR containing a stretch of 52 glutamines in the fly eye and clearly demonstrated 
for the first time that pathology was dependent upon ligand-induced nuclear 
translocation. The second model (Chan et al., 2002) used quite a different approach, 
expressing only an N-terminal fragment of the AR with a polyQ region of 112 to 
demonstrate aggregation and neurodegeneration. More importantly, this study showed 
that increased chaperone activity alleviated degeneration while disruption of proteasome 
activity resulted in enhanced neurodegenerative phenotypes. The most recent addition to 
the SBMA models has also used Drosophila to investigate aspects of the ubiquitin-
proteasome system involved in the disease (Pandey et al., 2007). By directing expression 
of a full-length AR with 121 glutamines to the fly eye, this study showed that proteasome 
impairment was associated with ligand-induced toxicity. Furthermore, it was found that 
expression of histone deactylase 6 (HDAC6), a microtubule-associated deacetylase that 
interacts with polyubiquitinated proteins, alleviated toxicity by promoting compensatory 
autophagy of the aberrant protein. Therefore, regulation of HDAC6 may be a possible 
therapeutic approach for intervening with the neurodegeneration process.  
 As seen in the SBMA models discussed above, some of the essential reasons for 
use of polyQ animal model systems are the ability to further elucidate the mechanisms of 
the disorders in vivo through manipulation of cellular pathways and possible interaction 
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partners, investigation of in vivo aggregate formation, and use of this information for the 
screening and testing of compounds to alter aggregate formation and toxicity ((Furutani 
et al., 2005; Desai et al., 2006; kQi et al., 2007; Latouche et al., 2007).  
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1.4 The path to therapy- therapeutic compounds for inhibiting 
polyglutamine toxicity 
 All paths of research of the polyQ disorders eventually lead to the question, “How 
can this research benefit those suffering from the rare disorders?” In this respect, both 
mouse and Drosophila models have been critical in the screening and testing of various 
potential therapeutic agents. As is the case with many of the aforementioned studies, 
some findings have been applicable in only the context of a specific protein and disease, 
such as the AR and SBMA. However, a few tested treatments have been aimed at the 
common aspects of the diseases and have thus been found appropriate for multiple polyQ 
disorders.  
 
1.4.1 SBMA specific therapies 
 The unique aspect of SBMA being a ligand-induced polyQ disorder also means 
that the disease has a unique therapeutic target, the AR ligand testosterone. This is 
evident in the full-length polyQ AR Drosophila models in that no neurodegeneration is 
seen in the absence of hormone administration. Mouse models have been used to 
demonstrate that deprivation of androgens result in a vast improvement over the 
pathological phenotype. The elimination of androgens by surgical castration of an SBMA 
male mouse with an AR of 112 glutamines resulted in a partial recovery of motor 
function. Neurofilament heavy chain levels, which were reduced in the SBMA model, 
were also partially restored (Chevalier-Larsen et al., 2004). An alternative to surgical 
castration is the use of leuprolin as a therapeutic compound. Leuprolin is a lutenizing 
hormone-releasing hormone agonist that reduces testosterone levels from the testis; 
essentially it is an agent for chemical castration. In a mouse model expressing a full-
length AR with a polyQ stretch of 97 residues, administration of leuprolin rescued motor 
dysfunction and nuclear aggregation of the mutant AR in male mice (Katsuno et al., 
2003). Although androgen ablation therapy shows much promise as a method for treating 
SBMA, the treatment comes with many drawbacks for the patient. Surgical or even 
chemical castration is not something to be taken lightly as both sexual function and 
fertility are highly affected. Therefore, researchers are continually seeking out other 
possible therapeutic targets for SBMA. 
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 Another specific target for SBMA therapy came to light when Sopher et al., 
published a mouse model that implicated altered expression of vascular endothelial 
growth factor (VEGF) in the motor neuronal death that is characteristic of the disease 
(Sopher et al., 2004). VEGF is important in the maintenance of motor neuronal health 
and survival; and its expression is regulated by the transcriptional cofactor CBP, whose 
function has been shown to be disrupted in the polyQ disorders by sequestration along 
with other transcriptional regulators into the mutant protein aggregates (Nucifora et al., 
2001). A recent study found that the synthetic chemical compound 5-hydroxy-1,7-
bis(3,4-dimethoxyphenyl)-1,4,6-heptatrien-3-one (ASC-J9), a compound loosely based 
on a component of the spice curcumin, was able to disrupt the interaction of the mutant 
AR with AR coregulators in the aggregate species in an SBMA mouse model (Yang et 
al., 2007). This not only led to a decrease in aggregation but also to an increase in the 
expression of the VEGF isoform VEGF164, the mouse equivalent of isoform VEGF165 
in humans. Motor impairment was also greatly improved. These results point to an 
alternative SBMA treatment that eliminates the side effects of altering serum testosterone 
levels. Other alternatives may also be found in treatments that are appropriate for more 
general polyQ targets.  
  
1.4.2 General polyQ inhibitors 
 Many therapeutic strategies have concentrated on suppressing protein aggregation 
or inhibiting neuronal apoptosis in a particular polyQ disorder. Because such themes are 
common to the polyQ diseases as a group, these strategies have proven to be generally 
applicable. For example, upregulation of heat shock proteins and molecular chaperones 
such as Hsp40 and Hsp70 that play critical roles in protein folding has been shown to 
inhibit toxicity in several different models (Chai et al., 1999; Cummings et al., 2001; 
Adachi et al., 2003). Inhibition or modulation of the function of Hsp90, which regulates 
the activity, turnover, and trafficking of many proteins, has also been shown to reduce 
aggregation and ameliorate the toxic phenotypes of SBMA and Huntington’s (Sittler et 
al., 2001; Thomas et al., 2006a). Neuronal death has been tackled by investigating ways 
to inhibit caspase-associated cell death (Sanchez et al., 1999) and testing various agents 
with neuroprotective properties such as lithium chloride, basic fibroglast growth factor 
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(FGF-2), humanin, glial cell-line derived neurotrophic factor (GDNF), and estrogen 
(Darrington et al., 2003; McBride et al., 2003; Jin et al., 2005; Kariya et al., 2005; Watase 
et al., 2007). Another method that encompasses reducing both aggregation and cell death 
has been to target transcriptional dysregulation, which is believed to be a major cause of 
neuronal dysfunction in the polyQ disorders. 
  
1.4.2.1 HDAC inhibitors 
 Histone deacetylases (HDAC) and histone acetyl transferases (HAT) work in 
conjunction to modify chromatin by removing or adding acetyl groups to histones and 
thereby inhibiting or activating transcription, respectively (Marks et al., 2001). In the 
polyQ disorders, the HAT activity of transcriptional regulators such as CBP is disrupted 
due to recruitment into polyQ aggregates (Kazantsev et al., 1999). This interference with 
the transcriptional machinery results in cell death that is directly associated with the 
decreased histone acetylation (McCampbell et al., 2001). Correcting this imbalance of 
acetylation/deacetylation with administration of HDAC inhibitors has been found to 
greatly reduce polyQ toxicity in Drosophila and mouse models (Hockly et al., 2003; 
Agrawal et al., 2005).  
 Specific HDAC inhibitor compounds that have been tested for the polyQ 
disorders include suberoylanilide hydroxamic acid (SAHA) and sodium butyrate. SAHA 
is a hybrid polar compound that inhibits HDAC1 and HDAC3 and causes 
hyperacetylation of histone H4 (Richon et al., 1998). With SAHA’s ability to cross the 
blood-brain barrier, administration of the compound was able to improve motor 
impairment in a Huntington’s mouse model (Hockly et al., 2003). However, major 
drawbacks to the use of SAHA are its insolubility in aqueous solution and the potential 
lethal toxicity of the compound. An alternative to SAHA is the less toxic HDAC inhibitor 
sodium butyrate, a short-chain fatty acid that is produced in the colonic lumen as a 
consequence of microbial degradation of dietary fibers (Joseph et al., 2004). Sodium 
butyrate has shown potential therapeutic benefits of reduced toxicity and motor 
improvement in Drosophila models of Huntington’s and SCA7 as well as mouse models 
of SBMA and DRPLA (Steffan et al., 2001; Minamiyama et al., 2004; Ying et al., 2006; 
Latouche et al., 2007). However, as noted in the study of the SBMA mouse model, the 
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dosage range of sodium butyrate that yields these benefits is very narrow; thus making 
dosage determination for clinical studies potentially problematic. 
  
1.4.2.2 Melatonin as a candidate polyglutamine inhibitor 
 Although there have been a few success stories of therapeutic compounds 
performing well in animal models, a smooth path to clinical trials is rarely imminent. 
This is especially true for novel synthetic compounds that may show toxic side effects. 
Therefore, instead of reinventing the wheel, an alternative method is to examine 
compounds that have been through clinical testing for other purposes and are known to be 
safe for human patient administration. An example of such a candidate inhibitor for the 
polyglutamine disorders is melatonin. Melatonin, a hormone secreted mainly by the 
pineal gland in humans, plays a central role in the circadian cycle and is also well-
recognized as a powerful antioxidant. It has been marketed as a general health 
supplement in the United States since 1993 (Lewis and Clouatre, 1999) and has been 
studied for the treatment of cancer, immune disorders, cardiovascular diseases, 
depression, seasonal affective disorder, and sexual dysfunction (Waldhauser et al., 1993; 
Sewerynek, 2002; Shiu, 2007). However, it is melatonin’s role as a free radical scavenger 
and general antioxidative protectant that researchers first recognized may be beneficial 
for several neurodegenerative disorders. 
 Production of melatonin declines in a physiological-age dependent manner, and 
this reduction in melatonin levels has been associated with the oxidative stress and 
degenerative changes that occur with aging (Srinivasan, 1997). Moreover, such oxidative 
damage has been implicated as a major factor in age-associated disorders such as 
Alzheimer’s, Parkinson’s, and the polyglutamine disorders (Markesbery, 1997; Goswami 
et al., 2006; Lavoie et al., 2007). A major source of oxidative damage in these disorders 
is due to mitochondrial dysfunction. Melatonin has been found to be a potent antagonist 
of mitochondrial radical formation, thus demonstrating neuroprotective benefits. In 
addition to its antioxidant role, melatonin has also been shown to have antifibrillogenic 
actions that can disrupt β-amyloid toxicity (Matsubara et al., 2003; Cheng and van 
Breemen, 2005).  These properties give melatonin much potential as an inhibitor of 
polyQ toxicity. 
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1.5 Aims 
 For the group of debilitating neurodegenerative diseases known as the 
polyglutamine disorders, there is still much to be discovered on the path to effective 
therapies. Previous studies have shown that much can be learned from investigation of 
the individual diseases. Utilizing the disorder spinal and bulbar muscular atrophy as a 
model for polyQ toxicity due to the unique properties of its associated polyQ protein, the 
androgen receptor; the aim of this work was to further investigate how specific sites 
neighboring the polyQ region affect aggregation and toxicity in both expanded polyQ and 
wild type situations. A further point to be addressed was how any alterations in aggregate 
species correlated with differences in toxic properties exhibited in a Drosophila model of 
SBMA. Lastly, the ability of the HDAC polyQ inhibitor sodium butyrate to affect the 
varied toxic properties brought about by the mutation of neighboring sites was 
investigated in conjunction with investigating the therapeutic potential of melatonin. 
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2.0 MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Chemicals and consumables 
Name Source 
Acrylamide Roth, Karlsruhe 
Agar (strands) Probio GmbH, Eggenstein 
Agarose Peqlab, Erlangen 
Ampicillin Roth, Karlsruhe 
Ammonium Persulfate (APS) Roth, Karlsruhe 
5α-Androstan-17ß-ol-3-one (DHT) Sigma-Aldrich Chemie, Steinheim 
Bovine Serum Albumin (BSA) PAA Laboratories GmbH, Pasching 
Apple Juice Various sources 
Bacto-Agar Otto Nordwald GmbH, Hamburg 
Bacto-Trypton Roth, Karlsruhe 
Beer Yeast Probio GmbH, Eggenstein 
Bromophenol blue Sigma-Aldrich Chemie, Steinheim 
Chloroform Merck, Darmstadt 
Cornmeal Friedrichstal Mühle, Stutensee 
Dimethylsulfoxide (DMSO) Fluka, Neu Ulm 
Dithiothreitol (DTT) Gibco, Invitrogen, Karlsruhe 
DNA Marker 1kb PeqLab, Erlangen 
Dulbecco’s Modified Eagle Medium Gibco, Invitrogen, Karlsruhe 
Ethylenediamine Tetraacetic Acid (EDTA) Roth, Karlsruhe 
Ethanol (EtOH) Roth, Karlsruhe 
Ethidium Bromide Roth, Karlsruhe 
Glycylglycerine Roth, Karlsruhe 
Glycine Roth, Karlsruhe 
Glycerol Roth, Karlsruhe 
Glucose Roth, Karlsruhe 
Hydrogen Chloride (HCl) Merck, Darmstadt 
Isopropanol, Propan-2-ol Merck, Darmstadt 
D-Luciferin Firefly Biosynth AG, Staad 
Magnesium Chloride Roth, Karlsruhe 
Magnesium Sulfate Roth, Karlsruhe 
Melatonin Sigma-Aldrich Chemie, Steinheim 
Methanol (MeOH) Roth, Karlsruhe 
β -Mercaptoethanol Roth, Karlsruhe 
Milk Powder Saliter, Obergünzburg 
Mowiol 40-88 (Polyvinyl alcohol) Sigma-Aldrich, Taufkirchen 
Nipagin (Methyl-p-Hydroxybenzoate) Sigma-Aldrich, Taufkirchen 
1X and 10X Phosphate Buffered Saline 
(PBS) - /- Ca 2+ and Mg 2+ 
Gibco, Invitrogen, Karlsruhe 
Penicillin/Streptomycin Gibco, Invitrogen, Karlsruhe 
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Phenol Roth, Karlsruhe 
Potassium Chloride Merck, Darmstadt 
Protein marker PeqLab, Erlangen 
Rotisol Roth, Karlsruhe 
Saccharose Roth, Karlsruhe 
Sodium Acetate Roth, Karlsruhe 
Sodium Butyrate Sigma-Aldrich Chemie, Steinheim 
Sodium Chloride Roth, Karlsruhe 
Sodiumdodecylsulfate (SDS) Roth, Karlsruhe 
Sodium Hydroxide Roth, Karlsruhe 
Sodium Hypochlorite Solution Roth, Karlsruhe 
Sugar Syrup Grafschafter Krautfabrik, Meckenheim 
Tetramethylethylenediamine (TEMED) Roth, Karlsruhe 
Tris-Base Roth, Karlsruhe 
Tris-HCl Roth, Karlsruhe 
Triton X-100 Sigma-Aldrich, Taufkirchen 
Trypsin Difco, Detroit 
Tween 20 Roth, Karlsruhe 
Voltalef Halocarbon Oil Lehmann and Voss and Co., Hamburg 
Yeast (fresh) Various sources 
Yeast extract Gibco, Invitrogen, Karlsruhe 
 
 
2.1.2 Enzymes 
All restriction endonucleases and other modifying enzymes were purchased from 
Invitrogen GmBH (Karlsruhe, Germany), New England Biolabs (Beverly, USA) or 
Promega (Mannheim,Germany). 
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2.1.3 Plasmids and constructs 
 
Reporter gene and expression-plasmids for transient transfection in cells: 
 
Name Description 
pGl3MMTV Encodes the firefly luciferase gene under the control 
of the mouse mammary tumour virus (MMTV) long 
terminal repeat cloned as a BamHI/BglII fragment 
from the plasmid pHCwtCAT (Kaspar et al., 1993) 
Renilla-tk-luc Vector containing cDNA encoding Renilla luciferase. 
Used as internal control. Obtained from Promega. 
(Mannheim, Germany) 
pSG5-ARwt Expression plasmid with the cDNA of the human wild 
type androgen receptor. The receptor contains a 
polyglutamine region of 22 amino acids. 
pSG5-ARQ77 Expression plasmid with the cDNA of the human 
androgen receptor with an expanded polyglutamine 
region of 77 amino acids. 
pSG5-ARwt MAPk/423 Ala 
(ARQ22dm) 
Expression plasmid with the cDNA of the human 
androgen receptor with polyglutamine region of 22 
amino acids. Serines 424 and 514 are mutated to 
alanine. 
pSG5-ARQ77 MAPk/423 Ala 
(ARQ77dm) 
Expression plasmid with the cDNA of the human 
androgen receptor with expanded polyglutamine 
region of 77 amino acids. Serines 424 and 514 are 
mutated to alanine. 
 
ARQ22 and ARQ77 were obtained by subcloning the respective AR sequence 
into the expression vector pSG5 as previously described (Becker et al., 2000). Serine 
residues at positions 424 and 514 were exchanged into alanines by the Quikchange 
mutagenesis method (Stratagene., La Jolla, CA) to generate ARQ22dm and ARQ77dm 
expression vectors. 
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Vectors and expression-plasmids for Drosophila injection: 
 
Name Description 
pΔ2,3 Helper-plasmid for P-element vector 
pUAST P-element vector with white eye gene that acts as a 
marker for successful incorporation into the 
Drosophila genome 
pUASt-ARwt 
 
Drosophila P-element plasmid containing cDNA of 
the human wild type androgen receptor. The receptor 
contains a polyglutamine region of 22 amino acids. 
pUASt-ARQ77 
 
Drosophila P-element plasmid containing cDNA of 
the human androgen receptor with an expanded 
polyglutamine region of 77 amino acids. 
pUASt-ARwt MAPk/ 423 Ala 
(ARQ22dm) 
Drosophila P-element plasmid containing cDNA of 
the human androgen receptor with polyglutamine 
region of 22 amino acids. Serines 424 and 514 are 
mutated to alanine. 
pUASt-ARQ77 MAPk/ 423 
Ala 
(ARQ77dm) 
 
Drosophila P-element plasmid containing cDNA of 
the human androgen receptor with expanded 
polyglutamine region of 77 amino acids. Serines 424 
and 514 are mutated to alanine. 
 
Each of the AR sequences (ARQ22, ARQ22dm, ARQ77, and ARQ77dm) was 
cloned into the BamHI/BglII site of the P element vector pPUAST (Brand and Perrimon, 
1993). 
  
 
2.1.4 Bacteria and eukaryotic cells 
 
Bacterial cells 
 
Name Genotype 
E. coli DH 5 α (for cloning) 
 
F-, end A1, hsd R17 (rk-, mk+), sup E44, thi-1, λ-, rec A1, 
gyr A96, relA1 
 
Eukaryotic cell lines 
 
Name Description 
COS7 
 
Simian kidney cell line: androgen receptor deficient. 
COS7 cells were cultivated in DMEM supplemented with 
10% fetal bovine serum (FBS) unless otherwise indicated. 
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2.1.5 Drosophila melanogaster lines 
 
Name  Description (Source) 
w1118 Drosophila line used for injections. Expresses gene for 
white eyes. (Bloomington Drosophila Stock Center) 
ELAV-Gal4 
(embryonic lethal, 
abnormal vision) 
Used for crossing experiments. Pan-neural expression. 
(Bloomington Drosophila Stock Center) 
GMR-Gal4 
(glass multimer reporter) 
Used for crossing experiments. Expression in 
photoreceptor neurons. (Bloomington Drosophila Stock 
Center) 
 
 
 
2.1.6 Antibodies 
 
Pre-immune sera 
Rabbit and goat pre-immune sera were obtained from VECTOR Laboratories Inc., 
CA, U.S.A..  
 
Primary antibodies  
 
Name Description (Source) 
anti-AR 44 Rabbit polyclonal antibody against aa 543-557 of the 
human androgen receptor. 
anti-AR F39.4.1 Mouse monoclonal antibody against aa 301-320 of the 
human androgen receptor (BioGenex) 
anti-AR (C-19) Rabbit polyclonal antibody against the C-terminus of the 
human androgen receptor (Santa Cruz Biotechnology Inc.) 
anti-AR (N-20) Rabbit polyclonal antibody against the N-terminus of the 
human androgen receptor (Santa Cruz Biotechnology Inc.) 
anti-ERK 2 (D-2) Mouse monoclonal antibody against the C-terminus of the 
human ERK 2 Map kinase p42 (Santa Cruz Biotechnology 
Inc.) 
anti-Polyglutamine-
Expansion Diseases 
Marker (1C2) 
Mouse monoclonal antibody that recognizes 
polyglutamine stretches greater than 37 aa. 
anti-α Tubulin (H-300) Rabbit polyclonal antibody against aa 149-448 of human α 
Tubulin 
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Secondary antibodies   
All secondary antibodies HRP conjugated were purchased from DAKO 
Diagnostika GmbH, (Hamburg, Germany). All secondary fluorescently labeled 
antibodies were purchased from Jackson Immuno Research (USA).  
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2.2 Methods 
 
2.2.1 DNA - cloning techniques 
 
2.2.1.1 DNA fragmentation with restriction enzymes 
One unit of an enzyme is defined as the amount of enzyme required to completely 
digest 1μg of Phage Lambda (λ) DNA in one hour. For the preparation and digestion of 
DNA for cloning, 10 units of the necessary enzyme were used per μg of DNA. A mixture 
of DNA, enzyme, and the appropriate buffer were left to incubate at the required 
temperature (usually 37°C) for a period of 3 hours to overnight. The volume of the 
reaction was such that the final volume consisted of only up to ten percent glycerol from 
the enzyme and buffer solutions. For the analysis of fragment size and the isolation of 
fragments after digestion, the DNA fragments were separated by agarose gel 
electrophoresis. 
 
2.2.1.2 Separation of DNA fragments by agarose gel electrophoresis 
The separation and analysis of DNA fragments was performed on a horizontal 
agarose gel consisting of 1-2% agarose, depending on the expected size of the fragments. 
The amount of agarose for the desired gel concentration was dissolved by boiling in 1 X 
TAE buffer. After the solution cooled to an approximate temperature of 60°C, ethidium 
bromide was added for an end concentration of 0.4μg/ml. The solution was then poured 
into a horizontal gel chamber to solidify, and a comb was placed near the top to provide 
slots for the samples to be loaded. The 1 X TAE buffer was poured over the hardened gel 
and samples were mixed with DNA sample buffer and loaded in the gel. A 1kb DNA 
standard ladder was also loaded in the first lane of the gel. The gel was run with 80-
100V. Separation of the fragments was visualized under a UV-Transilluminator and then 
photographed. 
 
Buffers Composition 
TAE 0.04 M Tris pH 7.2, 0.02 M sodium acetate, 1 mM EDTA 
DNA sample buffer 5 mM EDTA, 50% glycerol, 0.01 g bromophenol blue 
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2.2.1.3 DNA extraction from agarose gel 
The band of an isolated DNA fragment was identified under UV-light and 
removed from the gel with a scalpel and placed in a 1.5 ml Eppendorf tube. The DNA 
was then extracted using the manufacturer’s instructions from an Easy-Pure kit (Biozym 
Diagnostik GmbH, Oldendorf, Germany). The tube was filled to the top with SALT-
buffer and incubated at 55°C on a shaker for 5 minutes. The solution was vortexed and 
9μl BIND was added and mixed by inverting the tube. After a 5 minute incubation at 
room temperature (RT), the mixture was centrifuged briefly at 12000 rpm. The 
supernatant was disposed, and the pellet was resuspended in 1ml of WASH. The mixture 
was incubated at room temperature for 5 minutes and again briefly centrifuged at 12000 
rpm. The supernatant was disposed and the pellet was centrifuged again in order to 
pipette off any remaining liquid. The pellet was dried for several minutes and then eluted 
with 25μl H2O. After 5 minutes incubation, the new mixture was centrifuged for 1 minute 
at 12,000 rpm, and the DNA supernatant was pipetted into a new 1.5 ml Eppendorf tube. 
 
2.2.1.4 Ligation of DNA fragments into plasmid vectors 
DNA content of fragments to undergo the ligation reaction was checked by 
running both the vector and insert on an agarose gel. The appropriate combination for 
ligation was approximately 3-4X the amount of insert for 1X the amount of vector (~50-
100ng). The correct ratio of DNA fragments were combined with 1.5μl T4-DNA-Ligase 
and 1 μl 10 X Ligase Buffer for a total reaction volume of 10 μl and allowed to incubate 
overnight at 16°C.  
 
2.2.1.5 Transformation of bacteria 
A volume of 5 μl of ligation mixture or 20-40 ng plasmid-DNA was given to 50 
μl of DH5-α competent cells, and the mixture was incubated on ice for 30 minutes. After 
a 90 second heat shock at 42°C and then 2 minutes on ice, 450 μl SOC-Medium was 
added to the bacteria and allowed to incubate on a shaker at 37°C for at least 45 minutes. 
The suspension was spread onto selective agar plates, and the plates were incubated 
overnight at 37°C. Bacteria with recombinatorial DNA were identified by restriction 
enzyme analysis of DNA prepared from a mini-preparation.   
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Buffers Composition 
SOC-Medium 2% bacto-tryptone, 0.5% yeast extract, 10mM NaCl, 
2.5mM KCl, 10mM MgCl, 10mM MgSO4, 20mM glucose 
 
2.2.2 Preparation of recombinant plasmid DNA from transformed bacteria 
 
2.2.2.1 Mini-preparation of plasmid DNA  
Single bacterial colonies were picked, inoculated in 3 ml of LB medium 
containing the appropriate antibiotic and grown overnight under constant shaking at 
37ºC. 1.5 ml of these cultures were transferred to a fresh vial and the bacteria were 
collected as a pellet by centrifugation at 12000 rpm (centrifuge Eppendorf 5417 R) for 10 
min at RT. Briefly, the bacterial pellet was resuspended in 150 μl of solution P1 
containing RNase A, from the MaxiPrep Kit (Qiagen) and left for 5 min at RT. Then 300 
μl of solution P2 were added and the mixture was incubated for 5 min on ice. After 
addition of 225 μl of solution P3 followed by vortexing, the lysate was again left for 5 
min on ice. After centrifugation at 12000 rpm for 10 min at 4ºC, 400 μl of the supernatant 
were collected and transferred to a fresh tube containing 1 ml of ice-cold ethanol. 
Incubation for 30 min at -80ºC allowed for the precipitation of nucleic acids. The plasmid 
DNA pellet was collected by centrifugation at 12000 rpm for 10 min at 4ºC and was 
washed once with 70% ethanol. The resulting pellet was air-dried and resuspended in 50 
μl of H2O.  
 
2.2.2.2 Maxi-preparation of plasmid DNA 
Plasmid DNA was prepared on a large scale using the Qiagen Plasmid Maxi Kit 
(Qiagen) following the manufacturer's instructions. A volume of 200-250 ml of LB 
medium supplemented with the appropriate antibiotic was inoculated with 1.5 ml of the 
remaining mini-preparation and incubated with shaking (220 rpm) at 37ºC overnight until 
the bacteria had reached a stationary growth phase. The bacteria were pelleted by 
centrifugation in a fixed angle rotor at 6000 rpm (centrifuge Hermle ZK 401) for 5 min 
and the pellet resuspended in 10 ml solution P1. Following 5-10 min incubation at RT, 
the cells were lysed by addition of 10 ml solution P2. Once the solution had taken an 
opaque appearance, the mixture was neutralized with 10 ml of solution P3 and the entire 
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content inverted gently to aid the mixing of the solutions. After an additional 10 min on 
ice, the cell wall fragments and the bacterial chromosomal DNA were sedimented by 
centrifugation at 7500 rpm for 30 min at 4ºC (centrifuge Hermle ZK 401). The retained 
supernatant was then added directly to a pre-equilibrated (15 ml Buffer QBT) Qiagen-tip 
500 column and entered the resin by gravity flow. The QIAGEN-tip 500 was then 
washed twice with 30 ml of Buffer QC, and the plasmid DNA was eluted in 15 ml of 
Buffer QF. The DNA was then precipitated by adding 11 ml of isopropanol to the DNA 
fraction. The samples were then centrifuged for 30 min (centrifuge Beckman Coulter) 
and washed in 5 ml 80% ethanol before being re-suspended to a final concentration of 1-
3 mg/ml in TE buffer and stored at -20ºC. 
  
Media and Buffers Composition 
LB Medium 10 g tryptone, 5 g yeast extract, and 10 g NaCl for 
1 l (autoclaved before use) 
Buffer P1 (Resuspension Buffer) 10 mM EDTA, 50 mM Tris-HCl pH 8.0, and 400 
mg/ml RNAse A 
Buffer P2 (Lysis Buffer) 200 mM NaOH, 1% SDS 
Buffer P3 (Neutralization Buffer) 3 M Na acetate, pH 4.8 
Buffer QBT (Equilibration Buffer) 700 mM NaCl, 50 mM MOPS pH 7.0, 15% 
isopropanol (v/v), 0.15% Triton X-100 (v/v) 
Buffer QC (Wash Buffer) 1 M NaCl, 50 mM MOPS pH 7.0, 15% 
isopropanol (v/v) 
Buffer QF (Elution Buffer) 125 mM NaCl, 50 mM Tris-HCL pH 8.5, 15% 
isopropanol (v/v) 
TE buffer 10 mM Tris-HCl, 1 mM EDTA pH 8.0 
 
 
2.2.2.3 Phenol/chloroform extraction of plasmid DNA  
To remove unwanted protein contaminants from nucleic acid solutions an equal 
volume of Tris-buffered phenol and chloroform at a ratio of 1:1 (v/v) was added and the 
mixture was vortexed. The two phases were separated by centrifugation at 12000 rpm for 
10 min. The upper aqueous nucleic acid-containing phase was transferred to a fresh 
reaction tube and subjected to a further round of extraction with phenol/chloroform (1:1, 
v/v).  
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2.2.2.4 Ethanol precipitation of plasmid DNA  
In order to recover nucleic acids from solution, the salt concentration was brought 
to 200 mM by adding 1/10 of the original solution volume of 3 M Na-acetate (pH 4.8-
5.0) and 2.5 volumes of cold ethanol. After 30 min to overnight incubation at -20ºC or 30 
min at -80ºC, the precipitate was centrifuged at 12000 rpm for 15 min. The pellet was 
washed with 80% ethanol, centrifuged for another 3 min to remove the salt, and then 
dried. DNA was resuspended in H2O. 
 
2.2.2.5 Determination of nucleic acid concentration  
The concentration of nucleic acids was determined by measuring their optical 
density (OD) at 260 and 280 nm. An OD260 = 1 is equivalent to 50 μg/ml double 
stranded DNA. A ratio of OD260/OD280 ranging from 1.8 to 2.0 indicates an acceptable 
purity of the nucleic acid.  
 
2.2.3 Cell culture  
 
2.2.3.1 Passaging of cells 
COS7 cells were maintained at 37ºC in an incubator (Forma Scientific, Labortect 
GmbH, Göttingen, Germany) in 5% CO2 and 95% air humidity. All cells were grown in 
Petri dishes or flasks (Greiner, Frickenhausen, Germany) of varying sizes depending on 
the application. The cells were allowed to grow until a confluence of 80- 90% had been 
reached, whereupon the cells were subsequently split by trypsinization and re-seeded at a 
lower density. Trypsin treatment of cells was performed by removal of the culture 
medium from the cells, followed by one wash with 1X phosphate buffered saline (PBS). 
After removal of PBS, 0.25% trypsin was applied to the cells and the cells incubated at 
37ºC until they became detached. Fresh medium was then directly applied and the cells 
re-plated at the desired density in new Petri dishes.  
 
2.2.3.2 Freezing and thawing of cells 
 To prepare cells for long term storage, logarithmically growing cells were 
trypsinized and collected by centrifugation at 800-1500 rpm. The medium was removed 
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and the cells resuspended in culture medium with 10-50% FCS and 10% DMSO and 
placed in 1 ml aliquots in cryovials. After incubation on ice for 1 hour, the cells were 
placed at -80ºC for 16-24 h before finally being stored in liquid nitrogen. To re-propagate 
cells, the vials were removed from the liquid nitrogen and placed at 37ºC. 
 
2.2.3.3 Transient transfections 
FuGene6™ transfection reagent was used according to the manufacturer's 
instructions. Proliferating cells were sub-cultured the day before transfection, allowing 
cells to reach 50-80% confluency on the day of the experiment. For a 35 mm culture dish, 
3-6 μl of FuGene6™ reagent were diluted in serum-free medium to a total volume of 100 
μl and incubated at room temperature for 5 min. The diluted FuGene6™ solution was 
then added dropwise to a second sterile tube containing 1-2 μg of DNA and incubated at 
room temperature for 15 min. The mixture was finally transferred to the cells dropwise 
and by gentle swirling to ensure an even distribution. For AR transactivation studies, 
typically 1.2 μg of the desired reporter plasmid, 0.3 μg of renilla luciferase construct as 
an internal control, and 0.5 μg of an AR expression vector were transfected. 24 h after 
transfection the cells were treated either with vehicle alone or vehicle containing 10-7 M 
dihydrotestosterone (DHT) for another 20 h. Then the cells were harvested for the 
luciferase measurements. For protein localization and aggregation experiments the cells 
were transfected with 1.5-3 μg of the AR expression vector(s). The cells were treated 
with hormone 36 h after transfection for 3 h. For all transfection experiments the cells 
were kept in the DMEM medium without phenol red and containing 3% charcoal treated 
FCS (CCS) to remove residual steroids. 
 
2.2.3.4 Analysis of gene expression through luciferase activity test 
  
Measurement of firefly luciferase activity 
After transfection, cells were in culture for at least 24-48 h to allow expression of 
the transfected reporter gene. Typically they were kept in 6-well plates. Cells were then 
washed twice in PBS without Ca 2+ and Mg 2+. PBS was then removed and the cells 
harvested in 300 μl 1X lysis buffer (Passive Lysis Buffer, Promega, Mannheim, 
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Germany). The cells were kept on ice for 10 min and occasionally rocked to distribute the 
buffer evenly and favour the detachment of the cells from the plates. The cell lysates 
were pipetted up and down several times, collected with a rubber policeman, and finally 
transferred to pre-cooled vials. 100 μl of cell lysate were transferred to a reading tube, 
and 350 μl of assay buffer and 100 μl of luciferin assay solution were then added by 
autoinjection. Luciferase activity was measured by use of a luminometer (Berthold, 
Wildbad, Germany). 
 
Buffers Composition 
Assay buffer 1mM DTT, 1 mM ATP in glycylglycine 
buffer 
Glyclylglycine buffer 25 mM glycylglycine, 15 mM MgSO4 and 
4 mM EGTA 
Luciferin assay solution 1mM luciferin; stock solution: 0.28 mg/ml 
 
 
Measurement of Renilla luciferase activity  
100 μl of cell lysates were mixed with 500 μl of coelenterasin buffer together with 
substrate solution. Luminescence was measured by use of a luminometer (Berthold, 
Wildbad, Germany).  
 
Buffers Composition 
Coelenterasin buffer 0.1 M KPi-buffer, 0.5 NaCl, 1 mM EDTA, 
pH 7.6 
kKPi-buffer 0.2 M KH2PO4 and 0.2 M K2HPO4, pH 
7.6 
substrate solution 25 nM end concentration coelenterazine, 
Byosinth AG, Gstaad, Switzerland 
 
 
2.2.3.5 Immunofluorescence 
 
Preparation of the paraformaldehyde solution  
To make a 10% stock solution 20 g of paraformaldehyde crystals were dissolved 
in 80 ml of water and heated up to 60ºC. To facilitate the dissolving of paraformaldehyde 
 44
several drops of NaOH were added. After the crystals were dissolved the solution was 
cooled down, mixed with 100 ml of 2x PBS, aliquotted, and stored at -20ºC.  
 
 Preparation of polyvinyl alcohol mounting medium 
 20 g polyvinyl alcohol was mixed with 80 ml of 1 X PBS and stirred overnight 
with a magnetic stirrer at a temperature of 60ºC. 50 ml of glycerin was added, and the 
solution was stirred until uniform. Several crystals of thymol were added as a 
preservative. The mixture was filtered and stored upside down in an airtight container.  
 
Immunofluorescent staining  
For immunofluorescence experiments, COS7 cells were seeded into 6-well plates 
at a density of 2x105 cells per well with a sterile coverslip put into every well. The next 
day the cells were transfected with the FuGene6 TM transfection reagent and 24 h after 
transfection treated with either the vehicle or 10-7 M DHT for up to 3 h. After treatment, 
the cells were washed 2 times with PBS and fixed for 20 min with 3% paraformaldehyde 
(in PBS). To remove the paraformaldehyde ions the cells were then incubated for 15 min 
in 50 mM NH4Cl (in PBS) and finally permeabilized in 0,1% Triton-100 (in PBS) for 5 
min. Afterwards the cells were washed 2 times with PBS and blocked for 1 h with PBS 
supplemented with 3% FCS (PBS-3%FCS).  
After the blocking, PBS-3%FCS was removed and 150 μl of the primary antibody 
solution (1:50 AR F39.4.1) in PBS-3%FCS was pipetted directly onto the coverslip and 
incubated for 1h. Then the cells were washed 3 times with PBS-3%FCS and covered with 
150 μl of the secondary antibody (1:200 Cy3 anti-mouse) for another 30-60 min. The 
cells were then washed 3 times with PBS.  
Finally the coverslips were taken from the 6-well plate and rinsed in dH2O. The 
water drops were removed, and the coverslip was placed onto the glass slide with a drop 
of fluorescence mounting medium with the cell covered side facing downwards. Then the 
slides were dried for 30-60 min at room temperature and stored in a dark place at 4ºC.  
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2.2.4 Drosophila methods 
 
2.2.4.1 Culturing of fly stocks 
Fly stocks were kept at 25ºC in polystyrene tubes with ceaprene stoppers (Greiner 
Bio-One) on standard fly-food medium. Every three to four weeks, fly stocks were placed 
in new tubes with fresh stock food.  
 
2.2.4.2 Preparation of fly food 
 For large quantities of stock food, 80 g of agar strands were soaked overnight in 
10 l H2O. The next day, the H2O and agar was boiled at 100ºC in a pressure cooker. Once 
the agar was completely in solution, the temperature was turned down to 90ºC. Then 1 l 
of sugar syrup was added while continuously stirring. In a separate container, 165 g beer 
yeast and 815 g cornmeal were dissolved in 3.3 l  H2O. The mixture was then added to 
the cooker and allowed to boil for 5-10 min at 100ºC. The mixture was then allowed to 
cool for 15 min until the temperature reached 65ºC. Finally, 20 ml of 10% Nipagin (20 g 
in 200 ml EtOH) was added and a pump was used to fill the small, medium, and large 
sizes of polystyrene tubes.  
 For food containing sodium butyrate, the above recipe was made on a 1/10 scale. 
A 500 mM solution of sodium butyrate was made with H2O, and 200 ml was added to 
130 ml H2O plus the 16.5 g beer yeast and 81.5 g cornmeal. This mixture was added to 
the cooker after the addition of sugar syrup, just as in the original protocol. 
 In order to make normal or sodium butyrate fly food containing EtOH, DHT, 
and/or melatonin, the recipe was again used on a 1/10 scale. Typically, 300 ml of food 
was used for each hormone/inhibitor combination. The amounts added were as follows 
for 300 ml: 
 
Type of food Amounts added 
EtOH 6 ml 80% EtOH 
DHT 3 ml 10-1M DHT and 3 ml 80% EtOH 
Melatonin 3 ml 1M Melatonin and 3 ml 80% EtOH 
Melatonin/DHT 3 ml 1 M Melatonin and 3 ml 10-1M DHT 
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Some crosses were performed on apple-agar plates. 8.25 g of agar-agar was 
dissolved in 300 ml dH2O in a 500 ml bottle and autoclaved. This solution could be 
stored at room temperature until needed. The agar was then microwaved until melted and 
10 g sucrose and 100 ml apple juice were added. The mixture was then cooled to 65ºC 
and 0.6 g Nipagin dissolved in 4 ml ethanol were added. The apple-agar solution was 
then added to small bacterial plates (Greiner Bio-One) and allowed to cool before stored 
at 4 ºC.  
 
2.2.4.3 Injections for germ-line transformation 
 
Injection mix purification 
 5 μg of the pΔ2,3 helper plasmid (10kb) was added to approximately 2 times 
more (molar ratio) of the P transgene of interest (i.e. pUASt-ARQ22, pUAST-ARQ77, 
etc). The volume was adjusted to 100 μl with dH2O. 100 μl of (1:1) Phenol/Chloroform 
was added and mixed by finger tapping. The mixture was centrifuged for 5 min, 14000 
rpm at 4ºC. 90 μl of the supernatant was put in a fresh eppendorf and 9 μl of 3M Sodium 
Acetate pH 4.8 was added. 225 μl of 100% cold EtOH was added, and the mixture was 
allowed to precipitate for at least 60 min at -80ºC. The mixture was then spun down for 
30 min, 14000 rpm at 4ºC, washed with 500 μl 80% EtOH and centrifuged again for 5 
min. The pellet was then allowed to dry for 30 min under a fume hood. After drying, the 
DNA pellet was resuspended in 37 μl of dH2O. 1 μl was saved to examine the 
quality/ratio of the injection mix whle the other 36 μl were stored at -20ºC. 
 
Quality/ratio controls 
 1 μl from the injection mixture was used for a digestion with the restriction 
enzyme EcoRI. A complete digestion yielded two bands of approximately 3.5 and 6.8 kb 
corresponding to the two fragments from the pΔ2,3 vector, as well as two bands 
corresponding to the pUASt-AR plasmid used (approximately 8.4 kb and 3.6 kb). The 
correct ratio of pUASt-AR  to pΔ2,3 vector was no less than 3:1.  
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Injection mix preparation 
 4 μl of 10X injection buffer was added to the stored 36 μl DNA mix, and 4x10 μl 
aliquots were made of the resulting “injection mix” and stored at -20ºC. 100 μl of sterile 
1X injection buffer was also prepared with dH2O and stored at -20ºC.  
 
Buffers Composition 
10X Injection buffer 0.1M Sodium Phosphate Buffer pH 6.8, 
5mM KCL 
1 M Sodium Phosphate Buffer pH 6.8 4.97 ml 1M Na2HPO4 and 5.03 ml 1M 
NaH2PO4 in 100 ml dH2O 
 
 
Injection procedure 
 At least two full large containers of w1118 flies were put in a large container with a 
10 cm apple-agar plate and yeast paste at 25ºC at least 18 h before the time of injection. 
Several hundred flies were needed to produce enough eggs/embryos, and females 
produced eggs best when they were about one week old and well fed. Flies also tended to 
lay more eggs when kept in the dark. On the day of injection, the apple-agar plate was 
changed at least twice in the morning and checked after 30 min each time to ensure that 
the flies were laying a sufficient amount of embryos. The apple-agar plate was replaced 
again, and the flies were allowed to lay eggs for 30-40 min. While the flies were allowed 
to lay eggs, the injection mix was thawed and centrifuged to pellet any dust particles or 
insoluble material. From then on, the injection mix was kept on ice. After 30-40 min of 
egg-laying, the apple-agar was plate was taken in order to collect the laid embryos and 
was replaced with a fresh plate.  
 The rest of the injection procedure took place in a room maintained at 18ºC. The 
embryos were collected from the apple-agar plate using a small paintbrush and 
transferred to a small sifting basket with a mesh bottom that was partially submerged in 
water. After a sufficient amount of embryos were transferred, excess water was removed 
by blotting the basket briefly on absorbent paper. Next, the embryos were dechorionated 
for 3-5 min in 1.8% bleach (sodium hypochlorite solution). In order to keep the bleaching 
time as short as possible, the process was monitored under a dissecting scope. The 
embryos were then rinsed several times with water, aiding the removal of the chorions.  
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 The dechorionated embryos were transferred by paintbrush to a slice of apple-
agar (5 x 50 mm) on a resting microscope slide. Now, the embryos could be lined up in a 
row using a small dissecting needle. The embryos were oriented so that the anterior end 
was close to the near edge of the agar slice.  Usually, 80-100 embryos were placed in the 
same direction, close together but not touching. The row of embryos was transferred to a  
coverslip (24 x 64 mm) with a 5-mm wide strip of double-sided tape along one edge. The 
coverslip was lowered carefully on the embryos so that the posterior end of the embryos 
pointed outward when attached to the tape and were set back approximately 0.5 mm. 
 Before injection, the embryos were briefly dried in order to reduce hydrostatic 
pressure. Optimal drying time depended on the humidity and temperature of the room 
(18ºC) as well as the state of the silica gel crystals used for drying. Older silica gel 
obtains a pinkish color and requires a longer drying time. Therefore, embryos were dried 
for 5-7 min and then covered with a thin layer of Voltalef halocarbon oil to prevent 
further drying. The coverslip with embyros was placed on a slide also using oil and 
adjusted into the slide holder for the microscope (Olympus).  
 While embryos were drying, the injection needle (Injection Needle Femtotips, 
Eppendorf) was loaded with 2 μl injection mix using microloader tips (Eppendorf). The 
injection needle was carefully placed in the holder of the injection apparatus (Leitz) and 
brought into focus under the microscope.  The injection needle was brought backwards as 
the slide with the embryos was brought into focus. The needle was then moved forwards 
so it was positioned slightly above the coverslip and oil. As the needle was brought into 
the oil, it was tested for suitable DNA flow through the needle tip. The tip was then used 
to puncture the posterior end of the embryos, and the DNA mix was injected using an 
Eppendorf Microinjector 5242. From egg collection to injection of embryos, the 
procedure took no more than 1.5 h. Any embryos that were deemed too old and had 
already begun the nucleation process were destroyed using the injection needle.  
  
Establishment of transgenic lines 
After injection the embryos were kept at 18ºC in oil until hatching (2-3 days). 
Newly hatched larvae were placed in standard stock fly food to develop. After eclosion, 
adult flies were backcrossed with three w1118 flies of the appropriate sex, making sure that 
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any transgenic or w1118 females were virgins. Because the pUASt vector contains a copy 
of the mini-white+ gene, any flies in the F1 generation that contained the transgene would 
have yellowish to orange eyes. These F1 generation flies were taken and backcrossed 
again with w1118 flies. Any F1 flies with red eyes were avoided as they most likely 
contained multiple copies of the transgene. Usually, 3-4 backcrosses were sufficient to 
establish a homozygote transgenic line.  
 
2.2.4.4 Genetic crosses 
  The Gal4/UAS system was utilized to express genes of interest (i.e ARQ22, 
ARQ77, etc.) in specific tissues of Drosophila melanogaster. To summarize, in any given 
“driver” fly line, a promoter (enhancer) directs expression of the yeast transcription factor 
GAL4 in a specific pattern. GAL4 then directs transcription of the Gal4-responsive 
(UAS) target gene in an identical pattern. GMR-GAL4 (glass multimer reporter) and 
ELAV-GAL4 (embryonic lethal abnormal vision) lines were used to direct expression of 
the AR in the photoreceptor neurons and throughout the central nervous system, 
respectively. To cross flies, virgin female flies were collected from the desired GAL4 
line. Typically 8-10 virgin females were crossed with 3-4 males from the desired UAS-
AR line. Depending on the experiment, crosses were either made on standard medium, 
medium containing hormone and/or inhibitors, or apple agar plates.  
  
2.2.4.5 Scanning electron microscopy 
 Flies of the correct age and phenotype were anesthetized with CO2, and heads 
were separated from the bodies. Freshly collected heads were then transferred stepwise to 
100% ethanol (1 h each in 30%, 50%, 70%, 90%, 95%).  
 For microscopy, three heads of each phenotype were mounted on an aluminum 
stub using double stick carbon tape. Samples were then introduced into the chamber of 
the sputter coater (Balsers) and coated with a very thin film of gold\palladium before 
SEM examination. 
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2.2.4.6 Immunohistochemistry 
 Wandering third-instar larvae were dissected in Ringer solution, separating the 
CNS. Brains were fixed in 1 ml 0.5 PBT + 4% formaldehyde for 1 h. The brains were 
then washed in PBT (5/5/15/30 min) and transferred stepwise to 100% methanol (5 min 
30%, 5 min 70% MeOH in Ringer solution). The samples were then stored at -20ºC in 
100% MeOH overnight.  
 The next day the brains stored in 100% MeOH were transferred stepwise back to 
Ringer solution (5 min 70%, 5 min 30% MeOH). The brains were then washed 
extensively (5/15/15/30/30/60 min) with PBT and blocked for 1 h in 0.5 PBT + 5% goat 
serum. The blocking solution was then exchanged and primary antibodies were added 
(1:1000 Draq5 and 1:200 AR C-19). The brains were incubated overnight, rotating at 
4ºC. 
 After overnight incubation, the supernatant was discarded, and the brains were 
washed extensively (5/5/15/30/60 min) with 0.1 PBT. The brains were blocked in 0.5 
PBT + 5% goat serum for 1 h. The blocking solution was exchanged and fluorescently 
labeled secondary antibody was added (1:200 anti-rabbit-Cy2). The brains were 
incubated for 1.5 h at room temperature in the dark or overnight at 4ºC. Finally they were 
washed in 0.1 PBT (5/15/15/30 min) and mounted in Mowiol. Slides were kept in a dark 
cool place to dry and eventually stored at 4ºC. 
 
Buffers Composition 
0.1 PBT 0.1% (v/v) TritonX100 in PBS 
0.5 PBT 0.5% (v/v) TritonX100 in PBS 
Ringer 182 mM KCL, 46mM NaCl, 3 mM CaCl2, 
10mM Tris 
Mowiol  24 ml glycerol, 9.6 g Mowiol, 24 ml H2O, 
48 ml 0.2M Tris-HCl pH 8.5 
 
 
2.2.4.7 Locomotion analysis 
Transgenic fly lines were crossed with ELAV-GAL4 flies on standard medium. 
Once crosses were producing a sufficient amount of viable eggs, crosses were transferred 
to apple-agar plates containing yeast paste. After 72 hours, first instar larvae were 
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collected from the agar and yeast paste, washed, and placed back on the apple agar plates. 
The first-instar larvae were then collected and placed in stock food containing the 
following hormone and inhibitor combinations: 
10-3M DHT + equivalent volume of 80% ethanol 
10-2M melatonin + one volume 80% ethanol 
100 mM sodium butyrate + one volume 80% ethanol 
2 volumes 80% ethanol 
10-3M DHT + 10-2M melatonin 
10-3M DHT + 100 mM sodium butyrate 
 After 72 hours, wandering third-instar larvae were placed individually in the center of a 
10 cm dish containing a flat layer of 0.7% agar on an evenly illuminated light box 
emitting infrared light (Lee et al., 2004). Movement of the larvae was recorded and 
analyzed using Noldus EthoVision version 3.1.16. The recording time was 2.5 minutes or 
until the larvae reached the edge of the agar, which was outside the recording arena. 
Parameters analyzed by the EthoVision program included velocity, angular velocity, and 
mean turn angle.  
 
2.2.4.8 Survival analysis 
Transgenic fly lines were crossed with ELAV-GAL4 flies on standard medium. 
Once crosses were producing a sufficient amount of viable eggs, crosses were transferred 
to apple agar plates containing yeast paste. After 36 hours, eggs were collected from the 
agar and yeast paste, washed, and placed back on apple agar plates until hatching. 
Directly after hatching, larvae were placed in stock food containing the following 
combinations of hormone and inhibitors: 
10-3M DHT + equivalent volume of 80% ethanol 
10-2M melatonin + one volume 80% ethanol 
100 mM sodium butyrate + one volume 80% ethanol 
2 volumes 80% ethanol 
10-3M DHT + 10-2M melatonin 
10-3M DHT + 100 mM sodium butyrate 
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Larvae were placed at a rate of 50 larvae per food vial. The percentage of larvae 
surviving to pupation and eclosion was then calculated. 
  
2.2.5 Methods for work with protein from cells and Drosophila 
 
2.2.5.1 Preparation of protein lysates 
 
Preparation of protein lysates from COS7 cells  
Cells at 80-90% confluency, typically grown in a 6-well or 10 cm plate, were 
washed twice with ice-cold PBS, collected in 1 ml PBS, spun down for 3 min at 4000 
rpm at 4ºC, resuspended in 100 μl of PBS + protease inhibitor cocktail, and lysed with 3 
freeze-thaw cycles. Then the lysates were centrifuged for 10 min at 12000 rpm at 4ºC, 
and the supernatants were taken and stored at -80ºC. Alternatively, after collection of 
cells in 1 ml PBS, cells were lysed with NP40 lysis buffer, and whole cell lysates were 
stored at -20ºC.  
 
Buffers Composition 
NP40 lysis buffer 150 mM NaCl, 50 mM Tris-HCl pH 8.0,  
5 mM EDTA pH 8.0, 1% NP40 
 
 
Drosophila lysates 
 Flies of the correct age and phenotype were collected and snap frozen by putting 
them in an eppendorf tube on dry ice. Working on dry ice, 50 heads were separated from 
bodies using forceps and a razor blade (Wilkinson-Sword) and placed in a tube on dry 
ice. 50 μl RIPA buffer was added, and heads were crushed using a glass rod. The 
homogenized mixture was sonified with 3 x 10 s pulses (Bioruptor) and then centrifuged 
for 5 min at 4ºC, 13000 rpm (centrifuge Eppendorf 5417 R). The supernatant was 
transferred to a fresh tube, and the head pellet was resuspended in 50 μl RIPA. The 
sonification and centrifugation steps were repeated, and the supernatant was added to the 
previous. When necessary, lysates were stored at -20ºC. 
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Buffer Composition 
RIPA buffer 50 mM Tris HCl pH 7.6, 1% Triton, 0.5% 
NaDOC, 150 mM NaCl, 0.1% SDS, 2 mM 
EDTA + 1:200 protease inhibitor cocktail 
 
 
2.2.5.2 Determination of protein concentration 
 The Bradford assay was used to determine the protein concentration of cell and 
Drosophila lysates. 0.5 μl lysate sample was mixed with 250 μl of 1X Bradford reagent 
(Bio-Rad) in an eppendorf tube. As a protein standard, 250 μl 1X Bradford reagent was 
mixed with increasing amounts of 1 μg/μl BSA solution (e.g. 0, 2, 4, 6) where the BSA 
had been diluted in the appropriate lysis buffer. 200 μl of each solution was transferred 
into an ELISA plate, and the optical density (OD) was measured immediately at 600 nm. 
 The standard curve was determined by using the results obtained from the BSA 
dilutions in the equation, y=ax + b.  
“y” = amount of protein in μg 
“x” = the OD reading.  
“a” = slope of the line 
“b” = origin on y axis 
 
2.2.5.3 Separation of proteins by SDS polyacrylamide gel electrophoresis 
 Usually 10% SDS-Polyacrylamide gels were used. The Penguin Doppelgelsystem 
P9DS apparatus (Peqlab, Erlangen, Germany) was used to cast the gel. 20 ml of resolving 
gel were poured and overlaid with Rotisol. After polymerization, Rotisol was washed off 
with deionized water. 10 ml of stacking gel were then added and allowed to polymerize. 
The gel was fixed within the gel tank and 1X Laemmli buffer (running buffer) was 
poured over the gel. The desired amounts of cell or Drosophila lysate were mixed 1:1 in 
2X SDS sample buffer, boiled at 95ºC for 5 min, and loaded by lane onto a SDS-PAGE. 
Samples were run into the stacking gel at 80V, and then run at 150V for approximately 3 
hours or 40V overnight. 
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Buffers and gel solutions Composition 
10% SDS-Polyacrylamide gel 9.9 ml acrylamide/bis-acrylamide 30:0.8, 
11.7 ml 1 M Tris-HCl pH 8.8, 8.4 ml bi-
distilled H2O, 150 ml 20% (w/v) SDS, 300 
ml 10% APS, 15 ml TEMED 
Stacking gel (5% SDS-polyacrylamide) 7.3 ml bi-distilled H2O, 1.68 ml 
acrylamide/bis-acrylamide, 0.69 ml 1 M 
Tris-HCl, pH 6.8, 56 ml 20% SDS; 45 ml 
10% APS and 15 ml TEMED 
 1X Laemmli buffer 25 mM Tris, 200 mM glycine, 0.1% (w/v) 
SDS 
2X SDS sample buffer (50 ml) 28.74 ml H2O, 6.26 ml Tris-HCl pH 6.8, 10 
ml 20% SDS, 5 ml β –Mercaptoethanol, a 
few grains of bromophenolblue 
 
 
2.2.5.4 Western blotting  
After proteins were separated by SDS-PAGE, they were electrically transferred 
onto Immobilon membrane (Millipore, type PVDF, pre-soaked in methanol) at 250-300 
mA for at least 6 hours in transfer buffer. Immunoblotting was performed according to 
individual instructions for each antibody. Typically, in order to reduce unspecific binding 
of the antibodies to the membrane, the blot was incubated in blocking solution at RT for 
1 h with shaking. For detection of proteins of interest the membrane was incubated in 
blocking solution containing the appropriate primary antibody (optimal working dilution 
was determined empirically) at room temperature for 3h or 4ºC overnight. After 3 washes 
of 5 min each in PBST, the membrane was incubated 1 hour in blocking solution 
containing a 1:2000 dilution of HRP-conjugated secondary antibody. Once the membrane 
had been washed 3 times for 5 min each, detection of specific proteins was achieved by 
enhanced chemiluminescence using ECL Western blotting detection reagents as 
recommended by the manufacturer (Amersham, Braunschweig, Germany) and exposure 
to ECL Hyperfilm (Amersham, Braunschweig, Germany) .  
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Buffers Composition 
Transfer buffer 25 mM Tris, 190 mM glycine, 20% (v/v) 
methanol, and 0.05% (w/v) SDS 
Blocking solution 1x PBS, 0.05% Tween, 3-5% milk powder 
PBST 1x PBS, 0.05% Tween 
Primary Antibodies Dilutions 
anti- AR F39.4.1 1:1000 
anti- AR (N-20) 1:200 
anti-ERK 2 (D-2) 1:3000 
anti-Polyglutamine-Expansion Diseases 
Marker (1C2) 
1:5000 
anti- α- Tubulin (H-300) 1:200 
 
 
2.2.5.5 Stripping of the Western blot membranes  
To allow more than a single use of Western blot membranes, the membranes were 
incubated with a stripping solution at 50ºC for 30 min with shaking. The membranes 
were then washed five times for 5 min in 1X PBS without Ca- and Mg-.  
 
Buffers Composition 
Stripping Solution 62.5 mM Tris, pH 6.8, 2% SDS, 0.75% 2- 
mercaptoethanol 
 
 
2.2.5.6 Filter trap analysis of aggregates 
 
Filter trap 
Transfected COS7 cells were harvested and lysed in NP40 lysis buffer. For larvae 
analysis, third-instar larvae were homogenized in RIPA buffer. Total protein 
concentration was measured using the Bio-Rad Bradford assay. Equal protein amounts of 
cell or larval lysate were brought to a concentration of 2% SDS/ 50mM DTT, boiled for 3 
min, and applied to a 0.22 μm cellulose acetate membrane (Schleicher and Schuell)  that 
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had been washed three times with 0.1% SDS, 10 mM Tris pH 8.0, 150mM NaCl in a slot 
blot apparatus. Samples were gently vacuumed, and the membrane was washed twice 
more with the same wash buffer.  Insoluble AR protein was analyzed using anti-AR 
antibody, (1:200 AR N-20) (Santa Cruz Biotechnologies).  
 
Dot blot 
To demonstrate equal AR expression in transfected cells, dot blot analysis was 
performed by applying 1 μg of protein lysate to a nitrocellulose membrane (Hybond-C 
pure). The membrane was allowed to dry and then probed with anti-AR antibody, AR N-
20. 
 
2.2.5.7 Immunoprecipitation 
 
Preparation of protein A sepharose beads 
 An amount corresponding to 300-500 μl of Protein A Sepharose beads were 
mixed with 10 ml TE in a 15 ml Falcon tube. The beads were shaken for 2 h at 4ºC and 
then centrifuged for 3 min at 2000 rpm. Beads were washed twice with TE and 
resuspended in 3 volumes TE for a 25% bead slurry. 
 
Buffers Composition 
TE buffer 10 mM Tris-HCl, 1 mM EDTA pH 8.0 
 
 
Immunoprecipitation of protein 
 Drosophila lysates were freshly prepared in RIPA buffer with added inhibitors. 
Lysates were brought to a volume of 950 μl with RIPA buffer + inhibitors. Primary 
antibody (50 μl AR44) was added, and the mix was incubated overnight, rotating at 4ºC.  
 The next day 100 μl 25% Protein A Sepharose bead slurry was added to the 
lysate/antibody mix and incubated for 3 h, rotating at 4ºC. Mixes were then centrifuged 
for 1 min at 4ºC, 14000 rpm. The resulting bead pellet was washed five times by 
vortexing with 500 μl RIPA + inhibitors. Beads were kept on ice during washes. Bead 
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pellets were resuspended in 40-50 μl of 2X sample buffer, boiled at 95ºC, and loaded 
onto SDS-PAGE. Samples were further analyzed by Western blotting. 
 
Buffers Composition 
RIPA + inhibitors 50 mM Tris HCl pH 7.6, 1% Triton, 0.5% 
NaDOC, 150 mM NaCl, 0.1% SDS, 2 mM 
EDTA , 1 mM Na3VO4, 50 μM ZnCl2,  
1:200 protease inhibitor cocktail 
2X SDS sample buffer 28.74 ml H2O, 6.26 ml Tris-HCl pH 6.8, 10 
ml 20% SDS, 5 ml β –Mercaptoethanol, a 
few grains of bromophenolblue 
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3.0 RESULTS 
 
3.1 Mutation of distinct serine residues at the N-terminus of the AR 
For the polyglutamine (polyQ) disorders, the details of the various pathways 
which begin with the presence of the polyQ stretch and lead to the misfolding of the 
affected proteins and death of specific subsets of neurons are still largely unknown. 
Several recent studies have shown that protein modification or sequences outside the 
amplified polyQ stretch exert significant effects on the disease progression (LaFevre-
Bernt and Ellerby, 2003; Okamura-Oho et al., 2003; Thomas et al., 2004; Luo et al., 
2005; Duennwald et al., 2006). Therefore candidate amino acid residues neighboring the 
polyQ stretch of the androgen receptor (AR) were identified and subsequently 
investigated as to whether alterations of these sites would affect the properties of this 
protein that are characteristic of polyQ cytotoxicity.  
 
3.1.1 Two possible phosphorylation sites shown in vitro 
As an attribute of being a steroid hormone receptor, the AR is dependent upon 
phosphorylation for its normal functional activity as a transcription factor (Lin et al., 
2001). In general, phosphorylation is also known to bring about conformational changes 
of proteins associated with neurodegeneration (Buee et al., 2000). Due to the fact that all 
of the polyQ proteins exhibit both gain-of-function features as well as undergo 
conformational changes in the disease processes (Ross, 2002), it is very likely that 
phosphorylation of the proteins through the various signalling cascades plays a 
significant role in the aggregation and toxicity of the polyQ disorders. In the specific case 
of SBMA, the MAPK/ERK signalling pathway has been implicated in the disease 
mechanisms. Previous studies have shown that a mutation at serine 514, a putative site of 
phosphorylation by a proline directed serine kinase at the N-terminus of the AR, blocked 
cell death induced by an AR with an amplified polyQ stretch (LaFevre-Bernt and Ellerby, 
2003). In an in vitro kinase assay performed by Dr. Sigrun Mink, a former member of the 
lab, it was confirmed that the N-terminal amino acid sequence 360-557 of the AR is 
phosphorylated by the proline directed serine kinase ERK (Fig. 3.1A). Although the 
levels were reduced in comparison to the normal ERK phosphorylation substrate, basic 
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myelin protein (MBP), amino-terminal fragments of the nuclear receptor coactivator 
p300 or dihydrofolate reductase (DHFR) proteins that were used as negative controls 
were not phosphorylated (Fig. 3.1A). Next, in attempt to localize which serine residues 
were responsible for the demonstrated phosphorylation by ERK, Dr. Mink analyzed the 
effect on in vitro phosphorylation of an alanine substitution of the known ERK consensus 
site at serine 514. Contrary to published data (Yeh et al., 1999), an alanine substitution at 
serine 514 did not abolish the in vitro phosphorylation by ERK2 (Fig. 3.1B). Therefore 
the nearby serine 424, which shares a similar sequence to the ERK consensus sequence, 
was also substituted with an alanine residue. Only with the simultaneous substitution of 
serines 514 and 424 by alanine residues was phosphorylation blocked. An exchange of 
serine 424 alone was also not enough to abolish the in vitro phosphorylation (Fig. 3.1B). 
Interestingly, serine 424 is one of five serine residues [16, 81, 256, 308 and 424] at the N-
terminus of the AR that shows an increased phosphorylation in the presence of androgen 
(Gioeli et al., 2002; Yang et al., 2005).  
Because simultaneous mutations at serines 424 and 514 were able to block in 
vitro phosphorylation of the AR by ERK and ERK signalling has been implicated in 
SBMA and Huntington’s (LaFevre-Bernt and Ellerby, 2003; Apostol et al., 2006), it was 
deemed plausible that a double mutation of these sites may also effect the conformation 
of the AR as well as the polyQ aggregation and toxicity associated with SBMA. These 
mutations were therefore introduced into the full length AR with a polyQ stretch of 22 or 
with an amplified polyQ tract of 77, termed ARQ22dm and ARQ77dm respectively, for 
determination of structural alterations.   
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Figure 3.1 In vitro MAP Kinase ERK2 phosphorylation of the region 360-536 of the AR reveals two 
possible phosphorylation sites 
The region between amino acids 360 -536 of androgen receptor can be phosphorylated by ERK2 
in vitro. Purified proteins were incubated with recombinant ERK2 in the presence of [γ-32P] ATP, separated 
by SDS page and visualized by autoradiography. Duplicate gels were stained with Coomassie blue to 
demonstrate equal loading (upper panels). (A) An in vitro phosphorylation assay shows MAP kinase 
phosphorylation of AR(360−536). AR(360-536) was used as a substrate for the phosphorylation reaction 
together with myelin basic protein (MBP) as a positive control and dihydrofolate reductase (DHFR) protein 
fragment and the amino terminal portion of p300 (amino acids 551-753) as negative controls. (B) Mutated 
AR(360−546) fused to GST is phosphorylated by ERK2. GST-fusion proteins of the AR(360-536) as well 
as the 360−546 sequence with the serine residues at position 424 or 514 or both exchanged for alanine 
residues were used as substrates for in vitro phosphorylation reactions. Shown is the autoradiograph of the 
phosphorylation analysis.  
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3.1.2 Conformational changes induced by substitution of serine residues 424 and 514 
In the polyQ disorders, one important step in the pathogenic mechanisms is 
accepted to be a misfolding or conformational change from the “wild type” structure of 
the polyQ proteins. The consequences of this misfolding include changes in protein-
protein interactions, changes in homeostasis, and aggregate formation (Paulson et al., 
2000). It is likely that any mutation of the protein that would have an effect on polyQ 
toxicity, especially mutations of sites for covalent modifications, would affect the 
structure of the protein. Hence, the first step in examining the effects of mutating AR 
serines 424 and 514 on possible aggregation and polyQ toxicity was to investigate local 
conformational changes in the AR N-terminal region brought about by the mutations. 
Demonstrating sensitivity of a protein to proteases has been shown to be one method of 
determining alterations in folding in a polyQ disease model (Gidalevitz et al., 2006). 
Additionally, limited proteolytic digestion has been successfully used by other 
investigators to demonstrate conformational changes in the AR and other nuclear 
receptors (Allan et al., 1992; Neuschmid-Kaspar et al., 1996; Lazennec et al., 1997).  
Therefore, a limited proteolytic digestion of the AR was performed in collaboration with 
Dr. Liubov Shatkina, a former member of the lab. 
The four variants of the AR (ARQ22/wild type, ARQ22dm, ARQ77, and 
ARQ77dm) were synthesized in vitro and radiolabeled with [35S] methionine so the 
receptors could later be visualized by fluorography. The receptors were then subjected to 
digestion by the serine protease trypsin, a commonly used protease in proteomics 
experiments for digestion of proteins into peptides. Trypsin was also the protease of 
choice for detecting structural alterations in the AR in previous studies (Neuschmid-
Kaspar et al., 1996; Reid et al., 2002). Digestion with trypsin was able to demonstrate 
distinct differences in the digestion patterns of ARQ22 and ARQ77 as well as between 
their cognate mutants (Fig. 3.2). A comparison of ARQ22 and ARQ22dm or ARQ77 and 
ARQ77dm showed two clear differences. First, although the digestion patterns for 
ARQ77 and ARQ77dm were similar, an upward shift was exhibited by the fourth and 
fifth bands (marked with asterisks) in the ARQ77dm pattern. These distinct protease 
digestion fragments ran at 55kDa and 60kDa on the polyacrylamide gel, thus being larger 
fragments than the corresponding fourth and fifth bands of the ARQ77. Second, the 
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ARQ22dm and ARQ77dm proteins were highly sensitive to protease digestion such that 
they were fully digested by 30 min of incubation with the trypsin solution. The ARQ22 
and ARQ77 proteins were relatively resistant to the tryptic digestion (Fig. 3.2). These 
results indicated that the two serine mutations did indeed produce an alteration in the 
structure of the AR.  
With this first experimental step clarified, the mutated receptors were then used in 
a cell culture model to examine the effect of the amino acid substitutions on properties of 
the AR associated with SBMA and polyQ toxicity in general. These altered properties are 
namely nuclear localization and the subsequent transactivation function of the receptor as 
well as aggregate formation and toxicity following treatment with androgen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Mutation of serine residues 424 and 514 leads to conformational changes in wild type AR 
and an AR with an extended polyQ stretch  
ARQ22, ARQ22dm, ARQ77 and ARQ77dm were in vitro transcribed and translated in a TNT 
coupled reticulocyte lysate system of Promega in the presence of [35S] methionine. The in vitro synthesized 
receptors were incubated at room temperature in the presence of trypsin (2.5 µg/ml) for the indicated time 
periods. The reactions were terminated by the addition of denaturing gel loading dye and the products were 
fractionated on an 8% SDS-polyacrylamide gel. The gels were dried and the radioactive peptides visualized 
by fluorography. The pictures demonstrate the fragment pattern generated from the androgen receptors 
loaded with agonist. The asterisks indicate the position of migration of the 55 and 60 kDa fragments 
generated from ARQ77dm. 
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3.2 Cell culture model used to investigate in vivo effects of serine site 
mutations 
 In order to characterize the four structurally diverse AR variants, the receptors 
were transiently expressed in COS7 cells, an African green monkey kidney fibroblast-like 
cell line that is AR deficient. This cell line was chosen due to its reliable transfection 
efficiency and because of its proven ability to act as a model for the different polyQ 
disorders (Ho et al., 2001; Nozaki et al., 2001; Bailey et al., 2002; Chou et al., 2006).  
 
3.2.1 Mutation of serine 424 and 514 residues affects nuclear localization and 
transactivation by the AR 
 The localization of the polyQ proteins to the nucleus has been deemed a key 
aspect in polyQ pathogenesis (Klement et al., 1998; Saudou et al., 1998; Diamond et al., 
2000). As a ligand-activated transcription factor, the AR is dependent on androgen 
binding for relocation from the cytoplasm to the nucleus. Therefore, models of SBMA 
are also dependent on the ligand binding that leads to nuclear localization for aggregation 
and toxicity to occur. Another aspect closely linked to this nuclear translocation is the 
alteration of transcriptional activity in polyQ affected neurons. Several reports have 
indicated the polyQ proteins in disruption of transcription (Riley and Orr, 2006). In the 
case of the polyQ expanded AR in SBMA, the AR itself is known to exhibit altered 
transcriptional activity (Thomas et al., 2006b).  Hence, an initial way to characterize the 
effects of mutating serine sites 424 and 514 in the wild type and polyQ AR was to 
examine changes in cytoplasmic-nuclear transport as well as differences in 
transactivation by the receptors following hormone treatment.  
 
 
 
 
 
 
 
 
 64
3.2.1.1 Accumulation of AR in nucleus altered with AR mutants 
To view changes in the compartmentalization of the AR, the wild type and 
mutated AR expression vectors were transiently transfected in COS7 cells. Cells were 
then treated with the androgen 5α-dihydrotestosterone (DHT) for varying time points up 
to 2.5 h to allow for redistribution. After harvesting and fixation of the cells, staining with 
an AR antibody that was then followed by a fluorescently labelled secondary antibody 
allowed for visualization of the subcellular distribution of the AR. All 
immunofluorescence experiments were performed in collaboration with Dr. Shatkina.   
The cytoplasmic-nuclear localizations of the receptors were grouped into four 
categories as illustrated in Fig. 3.3A, and the statuses of the AR variants were thus able to 
be compared at the different time points. First noted was a marked delay and decrease in 
nuclear accumulation of ARQ77 compared to ARQ22 as previously reported (Becker et 
al., 2000) (Figs. 3.3B and C). Surprisingly, when compared with the wild type ARQ22, 
the ARQ22dm also showed a lag in nuclear accumulation at 30 min and 1.5 h after 
treatment with DHT (Fig. 3.3D; *p≤0.05). The reverse effect was observed in the 
cytoplasmic-nuclear transport of ARQ77dm when compared with its ARQ77 counterpart 
in that there was an increase in the percentage of cells exhibiting a nuclear distribution, 
especially after 30 min and 1.5 h of DHT treatment (Fig. 3.3E; * p≤ 0.05). The majority 
of transfected cells containing each of the AR constructs showed nuclear staining after 
2.5 h of hormone treatment.  
From these experiments it could not be determined whether a true delay in nuclear 
transport was occurring or rather an increase in fast nuclear export of the receptor. In 
either scenario, it was reasoned that the presence or lack-thereof of the AR in the nucleus 
may affect transcriptional activity and other facets of polyQ pathogenicity.  
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Figure 3.3 Kinetics of cytoplasmic-nuclear transport is altered after mutation of serine residues 424 
and 514 
COS7 cells were transiently transfected with 1.5 µg ARQ22, ARQ22dm, ARQ77 or ARQ77dm 
expression vector. Approximately 48 h after transfection, the cells were treated either with vehicle or 10-7M 
DHT for the indicated time periods, harvested, and stained with a mouse monoclonal anti-AR antibody 
F39.4.1 followed by an anti-mouse antibody labeled with a fluorescent dye Cy3. The cells were visualized 
with a LSM 510 inverted Zeiss confocal microscope. (A) Subcellular localization of the AR proteins was 
determined by the percentage of positive stained cells and was categorized into the four indicated stages. 
The bar charts show the percentage of cells at each stage for (B) ARQ22, (C) ARQ77, (D) ARQ22dm, and 
(E) ARQ77dm after control and hormone treatment for the indicated time periods. For each AR construct, 
at each time point, 200-250 cells were analyzed in three different experiments. The results show the 
average values of these analyses and the results of ARQ22dm and ARQ22 as well as ARQ77dm and 
ARQ77 were compared by t-test *p≤0.05 
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3.2.1.2 Transactivation by wild type AR affected by polyQ stretch and serine mutations 
As demonstrated by the nuclear localization assay, treatment of the AR with DHT 
leads to accumulation of the AR in the nucleus. Once in the nucleus, the AR binds to 
androgen responsive elements (AREs) of DNA and regulates gene transcription. In order 
to determine whether the differences seen in the kinetics of nuclear localization translated 
into differences in transcriptional activity of the AR constructs, a luciferase-reporter gene 
assay was utilized to measure the transactivation activity by the wild type and mutated 
AR expression vectors. Each of the AR constructs were transiently transfected in COS7 
cells in conjunction with a reporter plasmid containing the firefly luciferase gene under 
the control of the mouse mammary tumor virus (MMTV), whose long-terminal repeat 
(LTR)-promoter contains hormone responsive elements. Therefore, any hormone-
dependent gene regulation through the AR would lead to production of luciferase, which 
emits light with interaction of its cognate substrate luciferin. Transactivation activity by 
the AR could thus be quantified by adding luciferin substrate to cell lysates and using a 
luminometer to measure light production. Aditionally, a Renilla luciferase reporter 
construct was co-transfected as an internal control. A comparison of firefly luciferase 
activity to Renilla luciferase activity yielded the relative luciferase/transactivation 
activity for each experiment.  
The most obvious disparity in transcriptional activity by the four receptors was 
due to the presence of the polyQ expansion. Not only did the ARQ77 background 
demonstrate lower basal activity in comparison to the receptors containing a polyQ 
stretch of 22 (Fig. 3.4A) but the fold induction was also considerably reduced (Fig 3.4B). 
This result corroborated the inverse correlation between polyQ length and transactivation 
by the AR that has been previously reported (Irvine et al., 2000; Thomas et al., 2006b). 
As for the effect of the serine site mutations, the ARQ22dm showed a significant 
decrease in basal activity in comparison to the wild type ARQ22 (Fig. 3.4A; *p≤0.05, 
**p≤0.005).  This decrease in basal activity also meant an overall decrease in 
transcriptional activity following treatment with DHT, a pattern similar to that of the 
toxic polyQ AR. However, the presence of the serine mutations resulted in an increase in 
fold-induction for the ARQ22 background (Fig. 3.4B), demonstrating this particular 
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Figure 3.4 Transactivation by the AR is altered in mutant variants 
 
COS7 cells were transiently transfected with 0.5 µg pSG5 vector, ARQ22, ARQ22dm, ARQ77 or 
ARQ77dm expression vector, 0.3 µg TKRenilla, and 1.2 µg MMTV or Probasin. Approximately 24 h after 
transfection, cells were treated either with vehicle or 10-7M DHT for 16 h. Cells were then harvested and 
assessed for luciferase activity. TKRenilla activity was used as an internal control. (A) Relative luciferase 
activity using the MMTV promoter was lower for the ARQ22dm in comparison to ARQ22. (B) However, 
the ARQ22dm shows a higher fold induction. The fold induction by DHT was calculated based on the 
mean relative luciferase activities. (C) The probasin promoter revealed the same trend of lower 
transcriptional activity. (D) Fold induction values for the probasin promoter were similar to that of the 
MMTV. *p≤0.05, **p≤0.005; Error bars represent standard deviation. 
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receptor’s unique properties. There were no significant differences in activity with and 
without hormone treatment between the ARQ77 and ARQ77dm constructs.  
As an alternative to the MMTV promoter, which responds not only to androgens 
and glucocorticoids but also mineralocorticoids and progestins through inverted repeat 
glucocorticoid responsive elements (GREs) (Ham et al., 1988), the probasin promoter 
was also used to assess changes in hormone-dependent transcriptional activity. The 
probasin gene codes for a rat prostate protein and is regulated in vitro (Dodd et al., 1983) 
and in vivo by androgens (Rennie et al., 1993). Androgen induction of expression of the 
probasin gene is mediated by two direct repeat androgen receptor binding sites and thus 
exhibits strong AR-specific regulation. Use of the probasin promoter did indeed lead to 
an increase in androgen responsiveness (compare Figs. 3.4 A and B with C and D). 
However, the overall depiction of transactivation was not so different from the MMTV 
results (Figs. 3.4C and D). With the probasin promoter, the overall activity of the 
ARQ22dm was again significantly reduced in comparison to the wild-type ARQ22 (Fig. 
3.4C; * p≤ 0.05), and the increase in fold induction by the ARQ22dm was reproduced. 
Also, the serine mutations again did not affect the lower basal transcriptional activity or 
fold inductions seen in the ARQ77 background (Figs. 3.4C and D).  
With alterations in nuclear localization (ARQ22dm and ARQ77dm) and 
transcriptional activity (ARQ22dm) established, it was deemed necessary to further 
explore how the serine site mutations altered the wild type and toxic polyQ AR 
properties. Therefore, the AR variants’ propensity to form the aggregates that are 
characteristic of the polyQ disorders was explored.  
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3.2.2 Mutation of serines 424 and 514 affects the formation of intracellular 
inclusions by the AR 
 A major defining feature of the polyQ disorders is the formation of polyQ protein 
aggregates. The complex biochemical process of aggregation encompasses everything 
from soluble monomers and oligomeric intermediates to small protofibrils and finally 
insoluble fibrilar aggregates (Ross, 2002). A large body of research has thus revolved 
around characterization of aggregate species and the role that these different species play 
in the polyQ disease mechanisms. Because aggregation is believed to originally stem 
from an altered conformational structure of the polyQ protein due to the presence of the 
polyQ stretch, it follows that other structural alterations would produce deviations in the 
aggregation pathway. Indeed, several studies have shown that alterations in covalent 
modifications can globally increase or inhibit aggregation of the polyQ proteins 
(Humbert et al., 2002; Emamian et al., 2003; Fei et al., 2007).  To take the premise one 
step further, the wild type and conformationally diverse AR variants were tested for their 
ability to form inclusions in the cell; and these aggregates were characterized by kinetics, 
structure, localization, and solubility.  
 
3.2.2.1 Inclusions differ in structural type and kinetics of formation 
In order to visualize cellular inclusions produced by the four AR constructs, 
immunofluorescence studies were performed in collaboration with Dr. Shatkina. Because 
nuclear localization of the AR is required for aggregation and toxicity in SBMA, the time 
course necessary for AR nuclear translocation was chosen to observe inclusion formation. 
The AR expression vectors were transiently transfected in COS7 cells, and the cells were 
treated with DHT for varying time points up to 2.5 h to allow for redistribution. The cells 
were then harvested, fixed, and stained with an AR antibody followed by a fluorescently 
labelled secondary antibody. Confocal microscopy was utilized to image the formed 
inclusions.  
A number of cells expressing the receptors showed intracellular inclusions. The 
inclusions formed by each of the AR constructs differed in size, structure, and 
localization. The aggregates were characterized as being cytoplasmic or nuclear (C or N)  
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Figure 3.5 Mutation of serine 424 and 514 alters kinetics of formation of intracellular inclusions 
COS7 cells were transiently transfected with 1.5 µg ARQ22, ARQ22dm, ARQ77 or ARQ77dm 
expression vector. Approximately 48 h after transfection, the cells were incubated on ice for 1 h, thereafter 
treated either with vehicle or 10-7M DHT at 37°C for the indicated time periods, harvested, and stained with 
a mouse monoclonal anti-AR antibody F39.4.1 followed by an anti-mouse antibody labeled with the 
fluorescent dye Cy3. The cells were visualized with a LSM 510 inverted Zeiss confocal microscope. 
Intracellular inclusions were determined by the percentage of positively stained cells containing AR 
inclusions after control treatment and incubation with the hormone. (A) Intracellular inclusions were 
categorized by type and localization: fibrous nuclear (fN), fibrous cytoplasmic (fC), globular nuclear (gN), 
or globular cytoplasmic (gC). The bar charts show the percentage of cells for each category for (B) ARQ22, 
(C) ARQ77, (D) ARQ22dm, and (E) ARQ77dm after control treatment and incubation with hormone. For 
each AR construct at each time point 200-250 cells were analyzed in three separate experiments. (F) Total 
cytoplasmic aggregation was quantified and ARQ22dm and ARQ77dm were compared by t-test to ARQ22 
and ARQ77 respectively.  *p<0.05, **p<0.001, ***p<0.0005 
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as well as being either of a diffuse, fibrous nature, or large and globular structures (f or g) 
(Fig. 3.5A). On the whole, no significant differences in inclusions in the nucleus among 
the AR constructs were detected (Figs. 3.5B-E). The majority of the inclusions seen in 
this and earlier experiments performed in the lab appear to be localized in the cytoplasm. 
Both the cytoplasmic fibrous and globular inclusions (fC and gC) were significantly 
increased in ARQ22dm expressing cells but decreased in ARQ77dm expressing cells in 
comparison to ARQ22 and ARQ77, respectively (Fig. 3.5 compare panels B with D and 
C with E). The overall quantification of the results showed that after 15 min of hormone 
treatment, cells with the ARQ77 showed a marked increase in intracellular inclusions 
(Fig. 3.5F). As this receptor moved into the nucleus, the number of cells with inclusions 
decreased but was still significantly higher than the ARQ22 cells. The mutation of the 
two serine residues had different effects on the receptors. In comparison to the wild type 
ARQ22, the ARQ22dm showed an increase in the percentage of cells with inclusions 
over the 2.5 h time-course of hormone treatment. In the ARQ77 background, the double 
mutation (ARQ77dm) reduced the intracellular inclusions throughout the 2.5 h treatment 
with DHT (Fig. 3.5F).  
 These results demonstrated that the mutation of AR serine sites 424 and 514 could 
either globally inhibit (ARQ77) or increase (ARQ22) inclusion formation, depending on 
the length of the polyQ stretch. More specifically, the inhibition or increase affected 
cytoplasmic inclusions and was fairly constant over the time course after an initiation at 
15 min. The next step in differentiating between the AR wild type situation and the 
demonstrated aggregation processes of the mutant AR variants was to examine the 
solubility of the inclusions. 
 
3.2.2.2 Both polyQ stretch and presence of serine mutations affect solubility of 
inclusions 
One of the first diagnostic markers for the polyQ disorders was the presence of 
detergent-insoluble aggregated polyQ protein in post-mortem tissue (DiFiglia et al., 
1997). An often used method to assay for the presence of aggregates has thus been to test 
the solubility of tissue or cellular fractions in the detergent sodium dodecyl sulphate 
(SDS), a denaturing agent that disrupts non-covalent bonds in the proteins. Two 
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particular assays used to analyze the solubility of cellular inclusions are the filter 
retardation assay and SDS-PAGE-western blot analysis of polyQ cellular lysates. In the 
filter retardation assay, the intracellular inclusions are trapped on cellulose acetate 
membrane as SDS-insoluble aggregates (Heiser et al., 2002) while SDS-PAGE-western 
blot analysis allows detection of SDS-insoluble aggregated protein that remains in the 
SDS-PAGE stacking gel (Merry et al., 1998).  
For the filter retardation assay, COS7 cells were transfected with the different AR 
expression vectors and treated up to 2.5 h with DHT to analyze inclusion solubility over 
the time course required for nuclear translocation. Cellular lysates were applied to a 
cellulose acetate membrane and vacuumed through, leaving any insoluble material 
behind. AR aggregates were then visualized by probing the membrane with an AR 
antibody and utilizing chemiluminescence detection. Insoluble material in both ARQ77 
and ARQ77dm transfected cells were detected throughout the time course of the 
experiment (Fig. 3.6A; upper panel). In the case of the ARQ22 and ARQ22dm expressing 
cells, insoluble material was only detected in ARQ22dm transfected cells at the earliest 
time points of DHT treatment (15min – 1 h). In contrast no significant insoluble material 
was identified for the ARQ22 expressing cells (Fig. 3.6A; upper panel). All four receptor 
variants were expressed to a similar level as determined by dot blot analysis of the same 
lysates (Fig. 3.6A; lower panel). 
As aggregation is a dynamic process, it was also desirable to examine the 
solubility of inclusions after longer time points. Intriguingly, after a lengthy 72 h of 
hormone treatment, insoluble material could only be detected in lysates of cells 
expressing ARQ77 and ARQ77dm (Fig. 3.6B). A comparable result was also obtained by 
SDS-PAGE-western blot analysis of lysates of transiently transfected COS7 cells treated 
for 16 h with DHT or vehicle (Fig. 3.6C). Again, the receptor variants were expressed to 
similar levels as determined by immunoblot assays (Fig. 3.6C; lower panel).  
From the above results, it seems that the ARQ22dm transfected cells that had 
previously been scored as showing an increase in intracellular inclusions in the 
immunofluorescence assay appear to contain receptor aggregates that are insoluble only 
at time points up to 1 h as determined in the filter retardation assay. It is therefore likely 
that these aggregated proteins are only transiently formed and decrease with time, or their 
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state of solubility changes with time. It also follows that these ARQ22dm inclusions 
structurally differ from those produced from the receptors with the ARQ77 background. 
Assays to determine the structure of the aggregates are thus necessary to fully distinguish 
between the AR variants.  
 
 
 
 
 
Figure 3.6 Differences in aggregate formation due to mutations at serine residues 424 and 514  
Filter retardation assays were performed to determine the solubility of aggregates formed by AR 
constructs. COS7 cells were transiently transfected and induced with vehicle or 10-7M DHT for the 
indicated time points. Cells were harvested and lysed in NP-40 lysis buffer. Protein concentration and AR 
expression were determined by Bradford assay and subjected to Western blot or dot blot analysis, 
respectively. Protein samples were diluted in 2% SDS/ 50mM DTT and loaded on a cellulose acetate 
membrane. Insoluble material was trapped on the membrane after application of a vacuum. (A) FT: filter 
trap assay using 5 μg protein from ARQ22, ARQ22dm, ARQ77, and ARQ77dm transfected cells after 
control treatment and incubation with hormone.  DB: Dot blot analysis of 1 μg protein of cell lysates used 
for the filter retardation assay demonstrates an approximately equal amount of AR expression.  (B) Filter 
trap assay using 0.5, 5, 10, and 20 μg protein from ARQ22, ARQ22dm, ARQ77, and ARQ77dm 
transfected cells after control treatment and incubation with hormone for 72 h (C) Western blot analysis of 
whole cell lysates after 16 h hormone treatment demonstrating aggregates in the stacking gel of a 4% 
stacking/ 12.5% running, SDS-polyacrylamide gel 
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3.2.2.3 1C2 antibody preferentially recognizes expanded polyQ region 
In an attempt to further characterize differences in aggregation and conformation 
of the AR due to the polyQ stretch and/or the serine site mutations, 1C2 
immunoreactivity was examined. The 1C2 antibody is thought to recognize an epitope, 
which is associated with toxicity, formed by misfolded proteins with long glutamine 
tracts (Trottier et al., 1995). For the purpose of distinguishing between the wild type and 
AR variants in this work, it was found that using equal amounts of the AR variants in 
immunoblot assays and staining them with the 1C2 antibody only identified the extended 
polyQ stretches in the ARQ77 and ARQ77dm proteins. The 1C2 antibody was unable to 
distinguish between more subtle structural alterations or changes in toxic properties (Fig. 
3.7). Thus more robust models that measure possible toxic effects of the ARQ22dm as 
well as changes in toxicity of the ARQ77dm were needed to clarify the alterations in 
nuclear localization, transcription, and inclusion formation and solubility that were 
evident in the cell culture model.  
 
 
 
 
Figure 3.7 Serine mutations do not alter 1C2 reactivity 
COS7 cells were transiently transfected and induced with vehicle or 10-7M DHT. Whole cell 
lysates were used for western blot analysis with AR F39.4.1 (1:1000) and 1C2 (1:5000) antibodies. The 
equally loaded lysates on the gel show that the 1C2 antibody preferentially recognizes the ARQ77, 
regardless of the presence of the serine site mutations.  
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3.3 Drosophila model of SBMA used to analyze effects of serine site 
mutations 
Drosophila have been successfully used to model human neurodegenerative 
diseases such as Parkinson´s pathology as well as polyQ expansion disorders such as 
SCA3, Huntington’s disease, and SBMA (Warrick et al., 1998; Feany and Bender, 2000; 
Fortini and Bonini, 2000; Takeyama et al., 2002). Each of these models have utilized a 
GAL4-UAS expression system in which a transgenic Drosophila line containing the 
yeast transcriptional activator GAL4 under the control of a specific promoter (or 
enhancer) is crossed with a second transgenic line containing the gene of interest under 
the control of the GAL4-repsonsive UAS target gene (Phelps and Brand, 1998). This 
allows for expression of the gene of interest (the polyQ proteins) in specific tissues 
according to the type of promoter/enhancer used. Using this Drosophila expression 
system, Takeyama et al., 2002, demonstrated neuronal degeneration upon hormone 
treatment through ectopic expression of the AR with an amplified polyQ stretch in the fly 
eye. A similar approach to analyze the potentially toxic properties of the mutant AR 
variants was employed by creating four transgenic AR lines by microinjection of ARQ22, 
ARQ22dm, ARQ77, and ARQ77dm constructs. Through crosses with GAL4 transgenic 
lines, the constructs were expressed in the photoreceptor neurons of the eye under the 
control of the glass multimer reporter (GMR) or throughout the central nervous system 
under the control of the pan-neuronal embryonic lethal abnormal visual system (ELAV) 
promoter. As in previous SBMA Drosophila models (Takeyama et al., 2002), ingestion 
of DHT during the larval stages of development was sufficient to induce toxicity. The 
chosen hormone concentrations were also in the range of those previously used 
(Takeyama et al., 2002; Pandey et al., 2007). 
 
3.3.1 Conformational changes induced by mutation of serines 424 and 514 in 
Drosophila 
 In order to verify that the Drosophila system could accurately model the toxic 
effects of the AR variants, it was confirmed that the initial results of structural alteration 
seen in vitro could also be validated in the animal model. Transgenic flies were first 
crossed with ELAV-GAL4 flies in order to have AR expression in the central nervous 
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system. Then, in the same vein as the limited proteolytic digestion of the in vitro 
translated receptors, a partial tryptic digest on lysates made from the AR-expressing 
Drosophila was performed. Although there were no clear differences in the pattern of 
digestion between the ARQ22 and ARQ22dm or the ARQ77 and ARQ77dm, the 
receptors containing the serine site mutations did show a greater resistance to the tryptic 
digestion (Fig. 3.8). Therefore, despite differences in pattern and digestion resistance in 
comparison to the in vitro translated receptors, it was verified that the serine site 
mutations also seemed to alter the AR structure in the Drosophila model. 
 
 
 
Figure 3.8 Mutation of serine residues 424 and 514 leads to conformational changes in androgen 
receptors expressed in Drosophila  
 AR fly lines and ELAV-GAL4 flies were crossed on normal stock medium. Lysates were made 
from adult progeny, and the protein concentrations were determined by Bradford assay. 20 μg of lysate was 
used for each trypsin concentration. The digestion reaction was carried out for 15 min at room temperature 
before being stopped by the addition of denaturing gel loading dye. The products were then fractionated on 
an 8% SDS-polyacrylamide gel and were visualized by western blot analysis using AR antibody (N-20).  
 
3.3.2 Mutations of serines 424 and 514 affect nuclear accumulation and aggregation 
of the AR in a fly model of SBMA 
 In an effort to corroborate results seen in cell culture as well as further validate 
the AR Drosophila model, in vivo nuclear localization and aggregation of the AR in the 
four transgenic lines were examined. The immunofluorescence and filter retardation 
assays from cell culture experiments were thus adapted for Drosophila tissues and protein 
lysates. 
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3.3.2.1 Mutant AR demonstrates altered nuclear localization in fly lines 
 To observe changes in compartmental distribution of the AR, 
immunohistochemical analysis was performed on the brains of transgenic third instar 
larvae treated with and without hormone. Experiments were performed utilizing both the 
GMR and ELAV drivers, both of which allowed for discernible AR expression in the eye 
imaginal discs. Flies expressing the GMR driver and AR constructs were allowed to grow 
on stock food without or with 10-3M DHT for the time period between hatching and the 
wandering third instar larval stage, while flies expressing the ELAV driver were only 
treated for 72 h due to the toxic effects on survival. Once the larvae reached the third 
instar stage, brains were fixed and stained for AR expression for viewing with confocal 
microscopy. Both the ELAV (not shown) and GMR drivers (Fig. 3.9A) produced similar 
results when employed to examine neurons expressing the AR constructs in the eye 
imaginal discs of third instar larvae. Equal expression of the AR constructs in the fly lines 
was demonstrated by western blot analysis (Fig. 3.9B). 
 In the GMR flies treated with or without hormone, the ARQ22 receptor showed a 
tendency towards nuclear localization (Fig. 3.9A); however, the effect was more 
pronounced upon DHT treatment (Fig. 3.9A see higher magnification yellow overlay 
color). ARQ22dm, ARQ77, and ARQ77dm expressing neurons in the eye imaginal discs 
all showed a propensity for the receptor to cluster in the cytoplasm after hormone 
treatment (Fig. 3.9A). For each of these three lines, although some nuclear localization 
was evident only after DHT treatment, there appeared to be a lack of nuclear 
accumulation, which was not evident in the ARQ22 larvae. Although this assay did not 
allow for discrimination between the ARQ22dm, ARQ77, and ARQ77dm, these in vivo 
results paralleled the reduced nuclear accumulation seen in cell culture experiments. The 
next verification of polyQ pathogenesis was to test for the presence of aggregates as well 
as additional structural features of the AR variants in the fly lines.  
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Figure 3.9 Nuclear localization of AR in Drosophila 
AR fly lines and GMR-GAL4 flies were crossed on medium containing vehicle (ethanol) or 10-3M 
DHT and progeny were allowed to feed until the third instar wandering larval stage. (A) Brains were 
dissected from larvae, fixed, and stained with AR C-19 and Draq5 for nuclear staining, followed by an anti-
rabbit antibody labelled with Cy2. Cells of the eye imaginal disc were visualized with an LSM 510 inverted 
Zeiss confocal microscope. (B) Lysates were made from adult flies of the same crosses used for 
immunfluorescence in order to demonstrate equal AR expression levels. 
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3.3.2.2 Aggregation and 1C2 recognition in fly lines comparable to cell model 
Because misfolding and aggregation of the mutant polyQ proteins is such a 
central theme in the polyQ disorders, it is important to establish disease models that can 
reproduce this feature. Therefore, aggregation of the AR driven by ELAV in third instar 
wandering larvae was examined by adapting the filter retardation assay used in the cell 
culture model (Fig. 3.10A). Two days after hatching, the transgenic larvae were placed 
on medium containing 10-3M DHT or vehicle for a total of 72 hours. By this time the 
larvae had reached the third instar stage of development and were then homogenized for 
protein extracts for aggregation analysis. As with the results of the filter retardation assay 
using lysate from cultured cells, larvae treated with DHT generated insoluble AR protein 
in the ARQ22dm, ARQ77, and ARQ77dm lines, in comparison to larvae treated with 
vehicle alone. However, ARQ77 larvae also showed slight levels of insoluble aggregate 
formation without hormone treatment. Any aggregation seen in the ARQ22 larvae treated 
without or with 10-3M DHT appeared to be negligible.  
 
 
 
Figure 3.10 Aggregation and conformation of AR in transgenic Drosophila 
(A) Aggregation was assessed using the filter trap assay. Third instar larvae treated without and 
with hormone were homogenized in 2 μl RIPA/larvae. Samples were then prepared as described for cell 
lysates. Protein concentrations of the larval lysates were measured by Bradford assay and 50 μg were 
loaded on the cellulose acetate membrane. (B) GMR-GAL4 flies were crossed with the AR transgenic flies 
on medium with 10-3M DHT or vehicle. Extracts were produced from heads of 50 adult progeny. 
Drosophila lysates were immunoprecipitated using the AR44 antibody. Western blot analysis was then 
used to demonstrate that the 1C2 antibody preferentially recognizes the ARQ77 also in Drosophila, 
regardless of the presence of the serine site mutations.  
 
 80
In a second attempt to associate a particular structural conformation with the 
levels of aggregation, 1C2 immunoreactivity was also tested on Drosophila extracts from 
adult flies treated with and without hormone. However, again staining of the Drosophila 
extracts was only observed for the ARQ77 and ARQ77dm samples as shown in the cell 
culture experiments (Fig. 3.10B). Lysates prepared from both ELAV and GMR crosses 
yielded identical results.  
The combined results regarding nuclear accumulation and aggregation together 
with the differences in basic AR conformation, all properties closely associated with 
polyQ toxicity, substantiated the cell culture data in an in vivo model and demonstrated 
that the Drosophila model was a reliable system. Therefore, the fly model was used to 
directly measure the differences in toxicity due to the serine site mutations. 
 
3.3.3 Neurodegeneration occurs in fly lines expressing AR with mutations at serine 
residues 424 and 514  
A frequently used assay to directly guage toxicity in Drosophila models of the 
polyQ disorders is to ectopically express the polyQ protein of interest in the eye of the fly 
and then score the flies for degeneration and morpholocial disruption of the eye (Jackson 
et al., 1998; Bonini, 1999; Takeyama et al., 2002). To examine neurodegeneration in the 
present Drosophila model, flies demonstrating similar expression levels of the AR under 
the control of the photoreceptor expressed GMR promoter (Fig. 3.11B) were treated 
without or with 10-3M DHT for the 5-day time period between hatching and pupation. 
After eclosion, fly eyes were preliminarily examined by light microscopy (LM) and then 
scanning electron microscopy (SEM) (Fig. 3.11A). Compound eyes of flies expressing 
ARQ22 and ARQ22dm looked normal even at higher image magnification (Fig. 3.11A). 
Flies expressing ARQ77 and ARQ77dm showed very slight deformations in the absence 
of hormone (Fig. 3.11A). Ingestion of DHT resulted in disruption of eye morphology for 
flies expressing ARQ77 as previously reported (Takeyama et al., 2002). DHT treatment 
also resulted in disruption of eye morphology for those flies expressing ARQ77dm and 
ARQ22dm but to somewhat reduced levels in comparison to ARQ77 flies (Fig. 3.11A). 
In contrast, the presence of DHT did not affect the eye morphology of the wild type 
ARQ22 transgenic flies.  
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Figure 3.11 Ligand-induced degeneration of photoreceptor neurons in flies containing amplified 
polyQ stretch and serine 424/514 mutations 
AR fly lines and GMR-GAL4 flies were crossed on medium containing vehicle (ethanol) or 10-3M 
DHT and progeny were allowed to feed for 5 days after hatching and before pupation. After eclosion of 
progeny, heads were collected and examined by light microscopy (LM). Afterwards, heads were fixed in 
increasing concentrations of ethanol for SEM analysis. (A) LM and SEM of the compound eyes of 
transgenic flies with and without DHT treatment. (B) Immunoblots with 20 μg lysate of the transgenic fly 
heads using anti-AR antibody and an anti- α-tubulin antibody.  
 
While the demonstrated differences in toxicity by introduction of the serine site 
mutations in the ARQ22 background were definitive, the slight differences between the 
ARQ77 and ARQ77dm were not as clear using the qualitative neurodegeneration assay. 
For this reason, a set of quantitative behavioral and survival experiments were designed 
to measure pathogenicity. 
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3.3.4 Mutation of serine residues 424 and 514 affects locomotion and survival of fly 
lines expressing ARQ22 and ARQ77 
 Neuronal expression of polyQ proteins has been reported to cause defects in larval 
development in polyQ Drosophila models (Lee et al., 2004). These defects can result in 
manifestations of behavioral abnormalities as well decreased rates of survival. The 
following locomotion and survival assays were hence used to assess toxic defects in 
larval development due to the presence of the polyQ stretch and/or the serine site 
mutations in the AR transgenic fly lines. 
 
3.3.4.1 Locomotion assay demonstrates subtle differences between AR mutant lines 
In order to better quantify differences in pathogenicity in the four fly lines, the 
transgenic flies expressing the AR under the control of the pan-neuronal ELAV promoter 
were used to monitor differences in locomotion and behavior. Larvae were allowed to 
develop for three days before hormone treatment due to toxic effects on survival. A set 
number of larvae were then transferred to medium without or with 10-3M DHT. After 
approximately 48 h of treatment, the then wandering third instar larvae were placed in the 
center of an agar plate that was evenly illuminated by a light box; and the larvae were 
monitored for 2.5 min using Noldus software for behavioral analysis. The Noldus 
program allowed for assessment of speed of motion and angular velocity. Angular 
velocity of the larvae was defined as change in direction of movement per unit time and 
was used to quantify the subtle directional changes of movement of the larvae.  
The wild type situation for the locomotion assay was demonstrated by the ARQ22 
larvae. On average, when a larva from this group was placed on the agar plate, it moved 
in a relatively straight path to the edge of the plate at a rate of approximately 0.16 mm/s. 
Hormone treatment was expectedly shown to have no significant effect on the speed or 
angular velocity for the ARQ22 larvae (Figs. 3.12A and B). The tendency to make an 
overall direct path was also not modified by administration of hormone (Fig. 3.12C). In 
the context of the ARQ22 background, mutation of the two serine sites resulted in a 
significant reduction in locomotor speed upon hormone treatment (***p<0.0005; Fig. 
3.12A). An increase in angular velocity provided further evidence for defects of the 
central motor pattern generator in the ARQ22dm larvae (Fig. 3.12B) as did the pattern of 
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the overall path of the larvae (Fig. 3.12C). As anticipated, larvae expressing the ARQ77 
and treated with hormone demonstrated great deficits in locomotor speed and patterning 
(Figs. 3.12A, B, C). The hormone treated ARQ77dm larvae also showed difficulty in 
movement in comparison to the wild type ARQ22 larvae, but there was a small but 
significant improvement in comparison to ARQ77 larvae (*p<0.05; Figs. 3.12A, B, C). 
These results gave the first significant evidence of changes in toxicity levels attributable 
to the AR mutations at serines 424 and 514. 
 
 
 
Figure 3.12 Locomotive and behavioral analysis of transgenic wandering third-instar larvae 
AR fly lines and ELAV-GAL4 flies were crossed on normal stock medium. Progeny were 
transferred after 72 h to medium containing vehicle (ethanol) or 10-3M DHT for 48 h treatment. A total of 
30 larvae were analyzed for each genotype and hormone treatment combination. (A) With hormone 
treatment ARQ22dm larvae showed a 20% deficit in speed in comparison to their ARQ22 counterparts. 
ARQ77dm larvae showed a 10% improvement over the ARQ77 larvae. (B) The subtle angular movement 
of the larvae as measured by angular velocity was greatly increased in the case of the ARQ22dm and 
ARQ77 larvae. Mutation of the serine resides in the ARQ77 background resulted in a small amelioration of 
the phenotype. *p<0.05, ***p<0.0005. (C) Sample overall locomotive paths of the wandering third-instar 
larvae. 
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3.3.4.2 Transgenic lines demonstrate changes in survival dependent upon serine site 
mutations 
A further way to distinguish between the toxic effects of the polyQ stretch and the 
serine site mutations was to examine survival rates of the transgenic Drosophila. For 
viability assays the AR was expressed pan-neuronally by crossing transgenic lines with 
the ELAV promoter line. Directly after hatching, the progeny were transferred to food 
containing DHT or EtOH alone as vehicle and allowed to feed until pupation for the full 
effects of hormone treatment. The first developmental stage where a divergence in 
survival rates could be calculated was the pupal stage, in which the larvae climb out of 
the food and pupate on the container walls. Therefore, the number of larvae reaching this 
pupal stage of development (Fig. 3.13A) was determined in addition to determining 
survival rates for the fully eclosed adult stage (Fig. 3.13B). Both stages of survival rates 
were calculated based on the total number of original larvae.  
The percentage of larvae expressing the ARQ22 that survived to the pupal or 
adult stages in the absence and presence of hormone was not significantly different, 
demonstrating no defects in larval development for this wild type group (Figs. 3.13A and 
B). In contrast, the ARQ22dm demonstrated a marked decrease in survival at both the 
pupal and adult stages in the presence of hormone. Larvae expressing ARQ77 survived 
poorly in the presence of hormone. However, in the context of the ARQ77 background, 
the double mutation showed a small improvement in the survival percentage in the 
presence of hormone (Figs. 3.13A and B).  
 The above survival analysis supplemented the data from the locomotion assay, 
demonstrating again quantitatively that the serine site mutations affected toxicity in a 
polyQ length-dependent manner. However, although the pathogenicity exhibited by the 
ARQ22dm was in vast contrast to the normal ARQ22 situation, it was apparent that the 
toxicity levels were also not quite on par with those of the ARQ77 SBMA model. It was 
deemed that one method of comparing the types of toxicity was to determine how 
specific inhibitors of polyQ toxicity would affect the AR variants. 
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Figure 3.13 Survival studies of larvae with ubiquitous neuronal expression of AR with amplified 
polyQ stretch and AR containing mutated serine sites  
AR fly lines and ELAV-GAL4 flies were crossed on normal stock medium. After hatching of 
progeny, larvae were transferred to medium containing vehicle (ethanol) or 10-3M DHT with a maximum of 
50 larvae per vial. The total larvae for each sample was >100. Data are from three separate experiments. 
The error bars represent standard deviation of the mean. (A) The percentage of larvae surviving to the 
pupal stage was determined by the number of pupae formed divided by the original number of larvae 
placed in the vial. (B) The percentage of larvae surviving to posteclosion was determined by the number of 
eclosed adult flies divided by the original number of larvae placed in the vial. *p<0.05, ***p<0.0005 
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3.4 Inhibitors of polyQ toxicity used to demonstrate differential toxicity 
due to serine site mutations 
Previous studies have been able to demonstrate in mouse and Drosophila models 
that sodium butyrate, a histone deactylase (HDAC) inhibitor, is a viable therapeutic agent 
for polyQ toxicity as well as other forms of neurodegeneration (McCampbell et al., 2001; 
Steffan et al., 2001; Minamiyama et al., 2004; Fischer et al., 2007). Of the many other 
drug possibilities that have been examined for the polyQ disorders, Parkinson’s, and 
Alzheimer’s disease, melatonin is also a suggested agent due to its widespread effects, 
which include antioxidant properties (Srinivasan et al., 2006). The effects of treating the 
four Drosophila lines with the known inhibitor sodium butyrate and melatonin were 
compared in order to determine firstly if melatonin is a capable inhibitor of polyQ 
toxicity and secondly to compare the effects of tested polyQ inhibitors on the serine 
mutant lines. The aim was to further distinguish the lesser toxicity seen with the 
ARQ22dm and ARQ77dm with toxicity caused purely by the expanded polyQ region. 
 
3.4.1 Sodium butyrate and melatonin inhibit neurodegeneration in expanded polyQ 
fly lines 
The effects of melatonin as an inhibitor of polyQ toxicity were preliminarily 
tested by examining the neurodegeneration and morphological damage in the eyes of 
Drosophila from crosses between the AR transgenic lines and GMR-GAL4 flies. Flies 
were treated with DHT or vehicle alone or in combination with the inhibitor compounds 
for the 5-day period between hatching and pupation. After eclosion, the flies were then 
examined by light microscopy (Fig. 3.14). The optimum concentration for sodium 
butyrate treatment was 100mM as determined by published studies (Minamiyama et al., 
2004; Agrawal et al., 2005) while a range of concentrations were initially tested for 
melatonin. Results shown are from treatment with 10-2M melatonin, which was the 
regimen shown to be the most effective. 
The known inhibitor, sodium butyrate, was able to slightly alleviate the 
neurodegeneration seen in ARQ77 flies treated with DHT alone. However, melatonin 
demonstrated an even more dramatic effect, eliminating almost all signs of morphological 
and structural damage (Fig. 3.14A). The results were not nearly as impressive for the flies 
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Figure 3.14 Sodium butyrate and melatonin inhibit polyQ toxicity, but serine mutations alter 
effectivity. 
 AR fly lines and GMR-GAL4 flies were crossed on medium containing vehicle (ethanol), 10-3M 
DHT, 100mM sodium butyrate, 10-2M melatonin, or a combination. Progeny were allowed to feed for 5 
days after hatching and before pupation. Heads were then freshly cut, and pictures were taken using a light 
microscope. (A) ARQ77 flies treated with DHT demonstrate morphological defects, see black arrow. 
Defects are significantly reduced with inhibitor treatment. (B) ARQ22dm flies demonstrated little to no 
recovery with sodium butyrate and melatonin treatment while ARQ77dm flies showed some slight 
improvement with melatonin. 
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with AR mutations at serines 424 and 514. Neither sodium butyrate nor melatonin was 
able to rescue the phenotype of the ARQ22dm flies (Fig 3.14B). ARQ77dm flies 
appeared to exhibit a slight improvement, but this improvement was not significantly 
better than the improvement already seen in the ARQ77dm flies in comparison to the 
toxic ARQ77.  
 The above results demonstrated that sodium butyrate and melatonin could 
comparably inhibit neurodegeneration in the SBMA Drosophila model. However, as with 
the previous neurodegeneration assay, these results were qualitative; and the slight 
improvements of the serine mutant lines were sometimes difficult to discern. For this 
reason, the locomotion and survival assays were again used for quantitative analysis. 
 
3.4.2 Serine mutations affect ability of sodium butyrate and melatonin to rescue 
polyQ phenotype in quantitative assays 
 Use of the sensitive locomotion and survival assays allowed for a more systematic 
method of testing whether the two mechanistically different compounds sodium butyrate 
and melatonin would be able to rescue the polyQ toxicity seen in the Drosophila models. 
Both assays were performed in the same manner as previously described in this body of 
work. The concentrations of sodium butyrate and melatonin that were determined 
appropriate for the neurodegeneration assay were also used to assess the developmental 
defects leading to alterations in behavior and survival. Treatments with and without DHT 
were repeated in conjunction with the new inhibitor compound combinations for accurate 
comparison. In order to depict the changes in locomotion and survival due to the inhibitor 
treatment regimens, the percentage recovery was calculated by determining the ratio of 
the average difference between inhibitor-treated and EtOH-treated larvae to the 
difference between DHT-treated and EtOH-treated larvae. 
 
3.4.2.1 Sodium butyrate and melatonin have varying effects on locomotion 
The locomotion assay was first used to confirm that the previously described 
inhibitor sodium butyrate as well as the newly tested melatonin could positively affect the 
ARQ77 larvae, the SBMA model. Both sodium butyrate and melatonin were indeed able 
to significantly increase the speed of ARQ77 larvae that had been treated with DHT (Fig. 
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3.15A), resulting in a rescue of 46% and 48% respectively (Fig. 3.15C).  A vast 
improvement was also seen for the parameter of angular velocity (Figs. 3.15B and D), 
38% for sodium butyrate and 25% for melatonin. Thus it was quantitatively established 
that both sodium butyrate and melatonin were inhibitors of polyQ toxicity in our model 
system.  
 Next it was tested if sodium butyrate and melatonin would be able to rescue the 
increased toxic effects seen in the ARQ22 background and lessened toxicity in the 
ARQ77 background that were a result of the serine mutations. In the ARQ22dm and 
ARQ77dm larvae, the melatonin treated larvae showed a significant recovery in speed of 
approximately 30% for both cases. However, sodium butyrate was ineffective in 
improving speed of locomotion (Fig. 3.15C). The opposite scenario was seen for the 
directional changes of the larvae measured by angular velocity. ARQ22dm and 
ARQ77dm larvae treated with sodium butyrate showed a 19% and 30% rescue, 
respectively, while treatment with melatonin provided little to no improvement (Fig 
3.15D).  
 As was hinted at with the previous neurodegeneration assay, the fly lines 
containing the serine site mutations seemed to display an altered type of toxicity that 
could not be rescued in the same manner as the ARQ77. Also, the inhibitors themselves 
showed variations in their ability to act on these mutants. The survival assay was 
subsequently used as a method of verifying these observations and further quantifying the 
differences between the AR variant lines. 
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Figure 3.15 Effects of sodium butyrate and melatonin on larval locomotion  
AR fly lines and ELAV-GAL4 flies were crossed on normal stock medium. Progeny were 
transferred after 72 h to medium containing vehicle (ethanol), 10-3M DHT, 100mM sodium butyrate, 10-2M 
melatonin, or a combination. A total of 30 larvae were analyzed for each genotype and hormone treatment 
combination. Treatment with sodium butyrate and melatonin was able to partially rescue the ARQ77 larvae 
for both (A) speed and (B) angular velocity. (C) ARQ22dm and ARQ77dm larvae only showed recovery of 
speed when treated with melatonin while a recovery of angular velocity (D) was preferentially seen with 
sodium butyrate treatment.  *p<0.05, **p<0.001, ***p<0.0005 
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3.4.2.2 Sodium butyrate and melatonin differ in ability to rescue AR mutants in 
survival analyses 
 The capabilities of melatonin as well as sodium butyrate as inhibitors of polyQ 
toxicity were further examined by testing their effects on survival rates. Progeny from 
crosses between ELAV-GAL4 flies and AR transgenic flies were allowed to feed on 
DHT or EtOH alone or in combination with the inhibitor compounds until pupation (Figs. 
3.17A and D) or eclosion (Figs. 3.16B and C). Sodium butyrate and melatonin’s effects 
were first tested on ARQ77 larvae and compared with the wild type (ARQ22) situation. 
The known inhibitor sodium butyrate was able to increase survival rates to pupation with 
a rescue rate of 14% (Figs. 3.16A and C), but the benefits were not extended to eclosion, 
or full adulthood (Figs. 3.16B and D). Melatonin, on the other hand, partially rescued the 
ARQ77 larvae in both stages of survival (Figs. 3.16A and B). Melatonin treatment 
resulted in a 29% rescue in survival to pupation (Fig. 3.16C) and a 20% rescue in survival 
to eclosion (Fig. 3.16D). 
 As with locomotion, the story became more complex when it came to rescuing the 
toxicity/survival in the transgenic Drosophila containing the serine site mutations. For 
these larvae, regardless of the size of the polyQ stretch, sodium butyrate was unable to 
significantly positively influence survival rates (Figs. 3.16C and D). To the contrary, the 
survival of the ARQ22dm flies was somewhat hindered with sodium butyrate treatment. 
However, this hindrance was slight and not statistically significant. Although the 
ARQ77dm survival appeared to improve after feeding on sodium butyrate food, this 
difference was also not statistically significant. Melatonin was much more successful in 
inhibiting the toxicity seen in ARQ77dm and especially ARQ22dm flies (Figs. 3.16C and 
D). ARQ22dm larvae demonstrated an approximately 40% rescue in survival rates for 
both survival to pupation (Fig. 3.16C) and survival to eclosion (Fig. 3.16D). ARQ77dm 
larvae experienced a 44% rescue in survival to eclosion. 
 The survival data surprisingly showed melatonin to be a potent inhibitor of 
toxicity, besting the known inhibitor sodium butyrate for each of the AR variants. The 
differential results between the fly lines also solidified the earlier stated view that the 
ARQ77, ARQ22dm, and ARQ77dm demonstrate varying forms of toxicity.  
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Figure 3.16 Effects of sodium butyrate and melatonin on survival 
AR fly lines and ELAV-GAL4 flies were crossed on normal stock medium. After hatching of 
progeny, larvae were transferred to medium containing vehicle (ethanol), 10-3M DHT, 100mM sodium 
butyrate, 10-2M melatonin, or a combination with a maximum of 50 larvae per vial. The total larvae for 
each sample was >100. Data are from three separate experiments. The error bars represent standard 
deviation of the mean. (A) Survival of ARQ77 larvae to pupation was improved with sodium butyrate and 
melatonin treatment. (B) Survival to eclosion was only affected by melatonin. (C) Only ARQ22dm larvae 
treated with melatonin showed a significant improvement in survival to pupation while both ARQ22dm and 
ARQ77dm larvae demonstrated rescue in survival to eclosion with melatonin treatment (D) *p<0.05, 
**p<0.001 
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4.0 DISCUSSION 
In this work the effects that alteration of two serine residues at position 424 and 
514 in the AR have on the formation of inclusions in cultured cells and on aggregation 
and toxicity in a Drosophila model of SBMA have been analyzed. Individual 
experiments demonstrated that results in the cell culture model could generally be 
reproduced in the Drosophila model, albeit subtle variations did arise possibly due to the 
inherent differences in the two systems. Nevertheless, the general reproducibility allowed 
for comparison of the detailed cell culture inclusion studies with the toxicities and motor 
impairments exhibited in the more complex in vivo system. The collected data thus 
demonstrate that upon exchange of these two serine residues in the AR to alanine, the 
wild type receptor becomes toxic while the toxic effects of the normally pathogenic AR 
with an amplified polyQ stretch are lessened. The results also show that sodium butyrate 
and melatonin mitigate the toxic effect of the polyQ stretch but show differences toward 
the serine mutants in their ability to rescue the toxicity. Each of the AR variants therefore 
exhibits a unique toxic profile. 
 
4.1 Alteration of specific residues affects AR conformation and 
provides model system for evaluating polyQ toxicity 
In these studies, the AR serine sites 424 and 514 were chosen for simultaneous 
analysis because a double mutation was able to block in vitro phosphorylation of the AR 
by ERK whereas single mutations were insufficient. The results presented here show that 
this double serine to alanine exchange modulates the activity of the expanded polyQ 
stretch by reducing cellular inclusions and toxicity. However, a study by LaFevre-Brent 
and Ellerby (2003) showed that the single mutation of serine 514 into alanine was 
sufficient to block AR-induced cell death and generation of caspase 3-derived products in 
an AR with a polyQ stretch of 112. At this point, it cannot be determined whether or not a 
simultaneous mutation of the 424 site would have enhanced the effects seen by Lafevre-
Brent and Ellerby, especially if both sites are involved in the ERK signaling that is a 
central aspect to their results. In the same vein, it is also unclear whether the 514 site 
alone is sufficient to induce the toxic alterations to the wild type AR that have been 
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reported here. In any case, these studies do corroborate the work of LaFevre-Brent and 
Ellerby 2003 in identifying the serine 514 as one of the important sites that when mutated 
decreases the toxicity of the amplified polyQ tract in the AR.  
The previous point leads to the question as to why a single or double amino acid 
exchange would drastically affect the polyQ toxicity of the AR? One possibility is that 
the sites mutated destroy interfaces in protein-protein interactions. The other possibility is 
that they alter the folding (misfolding) of the protein. While there is not yet evidence of 
altered protein binding by the ARQ22dm and ARQ77dm, the results from the limited 
protease digestion studies in both in vitro and in vivo systems show that the conformation 
of the AR sequences is altered by the amino acid exchanges. The serine double mutation 
most likely changes the conformation of the ARQ22 and ARQ77 in such a way that the 
balance of protein folding quality control is disrupted leading to toxic or non-toxic 
aggregation, among other effects. Perutz and colleagues have reported that a single amino 
acid replacement can destabilize the native structure of proteins to unfold and form 
amyloids. Destabilization of no more than 2 kcal/mol can increase the probability of 
nucleation of disordered aggregates from which amyloids can grow 130,000-fold (Perutz 
et al., 2002). 
If a single amino acid exchange can have such profound effects, one must also 
question the specificity of these ensuing changes. Would any random amino acid 
exchange result in altered protein folding for the wild type and polyQ expanded AR? 
Palazzolo et al., (2007) recently answered this question in their investigation of AR serine 
sites 215 and 792. This study demonstrated that simultaneous phosphomimetic mutations 
of serines 215 and 792 reduced ligand binding, ligand-dependent nuclear translocation, 
transcriptional activation, and toxicity in an AR with a polyQ stretch of 65. However, 
mutations of these same sites to alanine did not affect the aggregation and toxicity of the 
wild type or pathogenic AR; thereby showing that only specific residue alterations affect 
polyQ protein structure and toxicity.  
An interesting finding that is perhaps unique to the specific serine mutations in 
this work is that the serine-to-alanine exchanges had differential effects on aggregation 
and toxicity depending upon the length of the polyQ stretch. In the context of the wild 
type receptor, they increase aggregation and make an otherwise non-toxic AR cytotoxic. 
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Thomas and colleagues had shown previously that mutation of totally different residues 
(lysine residues at positions 632 and 633 to alanine) in a wild type AR with a polyQ 
stretch of 24 caused a delay in nuclear transport of the receptor and an accumulation of 
cytoplasmic inclusions (Thomas et al., 2004). However, although the disruption of 
acetylation through mutation of these lysine sites resulted in a polyQ phenotype of 
toxicity in the wild type AR, no significant changes were noted in an AR with a polyQ 
stretch of 112. The authors hypothesized that reduced acetylation is a key property of AR 
polyQ pathogenesis; thus they were giving the wild type AR a feature that the mutant 
polyQ AR already possessed. The aforementioned study of Palazzo et al., where 
phosphomimetic mutations of serines 215 and 792 positively influenced the toxic polyQ 
AR, presents a different scenario. In this case, both the wild type and polyQ receptors 
demonstrated diminished ligand binding and nuclear localization, which contributed to a 
less toxic polyQ AR but did not alter the benign status of the wild type AR (Palazzolo et 
al., 2007). Therefore, the central role of these mutations was the disruption of the 
necessary pathogenic step of translocation to the nucleus. The unique consequences of 
the alteration of serines 424 and 514 appear to result from a combination of the above 
scenarios, triggered by the conformational changes that are evident in the limited 
proteolytic digestion assays. One way to look at the differential effects of these serine 
mutations is to take the conformational changes as the primary effect. Secondary effects 
would then be changes in nuclear localization, transcriptional activity, aggregation, and 
ultimately toxicity. Therefore, the change in conformation of the wild type receptor 
brought about by the serine mutations resulted in a cascade of secondary effects that gave 
the wild type AR toxic properties. In the same manner, the change in conformation of the 
polyQ receptor altered or disrupted some of the secondary effects required for polyQ 
toxicity. The indentification of serines 424 and 514 as specific sites whose manipulation 
results in different levels of toxicity for the AR is therefore beneficial for studying how 
the details of AR conformation and secondary effects result in toxic or non-toxic 
situations. 
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4.2 Altered conformations differentially affect nuclear accumulation 
and transcriptional activity 
 An altered transport pattern of the AR to and from the nucleus, which results in 
changes in nuclear accumulation as well as possible differences in transcriptional activity, 
is one of the secondary effects of the altered conformation brought about by the serine 
mutations. In general, nuclear shuttling activity is one of the few shared characteristics of 
the polyQ proteins (Truant et al., 2007). Altering this activity by sequestration of the 
polyQ proteins in the cytoplasmic or nuclear cellular compartments has been shown to 
have profound effects on polyQ toxicity (Klement et al., 1998; Peters et al., 1999; 
Bichelmeier et al., 2007). Several groups have shown that blocking the accumulation of 
the AR in the nucleus eliminates a critical step of the SBMA polyQ disease pathway, 
thereby blocking aggregation and cell death (Takeyama et al., 2002; Furutani et al., 2005; 
Palazzolo et al., 2007). However, the subtle difference of delaying rather than blocking 
nuclear localization can result in an aggravated phenotype (Thomas et al., 2004). The 
ARQ22dm in this work demonstrated this latter version of delayed accumulation in the 
nucleus following hormone treatment in cell culture experiments and an overall lack of 
nuclear accumulation in the Drosophila model. A plausible reason for this “delay” is that 
the altered conformation exhibited by the ARQ22dm yields an AR/chaperone complex 
that deviates in composition and/or conformation from that of the wild type situation and 
results in inefficient exposure of the NLS signal. Furthermore, it is plausible that changes 
in nuclear translocation could ensue if the AR conformation is such that ligand binding is 
affected. In the case of the AR containing the expanded polyQ stretch, a clinical study 
found that several SBMA patients exhibited abnormal ligand binding affinity, which 
correlated with severity of symptoms (MacLean et al., 1995). Ligand association is not 
only critical for nuclear import but has also been postulated to be required for retaining 
the AR in the nucleus (Roy et al., 2001). A structural alteration of the NTD due to the 
serine site mutations and/or the polyQ stretch could modify this association by interfering 
with an N-/C-terminal interaction of the AR that aids in holding the ligand in the ligand-
binding pocket (Ikonen et al., 1997; He et al., 1999). Therefore, an altered binding 
affinity could explain the observed changes in nuclear accumulation for the AR variants 
in this work and in other SBMA models (Becker et al., 2000; Thomas et al., 2004).  
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 The conformational state of the AR is also a significant factor for optimal 
transcriptional activity by the receptor. In the absence of ligand, the LBD of the C-
terminus exerts an inhibitory influence on the activity of the AF-1 in the NTD (Jenster et 
al., 1991). Ligand-binding of the AR allows for a conformational change that not only 
relieves this inhibitory influence on the AF-1 but also positions the AF-2 for interactions 
with coregulators. This structural change at the LBD is also thought to create a change in 
the NTD, enabling the NTD to interact with coactivators as well (Roy et al., 2001). 
Transcriptional regulation of target genes is reliant upon both the NTD and LBD domains 
for coordinated AF-1 and AF-2 activity (Jenster et al., 1995). Mutational analyses have 
demonstrated that almost the entire NTD is necessary for the receptor to reach its 
maximum transactivation potential (Bevan et al., 1999). Indeed, the transcriptional 
activity of the N-terminal AR variants containing the amplified polyQ stretch in this work 
deviated significantly from the wild type ARQ22. The presence of the expanded polyQ 
region resulted in reduced levels of hormone induction for both the ARQ77 and 
ARQ77dm, supporting other works that have shown that an amplified polyQ stretch 
negatively effects AR transcriptional activity (Irvine et al., 2000; Thomas et al., 2006b). 
The influence of the N-terminal serine residue exchanges, however, was more difficult to 
discern. While the serine mutations appeared to result in no changes in transcriptional 
activity for the ARQ77 background, the results for the ARQ22 background were more 
complex. Although overall levels of transcriptional activity were reduced for the 
ARQ22dm, hormone induction seemed to be higher than that of its wild type counterpart.  
In the case of the amplified polyQ stretch, the reduced transcriptional activation of target 
genes has been proposed to be a contributor to cellular toxicity, possibly through the loss 
of the AR’s trophic capabilities (Thomas et al., 2006b). At present, it is not clear if or 
how the anomalous result of the ARQ22dm affects the toxicity of this particular AR 
variant.  
 In analyzing the effects of the serine site mutations on transcriptional activity, one 
must keep in mind that the presented COS7 cell culture experiments may only give a 
limited view of the intricate in vivo scenario that involves coactivator and corepressor 
molecules that may or may not be active in COS7 cells. Along with an altered presence in 
the nucleus, the ability of coregulators to bind the AR greatly impacts the transactivation 
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activity of the receptor (Chmelar et al., 2007). Furthermore, the NTD is critical for 
interaction with the glutamine rich steroid receptor coactivator-1 (SRC-1) as well as other 
members of the p160 family of coactivators such as the glucocorticoid receptor-
interacting protein (GRIP-1)/TIF2 (transcription intermediary factor 2) (Bevan et al., 
1999). The length of the polyQ region of the NTD has previously been shown to affect 
this interaction, demonstrating an inverse correlation with the recruitment of p160 
coactivators SRC-1 and GRIP-1 (Irvine et al., 2000; Callewaert et al., 2003). Therefore, it 
is possible that the proposed alterations in the conformation of the AR NTD due to the 
exchange of serine residues 424 and 514 could also affect coactivator recruitment and 
result in changes in transcriptional activity that are not evident in the COS7 model. For 
this scenario, it is especially important to note that the N-terminal interaction domain of 
GRIP-1 has previously been mapped to AR amino acids 351-537 (Irvine et al., 2000), 
which encompasses the serine sites examined in these studies. Another coactivator whose 
recruitment could potentially be affected by the residue exchanges at serines 424 and 514 
is Ran/ARA24. This 24 kDa Ras-like small nuclear GTPase was also found to bind the 
polyQ region and enhance AR transactivation in a manner that was inversely correlated 
with the length of the glutamine stretch (Hsiao et al., 1999). A particularly interesting 
feature of this coactivator is its involvement in the nuclear transport of proteins (Rush et 
al., 1996). Differential recruitment of ARA24 could therefore also provide another link to 
the altered nuclear accumulation of the ARQ22dm, ARQ77, and ARQ77dm in addition to 
any changes in transactivation activity. Thus, overexpression studies investigating the 
recruitment of coregulators are needed to clarify if and how the serine site mutations alter 
transcriptional activation by the AR.  
 When examining the nuclear accumulation and transactivation patterns of the AR 
variants, changes in nuclear presence did not always directly correspond with changes in 
transcriptional activity. For example, even though the conformationally different 
ARQ77dm demonstrated improved nuclear localization kinetics in comparison to the 
ARQ77, the transcriptional activities of both receptors were similarly impaired. A 
comparison can also be drawn between the the ARQ22dm and the ARQ77dm; these 
receptors demonstrated similar nuclear accumulation kinetics but different patterns of 
transcriptional activation. Therefore, it seems that nuclear localization is a secondary 
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effect that can be disrupted or improved in a polyQ length-dependent manner due to 
conformational changes brought about by the serine mutations. However, although the 
effects of the serine exchanges on transcriptional activity need to be further elucidated in 
regards to coregulator recruitment, the general picture for the regulation of reporter genes 
depicted thus far shows alterations for the ARQ22 background but does not show an 
opposing effect in the ARQ77 background. The implication of these results is that the 
pathway of toxic secondary effects resulting from the residue exchanges at serines 424 
and 514 and the subsequent conformational changes of the wild type receptor likely 
differs from the pathway of secondary effects that make the ARQ77dm less toxic than its 
ARQ77 counterpart. Therefore, it is possible to manipulate polyQ toxicity at multiple 
points and elucidation of these points could reveal multiple therapeutic targets. 
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4.3 Altered AR conformations yield characteristically diverse 
aggregates 
 Aggregate formation as a result of misfolded protein conformations is a critical 
attribute of polyQ toxicity, and the differing aggregate profiles of the AR variants give 
further insight into what makes the ARQ22dm “more toxic” and the ARQ77dm “less 
toxic”. The first most obvious observation from the cell culture model is the differential 
effects of the serine mutations on the kinetics of inclusion formation with a global 
increase in inclusions for the ARQ22 background and a decrease for the ARQ77 
background. Such global changes in aggregation have been the basis for many reports of 
alleviation or augmentation of polyQ toxicity (Diamond et al., 2000; Apostol et al., 2003; 
Scappini et al., 2007). Interestingly, the presented opposing changes in aggregation 
stemming from the different polyQ lengths and the serine site exchanges actually meant 
that the ARQ22dm and ARQ77dm demonstrated similar rates for overall formation of 
inclusions.  These similar inclusion/aggregation rates in the cell culture model also 
corresponded with comparable levels of toxicity as determined by the locomotion and 
survival assays of the Drosophila model. However, focusing only on total inclusion 
formation numbers can be misleading due to the possibly varying effects of different 
types of aggregate structures (Bates, 2003; Arrasate et al., 2004). Rather, an association 
of the specific types of aggregates with alterations in polyQ toxicity has proven more 
informative (Li et al., 2007; Rusmini et al., 2007). Following this line of reasoning, the 
ARQ22dm and the ARQ77dm did demonstrate distinct differences when classified in the 
immunofluorescence and solubility experiments, clarifying that the toxic properties 
exhibited by these AR variants are not equivalent. 
 In this work, inclusions were initially classified as to their cellular 
compartmentalization and globular or fibrous appearance. For all of the AR constructs, 
most of the differences were only visible in the cytoplasmic compartment. The lack of 
intranuclear inclusions is most likely due to the specific experimental conditions of the 
immunofluorescence studies (i.e. cell type or time course of DHT treatment). A previous 
study reported that nuclear localization of inclusions is indeed more prominent in 
neuronal cells than COS cell lines (Merry et al., 1998). Nevertheless, examining 
differences in cytoplasmic inclusions is also relevant due to their presence in SBMA 
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patients (Adachi et al., 2005) as well as their confirmed toxic influence (Piccioni et al., 
2002; Lee et al., 2004). Although the serine mutations resulted in an increase or decrease 
in both globular and fibrous cytoplasmic inclusions for the ARQ22 and ARQ77 
backgrounds respectively, the changes were not entirely symmetric. The percentages of 
cells containing globular inclusions, which have especially been implicated in 
pathophysiology (Quist et al., 2005), were relatively equal for both serine mutated 
receptors. However, the ARQ22dm exhibited a noticeably greater frequency of fibrous 
cytoplasmic inclusions than the ARQ77dm. Without more intense structural 
investigation, it is difficult to speculate on the exact role of these extra fibrous inclusions 
in the pathogenicity of the ARQ22dm.  
 Differences among the AR variants were investigated by determining aggregate 
solubility in both COS7 cells and the Drosophila model. The aggregates formed by the 
ARQ22dm in COS7 cells were found to be SDS-insoluble at the earliest time points of 
androgen treatment. After prolonged hormone treatment, the ARQ22dm aggregates were 
not retained on the filter that normally traps insoluble aggregates formed by protein with 
amplified polyQ stretches (Heiser et al., 2002). Thus the ARQ22dm aggregates appeared 
to be rather transient in nature. Aggregates for both the ARQ77 and ARQ77dm, however, 
were retained at all time points investigated. As opposed to the cell culture model, all 
three AR variants expressed in Drosophila larvae formed aggregates that were SDS-
insoluble over an extended period of hormone treatment. Due to limiting experimental 
factors with the Drosophila model, the transience of these ARQ22dm aggregates could 
not be determined. However, studies utilizing fluorescence recovery after photobleaching 
(FRAP) have indicated that polyQ proteins are dynamic and aggregates can actually 
exchange between soluble and insoluble phases and move between inclusions in their 
cellular environment (Truant et al., 2007). Therefore, it is possible that the ARQ22dm 
aggregates of the Drosophila system were examined at an insoluble phase. The 
differences in cellular environmental factors between the two model systems could 
feasibly play a role in the timing and formation of such soluble and insoluble aggregate 
phases. In terms of characterizing the AR variants, it could prove beneficial to explore 
what factors are associated with the various phases of solubility. 
 102
The filter retardation assay utilized to determine the solubility states of the four 
ARs in both the cell and Drosophila models was unfortunately not sensitive enough to 
distinguish quantitatively between the AR variants, especially the ARQ77 and 
ARQ77dm. The dramatic differences in the appearance of inclusions as visualized by the 
immunofluorescence studies and the correlation of these results with toxicity levels in 
Drosophila did not translate to comparable differences in the solubility assays. The lack 
of a correlation between the presence of insoluble aggregates after extended hormone 
treatment and the exhibited toxicities of the AR variants points toward the argument of 
soluble intermediates rather than large insoluble inclusions as the toxic species (Ross and 
Poirier, 2004; Li et al., 2007). The likelihood of the different receptors to form such 
intermediates would most likely depend on their structural divergences. Attempts to make 
further conformational distinctions through immunostaining with the 1C2 antibody, 
however, were also unsuccessful. The aforementioned study by Thomas et al., showed 
that its AR containing 24 glutamines and acetylation site mutations was recognized by 
this antibody that normally only recognizes proteins with amplified polyQ stretches, 
suggesting a conformational change in the protein (Thomas et al., 2004). Although the 
ARQ22dm presented in this work displayed similar toxic characteristics as the 
acetylation mutant in the way of delayed nuclear accumulation and increased 
aggregation, it was not recognized by the 1C2 antibody; indicating that the inclusions 
formed by this protein are most likely different from those formed by the ARQ24 with 
the lysine mutations. Therefore, it seems to be generally applicable that polyQ proteins 
with subtle changes in neighboring sequences produce different types of aggregates with 
varying toxicities. Furthermore, there is a need to quantitatively and structurally 
characterize the primary conformational changes and the secondary aggregate formations 
of the protein variants presented here as well as in other studies (LaFevre-Bernt and 
Ellerby, 2003; Thomas et al., 2004). This would allow for more direct targeting of 
specific aggregate types by therapeutic agents. 
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4.4 Inhibitor compounds act on specific subsets of the varied AR 
toxicities 
Several compounds have been tested for their ability to ameliorate the toxic 
effects of the amplified polyQ disorders. Among the successful contenders are inhibitors 
of histone deacetylases (HDAC). The HDAC inhibitors, sodium butyrate and 
suberoylanilide  hydroxamic acid (SAHA) have been used to mitigate polyQ toxicity in 
both Drosophila and mouse models of SBMA and Huntington’s (McCampbell et al., 
2001; Steffan et al., 2001; Minamiyama et al., 2004). Sodium butyrate was therefore used 
along with melatonin, another candidate inhibitor of neurodegenerative disorders 
(Srinivasan et al., 2006) and a general health supplement (Lewis and Clouatre, 1999) to 
rescue the toxicity caused by the AR mutants. The inhibitors were initially tested for their 
capability of rescuing neurodegeneration of the fly eye. The results confirmed published 
findings that sodium butyrate reduces toxicity caused by the polyQ amplification (Steffan 
et al., 2001; Marsh and Thompson, 2004). Melatonin was found to function with a 
similar, perhaps better, efficiency as sodium butyrate in this assay.  Interestingly, the 
toxicities displayed by the serine mutants did not show a significant response to either 
compound, demonstrating that the pathogenic mechanisms for these mutants diverge 
from the classical polyQ scenario.  
Locomotive and survival studies that were used to distinguish between the 
toxicites of the AR variants were also used as a more sensitive approach to analyze the 
effects of the inhibitors. These Drosophila assays were employed rather than the 
frequently used pseudopupil technique that assesses the number of visible rhabdomeres 
by light microscopy (Steffan et al., 2001; Marsh and Thompson, 2004) due to the 
relevance of movement impairment and lifespan to the polyQ disorders. As evaluated by 
both the locomotive and survival assays, sodium butyrate and melatonin again proved 
capable of ameliorating polyQ toxicity in almost all tested aspects. The efficiencies in 
increasing lifespan did vary, though, with sodium butyrate only able to improve survival 
to the pupal stage. However, the two compounds demonstrated an even greater variation 
in their effect on the two serine mutants. Sodium butyrate was ineffectual in significantly 
improving locomotive speed and survival for the ARQ22dm and ARQ77dm while 
melatonin failed to improve the angular velocity of these mutant larvae. The combination 
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of the above results most likely stems from the demonstrated differing toxicities of the 
AR variants in addition to the inhibitors’ different modes of action. Sodium butyrate, like 
other HDAC inhibitors, prevents the removal of acetyl groups from core histones and as a 
result restores histone acetylation and improves neurodegenerative effects in Drosophila 
models (Taylor et al., 2003) and motor impairment in a mouse model of polyQ diseases 
(Minamiyama et al., 2004). However in a transgenic model of SBMA, it was observed 
that sodium butyrate ameliorated the neurological phenotype only within a narrow dose 
range. It did not inhibit aggregation nor the 1C2 staining arising from the amplified 
polyQ stretch of the AR (Minamiyama et al., 2004). In contrast, melatonin, which also 
shows neurodegenerative rescue, inhibited progressive formation of β-sheet and amyloid 
fibrils observed in Alzheimer´s disease (Pappolla et al., 1998). This anti-amyloidogenic 
property possibly results from structural intercalation of melatonin with the Aβ peptide of 
Alzheimer´s disease and possibly other conformationally toxic species. The differential 
effects of sodium butyrate and melatonin in rescuing specific subsets of the toxic action 
of polyQ stretches strongly support the idea of combinatorial drug regimens for the future 
treatment of polyQ disorders. This is underpinned by the fact that the polyQ toxicity 
involves multiple cellular mechanisms whose contribution to the disease may be additive 
or even synergistic. 
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4.5 Final conclusions and outlook for AR-specific and general 
polyglutamine toxicity studies 
The presented results have identified a mutant AR with a non-amplified polyQ 
stretch that demonstrates several characteristics that are similar to those of the pathogenic 
AR containing a polyQ expansion. These exhibited characteristics include delayed 
nuclear accumulation, possible alterations in transcriptional activity, and the formation of 
aggregate species that are toxic in a Drosophila model of neurodegeneration. This AR 
mutant is comparable with the ARQ77dm that also demonstrates a version of lessened 
polyQ toxicity but through what appears to be a slightly different pathway of alterations. 
Together with the classical SBMA polyQ receptor, ARQ77, these mutant receptors would 
provide useful material for future studies on how changes in protein conformation can 
lead to toxicity. More specifically, these receptors could be utilized to investigate two 
theoried key features of polyQ pathogenesis, transcriptional dysregulation and aggregate 
formation. The elucidation of altered transcriptional coregulator interactions with the 
different receptor versions has the potential to yield mechanistic insight and possible 
therapeutic targets for SBMA. Structural studies of the aggregates formed by the AR 
mutants could prove more generally applicable with the possibility of pinpointing 
specific conformational changes to varying degrees of polyQ toxicity. Furthermore, it 
would be useful to investigate how these detailed conformational alterations can be 
rescued by inhibitors that target different cellular processes. Since melatonin was shown 
to be a capable polyQ inhibitor in the studies presented here and it is known to affect Aβ 
fibril formation (Pappolla et al., 1998), it would be especially interesting to investigate its 
specific effects on the proposed different aggregate fomations of the AR mutants. One 
group has already proven that classification of aggregates can directly lead to therapeutic 
strategies (Nagai et al., 2003; Armen et al., 2005). In two separate studies, this group 
identified a toxic conformer peptide (polyQ-binding peptide 1/QBP1) that binds to an 
alpha-extended chain conformation, thereby inhibiting fibril formation (Armen et al., 
2005) and preventing polyQ-induced neurodegeneration in a Drosophila model (Nagai et 
al., 2003). Therefore, with the combination of future structural studies of the AR variants 
and the running Drosophila model presented in this body of work, a similar and perhaps 
more specific development of therapeutic strategies is feasible. 
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